Somatic	O	O
-	O	O
cell	O	O
selection	O	O
is	O	O
a	O	O
major	O	O
determinant	O	O
of	O	O
the	O	O
blood	O	O
-	O	O
cell	O	O
phenotype	O	O
in	O	O
heterozygotes	O	O
for	O	O
glucose	O	O
-	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
mutations	O	O
causing	O	O
severe	O	O
enzyme	B-Disease	 D008661
deficiency	I-Disease	 D008661
.	O	O

X	O	O
-	O	O
chromosome	O	O
inactivation	O	O
in	O	O
mammals	O	O
is	O	O
regarded	O	O
as	O	O
an	O	O
essentially	O	O
random	O	O
process	O	O
,	O	O
but	O	O
the	O	O
resulting	O	O
somatic	O	O
-	O	O
cell	O	O
mosaicism	O	O
creates	O	O
the	O	O
opportunity	O	O
for	O	O
cell	O	O
selection	O	O
.	O	O

In	O	O
most	O	O
people	O	O
with	O	O
red	O	O
-	O	O
blood	O	O
-	O	O
cell	O	O
glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
(	I-Disease	D005955
G6PD	I-Disease	D005955
)	I-Disease	D005955
deficiency	I-Disease	D005955
,	O	O
the	O	O
enzyme	O	O
-	O	O
deficient	O	O
phenotype	O	O
is	O	O
only	O	O
moderately	O	O
expressed	O	O
in	O	O
nucleated	O	O
cells	O	O
.	O	O

However	O	O
,	O	O
in	O	O
a	O	O
small	O	O
subset	O	O
of	O	O
hemizygous	O	O
males	O	O
who	O	O
suffer	O	O
from	O	O
chronic	B-Disease	D000746
nonspherocytic	I-Disease	D000746
hemolytic	I-Disease	D000746
anemia	I-Disease	D000746
,	O	O
the	O	O
underlying	O	O
mutations	O	O
(	O	O
designated	O	O
class	O	O
I	O	O
)	O	O
cause	O	O
more	O	O
-	O	O
severe	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
,	O	O
and	O	O
this	O	O
might	O	O
provide	O	O
an	O	O
opportunity	O	O
for	O	O
selection	O	O
in	O	O
heterozygous	O	O
females	O	O
during	O	O
development	O	O
.	O	O

In	O	O
order	O	O
to	O	O
test	O	O
this	O	O
possibility	O	O
we	O	O
have	O	O
analyzed	O	O
four	O	O
heterozygotes	O	O
for	O	O
class	O	O
I	O	O
G6PD	O	O
mutations	O	O
two	O	O
with	O	O
G6PD	O	O
Portici	O	O
(	O	O
1178G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
)	O	O
and	O	O
two	O	O
with	O	O
G6PD	O	O
Bari	O	O
(	O	O
1187C	O	O
-	O	O
-	O	O
>	O	O
T	O	O
)	O	O
.	O	O

We	O	O
found	O	O
that	O	O
in	O	O
fractionated	O	O
blood	O	O
cell	O	O
types	O	O
(	O	O
including	O	O
erythroid	O	O
,	O	O
myeloid	O	O
,	O	O
and	O	O
lymphoid	O	O
cell	O	O
lineages	O	O
)	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
excess	O	O
of	O	O
G6PD	O	O
-	O	O
normal	O	O
cells	O	O
.	O	O

The	O	O
significant	O	O
concordance	O	O
that	O	O
we	O	O
have	O	O
observed	O	O
in	O	O
the	O	O
degree	O	O
of	O	O
imbalance	O	O
in	O	O
the	O	O
different	O	O
blood	O	O
-	O	O
cell	O	O
lineages	O	O
indicates	O	O
that	O	O
a	O	O
selective	O	O
mechanism	O	O
is	O	O
likely	O	O
to	O	O
operate	O	O
at	O	O
the	O	O
level	O	O
of	O	O
pluripotent	O	O
blood	O	O
stem	O	O
cells	O	O
.	O	O

Thus	O	O
,	O	O
it	O	O
appears	O	O
that	O	O
severe	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
affects	O	O
adversely	O	O
the	O	O
proliferation	O	O
or	O	O
the	O	O
survival	O	O
of	O	O
nucleated	O	O
blood	O	O
cells	O	O
and	O	O
that	O	O
this	O	O
phenotypic	O	O
characteristic	O	O
is	O	O
critical	O	O
during	O	O
hematopoiesis	O	O
.	O	O

.	O	O

The	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
gene	O	O
product	O	O
,	O	O
a	O	O
constitutively	O	O
expressed	O	O
nuclear	O	O
protein	O	O
that	O	O
is	O	O
not	O	O
up	O	O
-	O	O
regulated	O	O
following	O	O
genome	O	O
damage	O	O
.	O	O

The	O	O
product	O	O
of	O	O
the	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
gene	O	O
(	O	O
ATM	O	O
)	O	O
was	O	O
identified	O	O
by	O	O
using	O	O
an	O	O
antiserum	O	O
developed	O	O
to	O	O
a	O	O
peptide	O	O
corresponding	O	O
to	O	O
the	O	O
deduced	O	O
amino	O	O
acid	O	O
sequence	O	O
.	O	O

The	O	O
ATM	O	O
protein	O	O
is	O	O
a	O	O
single	O	O
,	O	O
high	O	O
-	O	O
molecular	O	O
weight	O	O
protein	O	O
predominantly	O	O
confined	O	O
to	O	O
the	O	O
nucleus	O	O
of	O	O
human	O	O
fibroblasts	O	O
,	O	O
but	O	O
is	O	O
present	O	O
in	O	O
both	O	O
nuclear	O	O
and	O	O
microsomal	O	O
fractions	O	O
from	O	O
human	O	O
lymphoblast	O	O
cells	O	O
and	O	O
peripheral	O	O
blood	O	O
lymphocytes	O	O
.	O	O

ATM	O	O
protein	O	O
levels	O	O
and	O	O
localization	O	O
remain	O	O
constant	O	O
throughout	O	O
all	O	O
stages	O	O
of	O	O
the	O	O
cell	O	O
cycle	O	O
.	O	O

Truncated	O	O
ATM	O	O
protein	O	O
was	O	O
not	O	O
detected	O	O
in	O	O
lymphoblasts	O	O
from	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
patients	O	O
homozygous	O	O
for	O	O
mutations	O	O
leading	O	O
to	O	O
premature	O	O
protein	O	O
termination	O	O
.	O	O

Exposure	O	O
of	O	O
normal	O	O
human	O	O
cells	O	O
to	O	O
gamma	O	O
-	O	O
irradiation	O	O
and	O	O
the	O	O
radiomimetic	O	O
drug	O	O
neocarzinostatin	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
ATM	O	O
protein	O	O
levels	O	O
,	O	O
in	O	O
contrast	O	O
to	O	O
a	O	O
noted	O	O
rise	O	O
in	O	O
p53	O	O
levels	O	O
over	O	O
the	O	O
same	O	O
time	O	O
interval	O	O
.	O	O

These	O	O
findings	O	O
are	O	O
consistent	O	O
with	O	O
a	O	O
role	O	O
for	O	O
the	O	O
ATM	O	O
protein	O	O
in	O	O
ensuring	O	O
the	O	O
fidelity	O	O
of	O	O
DNA	O	O
repair	O	O
and	O	O
cell	O	O
cycle	O	O
regulation	O	O
following	O	O
genome	O	O
damage	O	O
.	O	O

.	O	O

Molecular	O	O
basis	O	O
for	O	O
Duarte	B-Disease	D005693
and	I-Disease	D005693
Los	I-Disease	D005693
Angeles	I-Disease	D005693
variant	I-Disease	D005693
galactosemia	I-Disease	D005693
.	O	O

Human	O	O
orythrocytes	O	O
that	O	O
are	O	O
homozygous	O	O
for	O	O
the	O	O
Duarte	B-Disease	D005693
enzyme	I-Disease	D005693
variant	I-Disease	D005693
of	I-Disease	D005693
galactosemia	I-Disease	D005693
(	O	O
D	O	O
/	O	O
D	O	O
)	O	O
have	O	O
a	O	O
characteristic	O	O
isoform	O	O
on	O	O
isoelectric	O	O
focusing	O	O
and	O	O
50	O	O
%	O	O
reduction	O	O
in	O	O
galactose	O	O
-	O	O
1	O	O
-	O	O
phosphate	O	O
uridyltransferase	O	O
(	O	O
GALT	O	O
)	O	O
enzyme	O	O
activity	O	O
.	O	O

The	O	O
Duarte	O	O
biochemical	O	O
phenotype	O	O
has	O	O
a	O	O
molecular	O	O
genotype	O	O
of	O	O
N314D	O	O
/	O	O
N314D	O	O
.	O	O

The	O	O
characteristic	O	O
Duarte	O	O
isoform	O	O
is	O	O
also	O	O
associated	O	O
with	O	O
a	O	O
variant	O	O
called	O	O
the	O	O
"	O	O
Los	O	O
Angeles	O	O
(	O	O
LA	O	O
)	O	O
phenotype	O	O
,	O	O
"	O	O
which	O	O
has	O	O
increased	O	O
GALT	O	O
enzyme	O	O
activity	O	O
.	O	O

We	O	O
evaluated	O	O
GALT	O	O
enzyme	O	O
activity	O	O
and	O	O
screened	O	O
the	O	O
GALT	O	O
genes	O	O
of	O	O
145	O	O
patients	O	O
with	O	O
one	O	O
or	O	O
more	O	O
N314D	O	O
-	O	O
containing	O	O
alleles	O	O
.	O	O

We	O	O
found	O	O
seven	O	O
with	O	O
the	O	O
LA	O	O
biochemical	O	O
phenotype	O	O
,	O	O
and	O	O
all	O	O
had	O	O
a	O	O
1721C	O	O
-	O	O
-	O	O
>	O	O
T	O	O
transition	O	O
in	O	O
exon	O	O
7	O	O
in	O	O
cis	O	O
with	O	O
the	O	O
N314D	O	O
missense	O	O
mutation	O	O
.	O	O

The	O	O
1721C	O	O
-	O	O
-	O	O
>	O	O
T	O	O
transition	O	O
is	O	O
a	O	O
neutral	O	O
polymorphism	O	O
for	O	O
leucine	O	O
at	O	O
amino	O	O
acid	O	O
218	O	O
(	O	O
L218L	O	O
)	O	O
.	O	O

In	O	O
pedigree	O	O
analyses	O	O
,	O	O
this	O	O
1721C	O	O
-	O	O
-	O	O
>	O	O
T	O	O
transition	O	O
segregated	O	O
with	O	O
the	O	O
LA	O	O
phenotype	O	O
of	O	O
increased	O	O
GALT	O	O
activity	O	O
in	O	O
three	O	O
different	O	O
biochemical	O	O
phenotypes	O	O
(	O	O
LA	O	O
/	O	O
N	O	O
,	O	O
LA	O	O
/	O	O
G	O	O
,	O	O
and	O	O
LA	O	O
/	O	O
D	O	O
)	O	O
.	O	O

To	O	O
determine	O	O
the	O	O
mechanism	O	O
for	O	O
increased	O	O
activity	O	O
of	O	O
the	O	O
LA	O	O
variant	O	O
,	O	O
we	O	O
compared	O	O
GALT	O	O
mRNA	O	O
,	O	O
protein	O	O
abundance	O	O
,	O	O
and	O	O
enzyme	O	O
thermal	O	O
stability	O	O
in	O	O
lymphoblast	O	O
cell	O	O
lines	O	O
of	O	O
D	O	O
and	O	O
LA	O	O
phenotypes	O	O
with	O	O
comparable	O	O
genotypes	O	O
.	O	O

GALT	O	O
protein	O	O
abundance	O	O
was	O	O
increased	O	O
in	O	O
LA	O	O
compared	O	O
to	O	O
D	O	O
alleles	O	O
,	O	O
but	O	O
mRNA	O	O
was	O	O
similar	O	O
among	O	O
all	O	O
genotypes	O	O
.	O	O

When	O	O
LA	O	O
/	O	O
D	O	O
and	O	O
D	O	O
/	O	O
D	O	O
GALT	O	O
biochemical	O	O
phenotypes	O	O
were	O	O
compared	O	O
to	O	O
N	O	O
/	O	O
N	O	O
GALT	O	O
phenotypes	O	O
,	O	O
both	O	O
had	O	O
50	O	O
%	O	O
,	O	O
as	O	O
compared	O	O
to	O	O
21	O	O
%	O	O
,	O	O
reduction	O	O
in	O	O
GALT	O	O
activity	O	O
in	O	O
the	O	O
wild	O	O
type	O	O
(	O	O
N	O	O
/	O	O
N	O	O
)	O	O
after	O	O
exposure	O	O
at	O	O
identical	O	O
initial	O	O
enzyme	O	O
activity	O	O
to	O	O
50	O	O
degrees	O	O
C	O	O
for	O	O
15	O	O
min	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
codon	O	O
change	O	O
N314D	O	O
in	O	O
cis	O	O
with	O	O
the	O	O
base	O	O
-	O	O
pair	O	O
transition	O	O
1721C	O	O
-	O	O
-	O	O
>	O	O
T	O	O
produces	O	O
the	O	O
LA	B-Disease	D005693
variant	I-Disease	D005693
of	I-Disease	D005693
galactosemia	I-Disease	D005693
and	O	O
that	O	O
this	O	O
nucleotide	O	O
change	O	O
increases	O	O
GALT	O	O
activity	O	O
by	O	O
increasing	O	O
GALT	O	O
protein	O	O
abundance	O	O
without	O	O
increasing	O	O
transcription	O	O
or	O	O
decreasing	O	O
thermal	O	O
lability	O	O
.	O	O

A	O	O
favorable	O	O
codon	O	O
bias	O	O
for	O	O
the	O	O
mutated	O	O
codon	O	O
with	O	O
consequently	O	O
increased	O	O
translation	O	O
rates	O	O
is	O	O
postulated	O	O
as	O	O
the	O	O
mechanism	O	O
.	O	O

.	O	O

An	O	O
intronic	O	O
mutation	O	O
in	O	O
a	O	O
lariat	O	O
branchpoint	O	O
sequence	O	O
is	O	O
a	O	O
direct	O	O
cause	O	O
of	O	O
an	O	O
inherited	B-Disease	D030342
human	I-Disease	D030342
disorder	I-Disease	D030342
(	O	O
fish	B-Disease	D007863
-	I-Disease	D007863
eye	I-Disease	D007863
disease	I-Disease	D007863
)	O	O
.	O	O

The	O	O
first	O	O
step	O	O
in	O	O
the	O	O
splicing	O	O
of	O	O
an	O	O
intron	O	O
from	O	O
nuclear	O	O
precursors	O	O
of	O	O
mRNA	O	O
results	O	O
in	O	O
the	O	O
formation	O	O
of	O	O
a	O	O
lariat	O	O
structure	O	O
.	O	O

A	O	O
distinct	O	O
intronic	O	O
nucleotide	O	O
sequence	O	O
,	O	O
known	O	O
as	O	O
the	O	O
branchpoint	O	O
region	O	O
,	O	O
plays	O	O
a	O	O
central	O	O
role	O	O
in	O	O
this	O	O
process	O	O
.	O	O

We	O	O
here	O	O
describe	O	O
a	O	O
point	O	O
mutation	O	O
in	O	O
such	O	O
a	O	O
sequence	O	O
.	O	O

Three	O	O
sisters	O	O
were	O	O
shown	O	O
to	O	O
suffer	O	O
from	O	O
fish	B-Disease	D007863
-	I-Disease	D007863
eye	I-Disease	D007863
disease	I-Disease	D007863
(	O	O
FED	B-Disease	D007863
)	O	O
,	O	O
a	O	O
disorder	O	O
which	O	O
is	O	O
caused	O	O
by	O	O
mutations	O	O
in	O	O
the	O	O
gene	O	O
coding	O	O
for	O	O
lecithin	O	O
cholesterol	O	O
acyltransferase	O	O
(	O	O
LCAT	O	O
)	O	O
.	O	O

Sequencing	O	O
of	O	O
the	O	O
LCAT	O	O
gene	O	O
of	O	O
all	O	O
three	O	O
probands	O	O
revealed	O	O
compound	O	O
heterozygosity	O	O
for	O	O
a	O	O
missense	O	O
mutation	O	O
in	O	O
exon	O	O
4	O	O
which	O	O
is	O	O
reported	O	O
to	O	O
underlie	O	O
the	O	O
FED	B-Disease	D007863
phenotype	O	O
,	O	O
and	O	O
a	O	O
point	O	O
mutation	O	O
located	O	O
in	O	O
intron	O	O
4	O	O
(	O	O
IVS4	O	O
T	O	O
-	O	O
22C	O	O
)	O	O
.	O	O

By	O	O
performing	O	O
in	O	O
vitro	O	O
expression	O	O
of	O	O
LCAT	O	O
minigenes	O	O
and	O	O
reverse	O	O
transcriptase	O	O
PCR	O	O
on	O	O
mRNA	O	O
isolated	O	O
from	O	O
leukocytes	O	O
of	O	O
the	O	O
patient	O	O
,	O	O
this	O	O
gene	O	O
defect	O	O
was	O	O
shown	O	O
to	O	O
cause	O	O
a	O	O
null	O	O
allele	O	O
as	O	O
the	O	O
result	O	O
of	O	O
complete	O	O
intron	O	O
retention	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
we	O	O
demonstrated	O	O
that	O	O
a	O	O
point	O	O
mutation	O	O
in	O	O
a	O	O
lariat	O	O
branchpoint	O	O
consensus	O	O
sequence	O	O
causes	O	O
a	O	O
null	O	O
allele	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
FED	B-Disease	D007863
.	O	O

In	O	O
addition	O	O
,	O	O
our	O	O
finding	O	O
illustrates	O	O
the	O	O
importance	O	O
of	O	O
this	O	O
sequence	O	O
for	O	O
normal	O	O
human	O	O
mRNA	O	O
processing	O	O
.	O	O

Finally	O	O
,	O	O
this	O	O
report	O	O
provides	O	O
a	O	O
widely	O	O
applicable	O	O
strategy	O	O
which	O	O
ensures	O	O
fast	O	O
and	O	O
effective	O	O
screening	O	O
for	O	O
intronic	O	O
defects	O	O
that	O	O
underlie	O	O
differential	O	O
gene	O	O
expression	O	O
.	O	O

.	O	O

Genetic	O	O
heterogeneity	O	O
in	O	O
hereditary	B-Disease	D061325
breast	I-Disease	D061325
cancer	I-Disease	D061325
:	O	O
role	O	O
of	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
.	O	O

The	O	O
common	O	O
hereditary	O	O
forms	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
have	O	O
been	O	O
largely	O	O
attributed	O	O
to	O	O
the	O	O
inheritance	O	O
of	O	O
mutations	O	O
in	O	O
the	O	O
BRCA1	O	O
or	O	O
BRCA2	O	O
genes	O	O
.	O	O

However	O	O
,	O	O
it	O	O
is	O	O
not	O	O
yet	O	O
clear	O	O
what	O	O
proportion	O	O
of	O	O
hereditary	B-Disease	D061325
breast	I-Disease	D061325
cancer	I-Disease	D061325
is	O	O
explained	O	O
by	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
or	O	O
by	O	O
some	O	O
other	O	O
unidentified	O	O
susceptibility	O	O
gene	O	O
(	O	O
s	O	O
)	O	O
.	O	O

We	O	O
describe	O	O
the	O	O
proportion	O	O
of	O	O
hereditary	B-Disease	D061325
breast	I-Disease	D061325
cancer	I-Disease	D061325
explained	O	O
by	O	O
BRCA1	O	O
or	O	O
BRCA2	O	O
in	O	O
a	O	O
sample	O	O
of	O	O
North	O	O
American	O	O
hereditary	B-Disease	D061325
breast	I-Disease	D061325
cancers	I-Disease	D061325
and	O	O
assess	O	O
the	O	O
evidence	O	O
for	O	O
additional	O	O
susceptibility	O	O
genes	O	O
that	O	O
may	O	O
confer	O	O
hereditary	B-Disease	D061325
breast	I-Disease	D061325
or	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
risk	O	O
.	O	O

Twenty	O	O
-	O	O
three	O	O
families	O	O
were	O	O
identified	O	O
through	O	O
two	O	O
high	O	O
-	O	O
risk	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
research	O	O
programs	O	O
.	O	O

Genetic	O	O
analysis	O	O
was	O	O
undertaken	O	O
to	O	O
establish	O	O
linkage	O	O
between	O	O
the	O	O
breast	B-Disease	D001943
or	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
cases	O	O
and	O	O
markers	O	O
on	O	O
chromosomes	O	O
17q	O	O
(	O	O
BRCA1	O	O
)	O	O
and	O	O
13q	O	O
(	O	O
BRCA2	O	O
)	O	O
.	O	O

Mutation	O	O
analysis	O	O
in	O	O
the	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
genes	O	O
was	O	O
also	O	O
undertaken	O	O
in	O	O
all	O	O
families	O	O
.	O	O

The	O	O
pattern	O	O
of	O	O
hereditary	B-Disease	D009386
cancer	I-Disease	D009386
in	O	O
14	O	O
(	O	O
61	O	O
%	O	O
)	O	O
of	O	O
the	O	O
23	O	O
families	O	O
studied	O	O
was	O	O
attributed	O	O
to	O	O
BRCA1	O	O
by	O	O
a	O	O
combination	O	O
of	O	O
linkage	O	O
and	O	O
mutation	O	O
analyses	O	O
.	O	O

No	O	O
families	O	O
were	O	O
attributed	O	O
to	O	O
BRCA2	O	O
.	O	O

Five	O	O
families	O	O
(	O	O
22	O	O
%	O	O
)	O	O
provided	O	O
evidence	O	O
against	O	O
linkage	O	O
to	O	O
both	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
.	O	O

No	O	O
BRCA1	O	O
or	O	O
BRCA2	O	O
mutations	O	O
were	O	O
detected	O	O
in	O	O
these	O	O
five	O	O
families	O	O
.	O	O

The	O	O
BRCA1	O	O
or	O	O
BRCA2	O	O
status	O	O
of	O	O
four	O	O
families	O	O
(	O	O
17	O	O
%	O	O
)	O	O
could	O	O
not	O	O
be	O	O
determined	O	O
.	O	O

BRCA1	O	O
and	O	O
BRCA2	O	O
probably	O	O
explain	O	O
the	O	O
majority	O	O
of	O	O
hereditary	B-Disease	D061325
breast	I-Disease	D061325
cancer	I-Disease	D061325
that	O	O
exists	O	O
in	O	O
the	O	O
North	O	O
American	O	O
population	O	O
.	O	O

However	O	O
,	O	O
one	O	O
or	O	O
more	O	O
additional	O	O
genes	O	O
may	O	O
yet	O	O
be	O	O
found	O	O
that	O	O
explain	O	O
some	O	O
proportion	O	O
of	O	O
hereditary	B-Disease	D061325
breast	I-Disease	D061325
cancer	I-Disease	D061325
.	O	O

.	O	O

The	O	O
tumor	B-Disease	D009369
suppressor	O	O
gene	O	O
Brca1	O	O
is	O	O
required	O	O
for	O	O
embryonic	O	O
cellular	O	O
proliferation	O	O
in	O	O
the	O	O
mouse	O	O
.	O	O

Mutations	O	O
of	O	O
the	O	O
BRCA1	O	O
gone	O	O
in	O	O
humans	O	O
are	O	O
associated	O	O
with	O	O
predisposition	O	O
to	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
ovarian	I-Disease	D001943
cancers	I-Disease	D001943
.	O	O

We	O	O
show	O	O
here	O	O
that	O	O
Brca1	O	O
+	O	O
/	O	O
-	O	O
mice	O	O
are	O	O
normal	O	O
and	O	O
fertile	O	O
and	O	O
lack	O	O
tumors	B-Disease	D009369
by	O	O
age	O	O
eleven	O	O
months	O	O
.	O	O

Homozygous	O	O
Brca1	O	O
(	O	O
5	O	O
-	O	O
6	O	O
)	O	O
mutant	O	O
mice	O	O
die	O	O
before	O	O
day	O	O
7	O	O
.	O	O

5	O	O
of	O	O
embryogenesis	O	O
.	O	O

Mutant	O	O
embryos	O	O
are	O	O
poorly	O	O
developed	O	O
,	O	O
with	O	O
no	O	O
evidence	O	O
of	O	O
mesoderm	O	O
formation	O	O
.	O	O

The	O	O
extraembryonic	O	O
region	O	O
is	O	O
abnormal	O	O
,	O	O
but	O	O
aggregation	O	O
with	O	O
wild	O	O
-	O	O
type	O	O
tetraploid	O	O
embryos	O	O
does	O	O
not	O	O
rescue	O	O
the	O	O
lethality	O	O
.	O	O

In	O	O
vivo	O	O
,	O	O
mutant	O	O
embryos	O	O
do	O	O
not	O	O
exhibit	O	O
increased	O	O
apoptosis	O	O
but	O	O
show	O	O
reduced	O	O
cell	O	O
proliferation	O	O
accompanied	O	O
by	O	O
decreased	O	O
expression	O	O
of	O	O
cyclin	O	O
E	O	O
and	O	O
mdm	O	O
-	O	O
2	O	O
,	O	O
a	O	O
regulator	O	O
of	O	O
p53	O	O
activity	O	O
.	O	O

The	O	O
expression	O	O
of	O	O
cyclin	O	O
-	O	O
dependent	O	O
kinase	O	O
inhibitor	O	O
p21	O	O
is	O	O
dramatically	O	O
increased	O	O
in	O	O
the	O	O
mutant	O	O
embryos	O	O
.	O	O

Buttressing	O	O
these	O	O
in	O	O
vivo	O	O
observations	O	O
is	O	O
the	O	O
fact	O	O
that	O	O
mutant	O	O
blastocyst	O	O
growth	O	O
is	O	O
grossly	O	O
impaired	O	O
in	O	O
vitro	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
death	O	O
of	O	O
Brca1	O	O
(	O	O
5	O	O
-	O	O
6	O	O
)	O	O
mutant	O	O
embryos	O	O
prior	O	O
to	O	O
gastrulation	O	O
may	O	O
be	O	O
due	O	O
to	O	O
a	O	O
failure	O	O
of	O	O
the	O	O
proliferative	O	O
burst	O	O
required	O	O
for	O	O
the	O	O
development	O	O
of	O	O
the	O	O
different	O	O
germ	O	O
layers	O	O
.	O	O

Fusion	O	O
genes	O	O
resulting	O	O
from	O	O
alternative	O	O
chromosomal	O	O
translocations	O	O
are	O	O
overexpressed	O	O
by	O	O
gene	O	O
-	O	O
specific	O	O
mechanisms	O	O
in	O	O
alveolar	B-Disease	D018232
rhabdomyosarcoma	I-Disease	D018232
.	O	O

Chromosomal	O	O
translocations	O	O
identified	O	O
in	O	O
hematopoietic	B-Disease	D019337
and	I-Disease	D019337
solid	I-Disease	D019337
tumors	I-Disease	D019337
result	O	O
in	O	O
deregulated	O	O
expression	O	O
of	O	O
protooncogenes	O	O
or	O	O
creation	O	O
of	O	O
chimeric	O	O
proteins	O	O
with	O	O
tumorigenic	O	O
potential	O	O
.	O	O

In	O	O
the	O	O
pediatric	O	O
solid	B-Disease	D009369
tumor	I-Disease	D009369
alveolar	B-Disease	D018232
rhabdomyosarcoma	I-Disease	D018232
,	O	O
a	O	O
consistent	O	O
t	O	O
(	O	O
2	O	O
;	O	O
13	O	O
)	O	O
(	O	O
q35	O	O
;	O	O
q14	O	O
)	O	O
or	O	O
variant	O	O
t	O	O
(	O	O
1	O	O
;	O	O
13	O	O
)	O	O
(	O	O
p36	O	O
;	O	O
q14	O	O
)	O	O
translocation	O	O
generates	O	O
PAX3	O	O
-	O	O
FKHR	O	O
or	O	O
PAX7	O	O
-	O	O
FKHR	O	O
fusion	O	O
proteins	O	O
,	O	O
respectively	O	O
.	O	O

In	O	O
this	O	O
report	O	O
,	O	O
we	O	O
demonstrate	O	O
that	O	O
in	O	O
addition	O	O
to	O	O
functional	O	O
alterations	O	O
these	O	O
translocations	O	O
are	O	O
associated	O	O
with	O	O
fusion	O	O
product	O	O
overexpression	O	O
.	O	O

Furthermore	O	O
,	O	O
PAX3	O	O
-	O	O
FKHR	O	O
and	O	O
PAX7	O	O
-	O	O
FKHR	O	O
overexpression	O	O
occurs	O	O
by	O	O
distinct	O	O
mechanisms	O	O
.	O	O

Transcription	O	O
of	O	O
PAX3	O	O
-	O	O
FKHR	O	O
is	O	O
increased	O	O
relative	O	O
to	O	O
wild	O	O
-	O	O
type	O	O
PAX3	O	O
by	O	O
a	O	O
copy	O	O
number	O	O
-	O	O
independent	O	O
process	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
PAX7	O	O
-	O	O
FKHR	O	O
overexpression	O	O
results	O	O
from	O	O
fusion	O	O
gene	O	O
amplification	O	O
.	O	O

Thus	O	O
,	O	O
gene	O	O
-	O	O
specific	O	O
mechanisms	O	O
were	O	O
selected	O	O
to	O	O
overexpress	O	O
PAX3	O	O
-	O	O
FKHR	O	O
and	O	O
PAX7	O	O
-	O	O
FKHR	O	O
in	O	O
alveolar	B-Disease	D018232
rhabdomyosarcoma	I-Disease	D018232
,	O	O
presumably	O	O
due	O	O
to	O	O
differences	O	O
in	O	O
regulation	O	O
between	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
loci	O	O
.	O	O

We	O	O
postulate	O	O
that	O	O
these	O	O
overexpression	O	O
mechanisms	O	O
ensure	O	O
a	O	O
critical	O	O
level	O	O
of	O	O
gene	O	O
product	O	O
for	O	O
the	O	O
oncogenic	O	O
effects	O	O
of	O	O
these	O	O
fusions	O	O
.	O	O

.	O	O

Pleiotropic	O	O
defects	O	O
in	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
protein	O	O
-	O	O
deficient	O	O
mice	O	O
.	O	O

We	O	O
have	O	O
generated	O	O
a	O	O
mouse	O	O
model	O	O
for	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
by	O	O
using	O	O
gene	O	O
targeting	O	O
to	O	O
generate	O	O
mice	O	O
that	O	O
do	O	O
not	O	O
express	O	O
the	O	O
Atm	O	O
protein	O	O
.	O	O

Atm	O	O
-	O	O
deficient	O	O
mice	O	O
are	O	O
retarded	O	O
in	O	O
growth	O	O
,	O	O
do	O	O
not	O	O
produce	O	O
mature	O	O
sperm	O	O
,	O	O
and	O	O
exhibit	O	O
severe	O	O
defects	O	O
in	O	O
T	O	O
cell	O	O
maturation	O	O
while	O	O
going	O	O
on	O	O
to	O	O
develop	O	O
thymomas	B-Disease	D013945
.	O	O

Atm	O	O
-	O	O
deficient	O	O
fibroblasts	O	O
grow	O	O
poorly	O	O
in	O	O
culture	O	O
and	O	O
display	O	O
a	O	O
high	O	O
level	O	O
of	O	O
double	O	O
-	O	O
stranded	O	O
chromosome	O	O
breaks	O	O
.	O	O

Atm	O	O
-	O	O
deficient	O	O
thymocytes	O	O
undergo	O	O
spontaneous	O	O
apoptosis	O	O
in	O	O
vitro	O	O
significantly	O	O
more	O	O
than	O	O
controls	O	O
.	O	O

Atm	O	O
-	O	O
deficient	O	O
mice	O	O
then	O	O
exhibit	O	O
many	O	O
of	O	O
the	O	O
same	O	O
symptoms	O	O
found	O	O
in	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
patients	O	O
and	O	O
in	O	O
cells	O	O
derived	O	O
from	O	O
them	O	O
.	O	O

Furthermore	O	O
,	O	O
we	O	O
demonstrate	O	O
that	O	O
the	O	O
Atm	O	O
protein	O	O
exists	O	O
as	O	O
two	O	O
discrete	O	O
molecular	O	O
species	O	O
,	O	O
and	O	O
that	O	O
loss	O	O
of	O	O
one	O	O
or	O	O
of	O	O
both	O	O
of	O	O
these	O	O
can	O	O
lead	O	O
to	O	O
the	O	O
development	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

.	O	O

Muscle	O	O
expression	O	O
of	O	O
glucose	B-Disease	D005955
-	I-Disease	D005955
6	I-Disease	D005955
-	I-Disease	D005955
phosphate	I-Disease	D005955
dehydrogenase	I-Disease	D005955
deficiency	I-Disease	D005955
in	O	O
different	O	O
variants	O	O
.	O	O

Muscle	O	O
expression	O	O
of	O	O
G6PD	B-Disease	D005955
deficiency	I-Disease	D005955
has	O	O
been	O	O
investigated	O	O
in	O	O
Mediterranean	O	O
,	O	O
Seattle	O	O
-	O	O
like	O	O
and	O	O
A	O	O
-	O	O
variants	O	O
.	O	O

G6PD	O	O
activity	O	O
was	O	O
detected	O	O
in	O	O
samples	O	O
obtained	O	O
from	O	O
biopsies	O	O
on	O	O
the	O	O
quadriceps	O	O
muscle	O	O
of	O	O
seven	O	O
males	O	O
and	O	O
one	O	O
female	O	O
.	O	O

The	O	O
type	O	O
of	O	O
genetic	O	O
variant	O	O
was	O	O
determined	O	O
by	O	O
molecular	O	O
analysis	O	O
of	O	O
DNA	O	O
,	O	O
extracted	O	O
from	O	O
blood	O	O
samples	O	O
.	O	O

All	O	O
variants	O	O
showed	O	O
the	O	O
enzyme	O	O
defect	O	O
in	O	O
muscle	O	O
.	O	O

A	O	O
statistically	O	O
significant	O	O
relationship	O	O
was	O	O
found	O	O
in	O	O
the	O	O
activity	O	O
of	O	O
G6PD	O	O
between	O	O
erythrocytes	O	O
and	O	O
muscle	O	O
of	O	O
the	O	O
male	O	O
subjects	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

968	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O

00008	O	O
)	O	O
.	O	O

The	O	O
equation	O	O
for	O	O
the	O	O
best	O	O
fit	O	O
line	O	O
was	O	O
Y	O	O
=	O	O
0	O	O
.	O	O

390X	O	O
+	O	O
0	O	O
.	O	O

198	O	O
198	O	O
.	O	O

The	O	O
results	O	O
suggest	O	O
that	O	O
,	O	O
for	O	O
a	O	O
given	O	O
variant	O	O
,	O	O
the	O	O
extent	O	O
of	O	O
the	O	O
enzyme	O	O
defect	O	O
in	O	O
muscle	O	O
may	O	O
be	O	O
determined	O	O
,	O	O
using	O	O
this	O	O
equation	O	O
,	O	O
from	O	O
the	O	O
G6PD	O	O
activity	O	O
of	O	O
erythrocytes	O	O
PTEN	O	O
,	O	O
a	O	O
putative	O	O
protein	O	O
tyrosine	O	O
phosphatase	O	O
gene	O	O
mutated	O	O
in	O	O
human	O	O
brain	B-Disease	D001932
,	I-Disease	D001932
breast	I-Disease	D001932
,	I-Disease	D001932
and	I-Disease	D001932
prostate	I-Disease	D001932
cancer	I-Disease	D001932
.	O	O

Mapping	O	O
of	O	O
homozygous	O	O
deletions	O	O
on	O	O
human	O	O
chromosome	O	O
10q23	O	O
has	O	O
led	O	O
to	O	O
the	O	O
isolation	O	O
of	O	O
a	O	O
candidate	O	O
tumor	B-Disease	D009369
suppressor	O	O
gene	O	O
,	O	O
PTEN	O	O
,	O	O
that	O	O
appears	O	O
to	O	O
be	O	O
mutated	O	O
at	O	O
considerable	O	O
frequency	O	O
in	O	O
human	O	O
cancers	B-Disease	D009369
.	O	O

In	O	O
preliminary	O	O
screens	O	O
,	O	O
mutations	O	O
of	O	O
PTEN	O	O
were	O	O
detected	O	O
in	O	O
31	O	O
%	O	O
(	O	O
13	O	O
/	O	O
42	O	O
)	O	O
of	O	O
glioblastoma	B-Disease	D005909
cell	O	O
lines	O	O
and	O	O
xenografts	O	O
,	O	O
100	O	O
%	O	O
(	O	O
4	O	O
/	O	O
4	O	O
)	O	O
of	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
cell	O	O
lines	O	O
,	O	O
6	O	O
%	O	O
(	O	O
4	O	O
/	O	O
65	O	O
)	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
cell	O	O
lines	O	O
and	O	O
xenografts	O	O
,	O	O
and	O	O
17	O	O
%	O	O
(	O	O
3	O	O
/	O	O
18	O	O
)	O	O
of	O	O
primary	B-Disease	D005909
glioblastomas	I-Disease	D005909
.	O	O

The	O	O
predicted	O	O
PTEN	O	O
product	O	O
has	O	O
a	O	O
protein	O	O
tyrosine	O	O
phosphatase	O	O
domain	O	O
and	O	O
extensive	O	O
homology	O	O
to	O	O
tensin	O	O
,	O	O
a	O	O
protein	O	O
that	O	O
interacts	O	O
with	O	O
actin	O	O
filaments	O	O
at	O	O
focal	O	O
adhesions	O	O
.	O	O

These	O	O
homologies	O	O
suggest	O	O
that	O	O
PTEN	O	O
may	O	O
suppress	O	O
tumor	B-Disease	D009369
cell	O	O
growth	O	O
by	O	O
antagonizing	O	O
protein	O	O
tyrosine	O	O
kinases	O	O
and	O	O
may	O	O
regulate	O	O
tumor	B-Disease	D009369
cell	O	O
invasion	O	O
and	O	O
metastasis	B-Disease	D009362
through	O	O
interactions	O	O
at	O	O
focal	O	O
adhesions	O	O
.	O	O

.	O	O

Somatic	O	O
alterations	O	O
of	O	O
the	O	O
DPC4	O	O
gene	O	O
in	O	O
human	O	O
colorectal	B-Disease	D015179
cancers	I-Disease	D015179
in	O	O
vivo	O	O
.	O	O

BACKGROUND	O	O
&	O	O
AIMS	O	O
The	O	O
chromosome	O	O
region	O	O
18q21	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
frequently	O	O
deleted	O	O
in	O	O
colorectal	B-Disease	D015179
cancers	I-Disease	D015179
,	O	O
and	O	O
such	O	O
frequent	O	O
allelic	O	O
loss	O	O
is	O	O
a	O	O
hallmark	O	O
of	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
tumor	O	O
-	O	O
suppressor	O	O
gene	O	O
.	O	O

The	O	O
DPC4	O	O
gene	O	O
,	O	O
which	O	O
is	O	O
located	O	O
at	O	O
18q21	O	O
,	O	O
has	O	O
been	O	O
identified	O	O
as	O	O
a	O	O
tumor	O	O
-	O	O
suppressor	O	O
gene	O	O
from	O	O
examination	O	O
of	O	O
pancreatic	B-Disease	D010190
cancers	I-Disease	D010190
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
if	O	O
it	O	O
might	O	O
also	O	O
be	O	O
altered	O	O
in	O	O
colorectal	B-Disease	D015179
cancers	I-Disease	D015179
.	O	O

METHODS	O	O
Mutation	O	O
analyses	O	O
of	O	O
the	O	O
DPC4	O	O
gene	O	O
were	O	O
performed	O	O
on	O	O
complementary	O	O
DNA	O	O
samples	O	O
from	O	O
31	O	O
primary	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
specimens	O	O
using	O	O
a	O	O
combination	O	O
of	O	O
polymerase	O	O
chain	O	O
reaction	O	O
,	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
,	O	O
and	O	O
DNA	O	O
sequencing	O	O
.	O	O

RESULTS	O	O
Four	O	O
missense	O	O
mutations	O	O
producing	O	O
amino	O	O
acid	O	O
substitutions	O	O
and	O	O
a	O	O
somatic	O	O
12	O	O
-	O	O
base	O	O
pair	O	O
deletion	O	O
in	O	O
the	O	O
coding	O	O
region	O	O
of	O	O
the	O	O
DPC4	O	O
gene	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
31	O	O
cancers	B-Disease	D009369
(	O	O
16	O	O
%	O	O
;	O	O
5	O	O
of	O	O
31	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
The	O	O
DPC4	O	O
gene	O	O
may	O	O
play	O	O
a	O	O
role	O	O
as	O	O
a	O	O
tumor	O	O
-	O	O
suppressor	O	O
gene	O	O
in	O	O
a	O	O
fraction	O	O
of	O	O
colorectal	B-Disease	D015179
cancers	I-Disease	D015179
;	O	O
however	O	O
,	O	O
while	O	O
allelic	O	O
loss	O	O
at	O	O
18q21	O	O
is	O	O
very	O	O
often	O	O
seen	O	O
in	O	O
colorectal	B-Disease	D015179
cancers	I-Disease	D015179
,	O	O
only	O	O
a	O	O
minority	O	O
show	O	O
DPC4	O	O
mutations	O	O
,	O	O
suggesting	O	O
that	O	O
there	O	O
might	O	O
be	O	O
another	O	O
tumor	O	O
-	O	O
suppressor	O	O
gene	O	O
in	O	O
this	O	O
chromosome	O	O
region	O	O
.	O	O

.	O	O

Complete	O	O
genomic	O	O
sequence	O	O
and	O	O
analysis	O	O
of	O	O
117	O	O
kb	O	O
of	O	O
human	O	O
DNA	O	O
containing	O	O
the	O	O
gene	O	O
BRCA1	O	O
.	O	O

Over	O	O
100	O	O
distinct	O	O
disease	O	O
-	O	O
associated	O	O
mutations	O	O
have	O	O
been	O	O
identified	O	O
in	O	O
the	O	O
breast	B-Disease	D061325
-	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
susceptibility	O	O
gene	O	O
BRCA1	O	O
.	O	O

Loss	O	O
of	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
allele	O	O
in	O	O
>	O	O
90	O	O
%	O	O
of	O	O
tumors	B-Disease	D009369
from	O	O
patients	O	O
with	O	O
inherited	O	O
BRCA1	O	O
mutations	O	O
indicates	O	O
tumor	B-Disease	D009369
suppressive	O	O
function	O	O
.	O	O

The	O	O
low	O	O
incidence	O	O
of	O	O
somatic	O	O
mutations	O	O
suggests	O	O
that	O	O
BRCA1	O	O
inactivation	O	O
in	O	O
sporadic	O	O
tumors	B-Disease	D009369
occurs	O	O
by	O	O
alternative	O	O
mechanisms	O	O
,	O	O
such	O	O
as	O	O
interstitial	O	O
chromosomal	O	O
deletion	O	O
or	O	O
reduced	O	O
transcription	O	O
.	O	O

To	O	O
identify	O	O
possible	O	O
features	O	O
of	O	O
the	O	O
BRCA1	O	O
genomic	O	O
region	O	O
that	O	O
may	O	O
contribute	O	O
to	O	O
chromosomal	O	O
instability	O	O
as	O	O
well	O	O
as	O	O
potential	O	O
transcriptional	O	O
regulatory	O	O
elements	O	O
,	O	O
a	O	O
117	O	O
,	O	O
143	O	O
-	O	O
bp	O	O
DNA	O	O
sequence	O	O
encompassing	O	O
BRCA1	O	O
was	O	O
obtained	O	O
by	O	O
random	O	O
sequencing	O	O
of	O	O
four	O	O
cosmids	O	O
identified	O	O
from	O	O
a	O	O
human	O	O
chromosome	O	O
17	O	O
specific	O	O
library	O	O
.	O	O

The	O	O
24	O	O
exons	O	O
of	O	O
BRCA1	O	O
span	O	O
an	O	O
81	O	O
-	O	O
kb	O	O
region	O	O
that	O	O
has	O	O
an	O	O
unusually	O	O
high	O	O
density	O	O
of	O	O
Alu	O	O
repetitive	O	O
DNA	O	O
(	O	O
41	O	O
.	O	O

5	O	O
%	O	O
)	O	O
,	O	O
but	O	O
relatively	O	O
low	O	O
density	O	O
(	O	O
4	O	O
.	O	O

8	O	O
%	O	O
)	O	O
of	O	O
other	O	O
repetitive	O	O
sequences	O	O
.	O	O

BRCA1	O	O
intron	O	O
lengths	O	O
range	O	O
in	O	O
size	O	O
from	O	O
403	O	O
bp	O	O
to	O	O
9	O	O
.	O	O

2	O	O
kb	O	O
and	O	O
contain	O	O
the	O	O
intragenic	O	O
microsatellite	O	O
markers	O	O
D17S1323	O	O
,	O	O
D17S1322	O	O
,	O	O
and	O	O
D17S855	O	O
,	O	O
which	O	O
localize	O	O
to	O	O
introns	O	O
12	O	O
,	O	O
19	O	O
,	O	O
and	O	O
20	O	O
,	O	O
respectively	O	O
.	O	O

In	O	O
addition	O	O
to	O	O
BRCA1	O	O
,	O	O
the	O	O
contig	O	O
contains	O	O
two	O	O
complete	O	O
genes	O	O
Rho7	O	O
,	O	O
a	O	O
member	O	O
of	O	O
the	O	O
rho	O	O
family	O	O
of	O	O
GTP	O	O
binding	O	O
proteins	O	O
,	O	O
and	O	O
VAT1	O	O
,	O	O
an	O	O
abundant	O	O
membrane	O	O
protein	O	O
of	O	O
cholinergic	O	O
synaptic	O	O
vesicles	O	O
.	O	O

Partial	O	O
sequences	O	O
of	O	O
the	O	O
1A1	O	O
-	O	O
3B	O	O
B	O	O
-	O	O
box	O	O
protein	O	O
pseudogene	O	O
and	O	O
IFP	O	O
35	O	O
,	O	O
an	O	O
interferon	O	O
induced	O	O
leucine	O	O
zipper	O	O
protein	O	O
,	O	O
reside	O	O
within	O	O
the	O	O
contig	O	O
.	O	O

An	O	O
L21	O	O
ribosomal	O	O
protein	O	O
pseudogene	O	O
is	O	O
embedded	O	O
in	O	O
BRCA1	O	O
intron	O	O
13	O	O
.	O	O

The	O	O
order	O	O
of	O	O
genes	O	O
on	O	O
the	O	O
chromosome	O	O
is	O	O
centromere	O	O
-	O	O
1FP	O	O
35	O	O
-	O	O
VAT1	O	O
-	O	O
Rho7	O	O
-	O	O
BRCA1	O	O
-	O	O
1A1	O	O
-	O	O
3B	O	O
-	O	O
telomere	O	O
Type	B-Disease	OMIM:217000
II	I-Disease	OMIM:217000
human	I-Disease	OMIM:217000
complement	I-Disease	OMIM:217000
C2	I-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
.	O	O

Allele	O	O
-	O	O
specific	O	O
amino	O	O
acid	O	O
substitutions	O	O
(	O	O
Ser189	O	O
-	O	O
-	O	O
>	O	O
Phe	O	O
;	O	O
Gly444	O	O
-	O	O
-	O	O
>	O	O
Arg	O	O
)	O	O
cause	O	O
impaired	O	O
C2	O	O
secretion	O	O
.	O	O

Type	B-Disease	OMIM:217000
II	I-Disease	OMIM:217000
complement	I-Disease	OMIM:217000
protein	I-Disease	OMIM:217000
C2	I-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
is	O	O
characterized	O	O
by	O	O
a	O	O
selective	O	O
block	O	O
in	O	O
C2	O	O
secretion	O	O
.	O	O

The	O	O
Type	O	O
II	O	O
C2	O	O
null	O	O
allele	O	O
(	O	O
C2Q0	O	O
)	O	O
is	O	O
linked	O	O
to	O	O
two	O	O
major	O	O
histocompatibility	O	O
haplotypes	O	O
(	O	O
MHC	O	O
)	O	O
that	O	O
differ	O	O
from	O	O
the	O	O
MHC	O	O
of	O	O
the	O	O
more	O	O
common	O	O
Type	B-Disease	OMIM:217000
I	I-Disease	OMIM:217000
C2	I-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
.	O	O

To	O	O
determine	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
Type	B-Disease	OMIM:217000
II	I-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
the	O	O
two	O	O
Type	O	O
II	O	O
C2Q0	O	O
genes	O	O
were	O	O
isolated	O	O
and	O	O
transfected	O	O
separately	O	O
into	O	O
L	O	O
-	O	O
cells	O	O
.	O	O

Subsequent	O	O
molecular	O	O
biology	O	O
,	O	O
biosynthetic	O	O
,	O	O
and	O	O
immunofluorescence	O	O
studies	O	O
demonstrated	O	O
that	O	O
C2	O	O
secretion	O	O
is	O	O
impaired	O	O
in	O	O
Type	B-Disease	OMIM:217000
II	I-Disease	OMIM:217000
C2	I-Disease	OMIM:217000
deficiency	I-Disease	OMIM:217000
because	O	O
of	O	O
different	O	O
missense	O	O
mutations	O	O
at	O	O
highly	O	O
conserved	O	O
residues	O	O
in	O	O
each	O	O
of	O	O
the	O	O
C2Q0	O	O
alleles	O	O
.	O	O

One	O	O
is	O	O
in	O	O
exon	O	O
5	O	O
(	O	O
nucleotide	O	O
C566	O	O
-	O	O
-	O	O
>	O	O
T	O	O
;	O	O
Ser189	O	O
-	O	O
-	O	O
>	O	O
Phe	O	O
)	O	O
of	O	O
the	O	O
C2Q0	O	O
gene	O	O
linked	O	O
to	O	O
the	O	O
MHC	O	O
haplotype	O	O
A11	O	O
,	O	O
B35	O	O
,	O	O
DRw1	O	O
,	O	O
BFS	O	O
,	O	O
C4A0B1	O	O
.	O	O

The	O	O
other	O	O
is	O	O
in	O	O
exon	O	O
11	O	O
(	O	O
G1930	O	O
-	O	O
-	O	O
>	O	O
A	O	O
;	O	O
Gly444	O	O
-	O	O
-	O	O
>	O	O
Arg	O	O
)	O	O
of	O	O
the	O	O
C2Q0	O	O
gene	O	O
linked	O	O
to	O	O
the	O	O
MHC	O	O
haplotype	O	O
A2	O	O
,	O	O
B5	O	O
,	O	O
DRw4	O	O
,	O	O
BFS	O	O
,	O	O
C4A3B1	O	O
.	O	O

Each	O	O
mutant	O	O
C2	O	O
gene	O	O
product	O	O
is	O	O
retained	O	O
early	O	O
in	O	O
the	O	O
secretory	O	O
pathway	O	O
.	O	O

These	O	O
mutants	O	O
provide	O	O
models	O	O
for	O	O
elucidating	O	O
the	O	O
C2	O	O
secretory	O	O
pathway	O	O
.	O	O

.	O	O

Targeted	O	O
disruption	O	O
of	O	O
ATM	O	O
leads	O	O
to	O	O
growth	B-Disease	D006130
retardation	I-Disease	D006130
,	O	O
chromosomal	B-Disease	D048629
fragmentation	I-Disease	D048629
during	I-Disease	D048629
meiosis	I-Disease	D048629
,	O	O
immune	B-Disease	D007154
defects	I-Disease	D007154
,	O	O
and	O	O
thymic	B-Disease	D013953
lymphoma	I-Disease	D013953
.	O	O

ATM	O	O
,	O	O
the	O	O
gene	O	O
mutated	O	O
in	O	O
the	O	O
inherited	B-Disease	D030342
human	I-Disease	D030342
disease	I-Disease	D030342
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
,	O	O
is	O	O
a	O	O
member	O	O
of	O	O
a	O	O
family	O	O
of	O	O
kinases	O	O
involved	O	O
in	O	O
DNA	O	O
metabolism	O	O
and	O	O
cell	O	O
-	O	O
cycle	O	O
checkpoint	O	O
control	O	O
.	O	O

To	O	O
help	O	O
clarify	O	O
the	O	O
physiological	O	O
roles	O	O
of	O	O
the	O	O
ATM	O	O
protein	O	O
,	O	O
we	O	O
disrupted	O	O
the	O	O
ATM	O	O
gene	O	O
in	O	O
mice	O	O
through	O	O
homologous	O	O
recombination	O	O
.	O	O

Initial	O	O
evaluation	O	O
of	O	O
the	O	O
ATM	O	O
knockout	O	O
animals	O	O
indicates	O	O
that	O	O
inactivation	O	O
of	O	O
the	O	O
mouse	O	O
ATM	O	O
gene	O	O
recreates	O	O
much	O	O
of	O	O
the	O	O
phenotype	O	O
of	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
.	O	O

The	O	O
homozygous	O	O
mutant	O	O
(	O	O
ATM	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
are	O	O
viable	O	O
,	O	O
growth	O	O
-	O	O
retarded	O	O
,	O	O
and	O	O
infertile	O	O
.	O	O

The	O	O
infertility	B-Disease	D007246
of	O	O
ATM	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
results	O	O
from	O	O
meiotic	O	O
failure	O	O
.	O	O

Meiosis	O	O
is	O	O
arrested	O	O
at	O	O
the	O	O
zygotene	O	O
/	O	O
pachytene	O	O
stage	O	O
of	O	O
prophase	O	O
I	O	O
as	O	O
a	O	O
result	O	O
of	O	O
abnormal	O	O
chromosomal	O	O
synapsis	O	O
and	O	O
subsequent	O	O
chromosome	O	O
fragmentation	O	O
.	O	O

Immune	B-Disease	D007154
defects	I-Disease	D007154
also	O	O
are	O	O
evident	O	O
in	O	O
ATM	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
,	O	O
including	O	O
reduced	O	O
numbers	O	O
of	O	O
B220	O	O
+	O	O
CD43	O	O
-	O	O
pre	O	O
-	O	O
B	O	O
cells	O	O
,	O	O
thymocytes	O	O
,	O	O
and	O	O
peripheral	O	O
T	O	O
cells	O	O
,	O	O
as	O	O
well	O	O
as	O	O
functional	O	O
impairment	O	O
of	O	O
T	O	O
-	O	O
cell	O	O
-	O	O
dependent	O	O
immune	O	O
responses	O	O
.	O	O

The	O	O
cerebella	O	O
of	O	O
ATM	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
appear	O	O
normal	O	O
by	O	O
histologic	O	O
examination	O	O
at	O	O
3	O	O
to	O	O
4	O	O
months	O	O
and	O	O
the	O	O
mice	O	O
have	O	O
no	O	O
gross	O	O
behavioral	B-Disease	D001523
abnormalities	I-Disease	D001523
.	O	O

The	O	O
majority	O	O
of	O	O
mutant	O	O
mice	O	O
rapidly	O	O
develop	O	O
thymic	B-Disease	D008223
lymphomas	I-Disease	D008223
and	O	O
die	O	O
before	O	O
4	O	O
months	O	O
of	O	O
age	O	O
.	O	O

These	O	O
findings	O	O
indicate	O	O
that	O	O
the	O	O
ATM	O	O
gene	O	O
product	O	O
plays	O	O
an	O	O
essential	O	O
role	O	O
in	O	O
a	O	O
diverse	O	O
group	O	O
of	O	O
cellular	O	O
processes	O	O
,	O	O
including	O	O
meiosis	O	O
,	O	O
the	O	O
normal	O	O
growth	O	O
of	O	O
somatic	O	O
tissues	O	O
,	O	O
immune	O	O
development	O	O
,	O	O
and	O	O
tumor	B-Disease	D009369
suppression	O	O
.	O	O

.	O	O

The	O	O
5	O	O
'	O	O
end	O	O
of	O	O
the	O	O
BRCA1	O	O
gene	O	O
lies	O	O
within	O	O
a	O	O
duplicated	O	O
region	O	O
of	O	O
human	O	O
chromosome	O	O
17q21	O	O
.	O	O

To	O	O
begin	O	O
to	O	O
address	O	O
the	O	O
hypothesis	O	O
that	O	O
abnormal	O	O
regulation	O	O
of	O	O
the	O	O
breast	B-Disease	D061325
/	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
susceptibility	O	O
gene	O	O
BRCA1	O	O
is	O	O
a	O	O
critical	O	O
step	O	O
in	O	O
sporadic	O	O
breast	O	O
/	O	O
ovarian	O	O
tumorigenesis	O	O
,	O	O
we	O	O
have	O	O
determined	O	O
the	O	O
detailed	O	O
structure	O	O
of	O	O
the	O	O
BRCA1	O	O
genomic	O	O
region	O	O
.	O	O

We	O	O
show	O	O
that	O	O
this	O	O
region	O	O
of	O	O
the	O	O
genome	O	O
contains	O	O
a	O	O
tandem	O	O
duplication	O	O
of	O	O
approximately	O	O
30	O	O
kilobases	O	O
,	O	O
which	O	O
results	O	O
in	O	O
two	O	O
copies	O	O
of	O	O
BRCA1	O	O
exons	O	O
1	O	O
and	O	O
2	O	O
,	O	O
of	O	O
exons	O	O
1	O	O
and	O	O
3	O	O
of	O	O
the	O	O
adjacent	O	O
1A1	O	O
-	O	O
3B	O	O
gene	O	O
and	O	O
of	O	O
the	O	O
previously	O	O
reported	O	O
295	O	O
base	O	O
pair	O	O
intergenic	O	O
region	O	O
.	O	O

Sequence	O	O
analysis	O	O
of	O	O
the	O	O
duplicated	O	O
exons	O	O
of	O	O
BRCA1	O	O
and	O	O
1A1	O	O
-	O	O
3B	O	O
and	O	O
flanking	O	O
genomic	O	O
DNA	O	O
reveals	O	O
maintenance	O	O
of	O	O
the	O	O
intron	O	O
-	O	O
exon	O	O
structure	O	O
and	O	O
a	O	O
high	O	O
degree	O	O
of	O	O
nucleotide	O	O
sequence	O	O
identity	O	O
,	O	O
suggesting	O	O
that	O	O
these	O	O
are	O	O
non	O	O
-	O	O
processed	O	O
pseudogenes	O	O
and	O	O
that	O	O
the	O	O
duplication	O	O
is	O	O
a	O	O
recent	O	O
event	O	O
in	O	O
evolutionary	O	O
terms	O	O
.	O	O

We	O	O
also	O	O
show	O	O
that	O	O
a	O	O
processed	O	O
pseudogene	O	O
of	O	O
the	O	O
acidic	O	O
ribosomal	O	O
phosphoprotein	O	O
P1	O	O
(	O	O
ARPP1	O	O
)	O	O
is	O	O
inserted	O	O
directly	O	O
upstream	O	O
of	O	O
pseudo	O	O
-	O	O
BRCA1	O	O
exon	O	O
1A	O	O
.	O	O

We	O	O
believe	O	O
that	O	O
these	O	O
findings	O	O
could	O	O
not	O	O
only	O	O
confound	O	O
BRCA1	O	O
mutation	O	O
analysis	O	O
,	O	O
but	O	O
could	O	O
have	O	O
implications	O	O
for	O	O
the	O	O
normal	O	O
and	O	O
abnormal	O	O
regulation	O	O
of	O	O
BRCA1	O	O
transcription	O	O
,	O	O
translation	O	O
and	O	O
function	O	O
.	O	O

.	O	O

atm	O	O
and	O	O
p53	O	O
cooperate	O	O
in	O	O
apoptosis	O	O
and	O	O
suppression	O	O
of	O	O
tumorigenesis	O	O
,	O	O
but	O	O
not	O	O
in	O	O
resistance	O	O
to	O	O
acute	B-Disease	D054508
radiation	I-Disease	D054508
toxicity	I-Disease	D054508
.	O	O

Mutations	O	O
in	O	O
atm	O	O
and	O	O
p53	O	O
cause	O	O
the	O	O
human	O	O
cancer	B-Disease	D009369
-	I-Disease	D009369
associated	I-Disease	D009369
diseases	I-Disease	D009369
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
and	O	O
Li	B-Disease	D016864
-	I-Disease	D016864
Fraumeni	I-Disease	D016864
syndrome	I-Disease	D016864
,	O	O
respectively	O	O
.	O	O

The	O	O
two	O	O
genes	O	O
are	O	O
believed	O	O
to	O	O
interact	O	O
in	O	O
a	O	O
number	O	O
of	O	O
pathways	O	O
,	O	O
including	O	O
regulation	O	O
of	O	O
DNA	O	O
damage	O	O
-	O	O
induced	O	O
cell	O	O
-	O	O
cycle	O	O
checkpoints	O	O
,	O	O
apoptosis	O	O
and	O	O
radiation	O	O
sensitivity	O	O
,	O	O
and	O	O
cellular	O	O
proliferation	O	O
.	O	O

Atm	O	O
-	O	O
null	O	O
mice	O	O
,	O	O
as	O	O
well	O	O
as	O	O
those	O	O
null	O	O
for	O	O
p53	O	O
,	O	O
develop	O	O
mainly	O	O
T	B-Disease	D016399
-	I-Disease	D016399
cell	I-Disease	D016399
lymphomas	I-Disease	D016399
,	O	O
supporting	O	O
the	O	O
view	O	O
that	O	O
these	O	O
genes	O	O
have	O	O
similar	O	O
roles	O	O
in	O	O
thymocyte	O	O
development	O	O
.	O	O

To	O	O
study	O	O
the	O	O
interactions	O	O
of	O	O
these	O	O
two	O	O
genes	O	O
on	O	O
an	O	O
organismal	O	O
level	O	O
,	O	O
we	O	O
bred	O	O
mice	O	O
heterozygous	O	O
for	O	O
null	O	O
alleles	O	O
of	O	O
both	O	O
atm	O	O
and	O	O
p53	O	O
to	O	O
produce	O	O
all	O	O
genotypic	O	O
combinations	O	O
.	O	O

Mice	O	O
doubly	O	O
null	O	O
for	O	O
atm	O	O
and	O	O
p53	O	O
exhibited	O	O
a	O	O
dramatic	O	O
acceleration	O	O
of	O	O
tumour	B-Disease	D009369
formation	O	O
relative	O	O
to	O	O
singly	O	O
null	O	O
mice	O	O
,	O	O
indicating	O	O
that	O	O
both	O	O
genes	O	O
collaborate	O	O
in	O	O
a	O	O
significant	O	O
manner	O	O
to	O	O
prevent	O	O
tumorigenesis	O	O
.	O	O

With	O	O
respect	O	O
to	O	O
their	O	O
roles	O	O
in	O	O
apoptosis	O	O
,	O	O
loss	O	O
of	O	O
atm	O	O
rendered	O	O
thymocytes	O	O
only	O	O
partly	O	O
resistant	O	O
to	O	O
irradiation	O	O
-	O	O
induced	O	O
apoptosis	O	O
,	O	O
whereas	O	O
additional	O	O
loss	O	O
of	O	O
p53	O	O
engendered	O	O
complete	O	O
resistance	O	O
.	O	O

This	O	O
implies	O	O
that	O	O
the	O	O
irradiation	O	O
-	O	O
induced	O	O
atm	O	O
and	O	O
p53	O	O
apoptotic	O	O
pathways	O	O
are	O	O
not	O	O
completely	O	O
congruent	O	O
.	O	O

Finally	O	O
-	O	O
and	O	O
in	O	O
contrast	O	O
to	O	O
prior	O	O
predictions	O	O
-	O	O
atm	O	O
and	O	O
p53	O	O
do	O	O
not	O	O
appear	O	O
to	O	O
interact	O	O
in	O	O
acute	B-Disease	D054508
radiation	I-Disease	D054508
toxicity	I-Disease	D054508
,	O	O
suggesting	O	O
a	O	O
separate	O	O
atm	O	O
effector	O	O
pathway	O	O
for	O	O
this	O	O
DNA	O	O
damage	O	O
response	O	O
and	O	O
having	O	O
implications	O	O
for	O	O
the	O	O
prognosis	O	O
and	O	O
treatment	O	O
of	O	O
human	O	O
tumours	B-Disease	D009369
.	O	O

.	O	O

Molecular	O	O
bases	O	O
of	O	O
C7	B-Disease	OMIM:610102
deficiency	I-Disease	OMIM:610102
:	O	O
three	O	O
different	O	O
defects	O	O
.	O	O

The	O	O
molecular	O	O
basis	O	O
of	O	O
C7	B-Disease	OMIM:610102
deficiency	I-Disease	OMIM:610102
has	O	O
been	O	O
investigated	O	O
in	O	O
two	O	O
Irish	O	O
families	O	O
and	O	O
a	O	O
number	O	O
of	O	O
Israeli	O	O
families	O	O
of	O	O
Moroccan	O	O
Sephardic	O	O
Jewish	O	O
origin	O	O
.	O	O

Exon	O	O
PCR	O	O
and	O	O
sequencing	O	O
revealed	O	O
a	O	O
heterozygous	O	O
point	O	O
mutation	O	O
at	O	O
the	O	O
3	O	O
splice	O	O
acceptor	O	O
site	O	O
of	O	O
intron	O	O
1	O	O
in	O	O
one	O	O
Irish	O	O
family	O	O
.	O	O

In	O	O
the	O	O
other	O	O
Irish	O	O
family	O	O
,	O	O
exons	O	O
7	O	O
and	O	O
8	O	O
failed	O	O
to	O	O
amplify	O	O
and	O	O
they	O	O
were	O	O
shown	O	O
to	O	O
be	O	O
deleted	O	O
.	O	O

Marker	O	O
haplotype	O	O
studies	O	O
of	O	O
the	O	O
C6	O	O
and	O	O
C7	O	O
gene	O	O
region	O	O
and	O	O
Southern	O	O
blots	O	O
show	O	O
that	O	O
the	O	O
Irish	O	O
family	O	O
with	O	O
the	O	O
splice	O	O
defect	O	O
also	O	O
segregate	O	O
for	O	O
the	O	O
deletion	O	O
,	O	O
which	O	O
is	O	O
not	O	O
easily	O	O
detected	O	O
in	O	O
heterozygotes	O	O
.	O	O

The	O	O
Israeli	O	O
C7	B-Disease	OMIM:610102
-	I-Disease	OMIM:610102
deficient	I-Disease	OMIM:610102
cases	O	O
all	O	O
share	O	O
a	O	O
C7	O	O
haplotype	O	O
and	O	O
are	O	O
homozygous	O	O
for	O	O
a	O	O
mis	O	O
-	O	O
sense	O	O
mutation	O	O
in	O	O
exon	O	O
9	O	O
.	O	O

However	O	O
,	O	O
one	O	O
individual	O	O
is	O	O
heterozygous	O	O
for	O	O
markers	O	O
at	O	O
adjacent	O	O
C6	O	O
loci	O	O
,	O	O
showing	O	O
that	O	O
there	O	O
has	O	O
been	O	O
an	O	O
intergenic	O	O
recombination	O	O
and	O	O
suggesting	O	O
that	O	O
the	O	O
deficiency	O	O
mutation	O	O
is	O	O
of	O	O
appreciable	O	O
antiquity	O	O
.	O	O

.	O	O

Identification	O	O
of	O	O
WASP	O	O
mutations	O	O
,	O	O
mutation	O	O
hotspots	O	O
and	O	O
genotype	O	O
-	O	O
phenotype	O	O
disparities	O	O
in	O	O
24	O	O
patients	O	O
with	O	O
the	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
.	O	O

The	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
(	O	O
WAS	B-Disease	D014923
)	O	O
,	O	O
an	O	O
X	B-Disease	D007153	D040181
-	I-Disease	D007153	D040181
linked	I-Disease	D007153	D040181
immunodeficiency	I-Disease	D007153	D040181
disease	I-Disease	D007153	D040181
caused	O	O
by	O	O
mutation	O	O
in	O	O
the	O	O
recently	O	O
isolated	O	O
gene	O	O
encoding	O	O
WAS	B-Disease	D014923
protein	O	O
(	O	O
WASP	O	O
)	O	O
,	O	O
is	O	O
known	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
extensive	O	O
clinical	O	O
heterogeneity	O	O
.	O	O

Cumulative	O	O
mutation	O	O
data	O	O
have	O	O
revealed	O	O
that	O	O
WASP	O	O
genotypes	O	O
are	O	O
also	O	O
highly	O	O
variable	O	O
among	O	O
WAS	B-Disease	D014923
patients	O	O
,	O	O
but	O	O
the	O	O
relationship	O	O
of	O	O
phenotype	O	O
with	O	O
genotype	O	O
in	O	O
this	O	O
disease	O	O
remains	O	O
unclear	O	O
.	O	O

To	O	O
address	O	O
this	O	O
issue	O	O
we	O	O
characterized	O	O
WASP	O	O
mutations	O	O
in	O	O
24	O	O
unrelated	O	O
WAS	B-Disease	D014923
patients	O	O
,	O	O
including	O	O
18	O	O
boys	O	O
with	O	O
severe	O	O
classical	O	O
WAS	B-Disease	D014923
and	O	O
6	O	O
boys	O	O
expressing	O	O
mild	O	O
forms	O	O
of	O	O
the	O	O
disease	O	O
,	O	O
and	O	O
then	O	O
examined	O	O
the	O	O
degree	O	O
of	O	O
correlation	O	O
of	O	O
these	O	O
as	O	O
well	O	O
as	O	O
all	O	O
previously	O	O
published	O	O
WASP	O	O
mutations	O	O
with	O	O
disease	O	O
severity	O	O
.	O	O

By	O	O
analysis	O	O
of	O	O
these	O	O
compiled	O	O
mutation	O	O
data	O	O
,	O	O
we	O	O
demonstrated	O	O
clustering	O	O
of	O	O
WASP	O	O
mutations	O	O
within	O	O
the	O	O
four	O	O
most	O	O
N	O	O
-	O	O
terminal	O	O
exons	O	O
of	O	O
the	O	O
gene	O	O
and	O	O
also	O	O
identified	O	O
several	O	O
sites	O	O
within	O	O
this	O	O
region	O	O
as	O	O
hotspots	O	O
for	O	O
WASP	O	O
mutation	O	O
.	O	O

These	O	O
characteristics	O	O
were	O	O
observed	O	O
,	O	O
however	O	O
,	O	O
in	O	O
both	O	O
severe	O	O
and	O	O
mild	O	O
cases	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

Similarly	O	O
,	O	O
while	O	O
the	O	O
cumulative	O	O
data	O	O
revealed	O	O
a	O	O
predominance	O	O
of	O	O
missense	O	O
mutations	O	O
among	O	O
the	O	O
WASP	O	O
gene	O	O
lesions	O	O
observed	O	O
in	O	O
boys	O	O
with	O	O
isolated	B-Disease	D013921
thrombocytopenia	I-Disease	D013921
,	O	O
missense	O	O
mutations	O	O
were	O	O
not	O	O
exclusively	O	O
associated	O	O
with	O	O
milder	O	O
WAS	B-Disease	D014923
phenotypes	O	O
,	O	O
but	O	O
also	O	O
comprised	O	O
a	O	O
substantial	O	O
portion	O	O
(	O	O
38	O	O
%	O	O
)	O	O
of	O	O
the	O	O
WASP	O	O
gene	O	O
defects	O	O
found	O	O
in	O	O
patients	O	O
with	O	O
severe	O	O
disease	O	O
.	O	O

These	O	O
findings	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
detection	O	O
of	O	O
identical	O	O
WASP	O	O
mutations	O	O
in	O	O
patients	O	O
with	O	O
disparate	O	O
phenotypes	O	O
,	O	O
reveal	O	O
a	O	O
lack	O	O
of	O	O
phenotype	O	O
concordance	O	O
with	O	O
genotype	O	O
in	O	O
WAS	B-Disease	D014923
and	O	O
thus	O	O
imply	O	O
that	O	O
phenotypic	O	O
outcome	O	O
in	O	O
this	O	O
disease	O	O
cannot	O	O
be	O	O
reliably	O	O
predicted	O	O
solely	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
WASP	O	O
genotypes	O	O
.	O	O

.	O	O

Identification	O	O
and	O	O
chromosomal	O	O
localization	O	O
of	O	O
Atm	O	O
,	O	O
the	O	O
mouse	O	O
homolog	O	O
of	O	O
the	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
gene	O	O
.	O	O

Atm	O	O
,	O	O
the	O	O
mouse	O	O
homolog	O	O
of	O	O
the	O	O
human	O	O
ATM	O	O
gene	O	O
defective	O	O
in	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
)	O	O
,	O	O
has	O	O
been	O	O
identified	O	O
.	O	O

The	O	O
entire	O	O
coding	O	O
sequence	O	O
of	O	O
the	O	O
Atm	O	O
transcript	O	O
was	O	O
cloned	O	O
and	O	O
found	O	O
to	O	O
contain	O	O
an	O	O
open	O	O
reading	O	O
frame	O	O
encoding	O	O
a	O	O
protein	O	O
of	O	O
3066	O	O
amino	O	O
acids	O	O
with	O	O
84	O	O
%	O	O
overall	O	O
identity	O	O
and	O	O
91	O	O
%	O	O
similarity	O	O
to	O	O
the	O	O
human	O	O
ATM	O	O
protein	O	O
.	O	O

Variable	O	O
levels	O	O
of	O	O
expression	O	O
of	O	O
Atm	O	O
were	O	O
observed	O	O
in	O	O
different	O	O
tissues	O	O
.	O	O

Fluorescence	O	O
in	O	O
situ	O	O
hybridization	O	O
and	O	O
linkage	O	O
analysis	O	O
located	O	O
the	O	O
Atm	O	O
gene	O	O
on	O	O
mouse	O	O
chromosome	O	O
9	O	O
,	O	O
band	O	O
9C	O	O
,	O	O
in	O	O
a	O	O
region	O	O
homologous	O	O
to	O	O
the	O	O
ATM	O	O
region	O	O
on	O	O
human	O	O
chromosome	O	O
11q22	O	O
-	O	O
q23	O	O
.	O	O

.	O	O

Mutation	O	O
of	O	O
MSH3	O	O
in	O	O
endometrial	B-Disease	D016889
cancer	I-Disease	D016889
and	O	O
evidence	O	O
for	O	O
its	O	O
functional	O	O
role	O	O
in	O	O
heteroduplex	O	O
repair	O	O
.	O	O

Many	O	O
human	O	O
tumours	B-Disease	D009369
have	O	O
length	O	O
alterations	O	O
in	O	O
repetitive	O	O
sequence	O	O
elements	O	O
.	O	O

Although	O	O
this	O	O
microsatellite	B-Disease	D053842
instability	I-Disease	D053842
has	O	O
been	O	O
attributed	O	O
to	O	O
mutations	O	O
in	O	O
four	O	O
DNA	O	O
mismatch	O	O
repair	O	O
genes	O	O
in	O	O
hereditary	B-Disease	D003123
nonpolyposis	I-Disease	D003123
colorectal	I-Disease	D003123
cancer	I-Disease	D003123
(	O	O
HNPCC	B-Disease	D003123
)	O	O
kindreds	O	O
,	O	O
many	O	O
sporadic	B-Disease	D009369
tumours	I-Disease	D009369
exhibit	O	O
instability	O	O
but	O	O
no	O	O
detectable	O	O
mutations	O	O
in	O	O
these	O	O
genes	O	O
.	O	O

It	O	O
is	O	O
therefore	O	O
of	O	O
interest	O	O
to	O	O
identify	O	O
other	O	O
genes	O	O
that	O	O
contribute	O	O
to	O	O
this	O	O
instability	O	O
.	O	O

In	O	O
yeast	O	O
,	O	O
mutations	O	O
in	O	O
several	O	O
genes	O	O
,	O	O
including	O	O
RTH	O	O
and	O	O
MSH3	O	O
,	O	O
cause	O	O
microsatellite	B-Disease	D053842
instability	I-Disease	D053842
.	O	O

Thus	O	O
,	O	O
we	O	O
screened	O	O
16	O	O
endometrial	B-Disease	D016889
carcinomas	I-Disease	D016889
with	O	O
microsatellite	B-Disease	D053842
instability	I-Disease	D053842
for	O	O
alterations	O	O
in	O	O
FEN1	O	O
(	O	O
the	O	O
human	O	O
homolog	O	O
of	O	O
RTH	O	O
)	O	O
and	O	O
in	O	O
MSH3	O	O
(	O	O
refs	O	O
12	O	O
-	O	O
14	O	O
)	O	O
.	O	O

Although	O	O
we	O	O
found	O	O
no	O	O
FEN1	O	O
mutations	O	O
,	O	O
a	O	O
frameshift	O	O
mutation	O	O
in	O	O
MSH3	O	O
was	O	O
observed	O	O
in	O	O
an	O	O
endometrial	B-Disease	D016889
carcinoma	I-Disease	D016889
and	O	O
in	O	O
an	O	O
endometrial	B-Disease	D016889
carcinoma	I-Disease	D016889
cell	O	O
line	O	O
.	O	O

Extracts	O	O
of	O	O
the	O	O
cell	O	O
line	O	O
were	O	O
deficient	O	O
in	O	O
repair	O	O
of	O	O
DNA	O	O
substrates	O	O
containing	O	O
mismatches	O	O
or	O	O
extra	O	O
nucleotides	O	O
.	O	O

Introducing	O	O
chromosome	O	O
5	O	O
,	O	O
encoding	O	O
the	O	O
MSH3	O	O
gene	O	O
,	O	O
into	O	O
the	O	O
mutant	O	O
cell	O	O
line	O	O
increased	O	O
the	O	O
stability	O	O
of	O	O
some	O	O
but	O	O
not	O	O
all	O	O
microsatellites	O	O
.	O	O

Extracts	O	O
of	O	O
these	O	O
cells	O	O
repaired	O	O
certain	O	O
substrates	O	O
containing	O	O
extra	O	O
nucleotides	O	O
,	O	O
but	O	O
were	O	O
deficient	O	O
in	O	O
repair	O	O
of	O	O
those	O	O
containing	O	O
mismatches	O	O
or	O	O
other	O	O
extra	O	O
nucleotides	O	O
.	O	O

A	O	O
subsequent	O	O
search	O	O
revealed	O	O
a	O	O
second	O	O
gene	O	O
mutation	O	O
in	O	O
HHUA	O	O
cells	O	O
,	O	O
a	O	O
missense	O	O
mutation	O	O
in	O	O
the	O	O
MSH6	O	O
gene	O	O
.	O	O

Together	O	O
the	O	O
data	O	O
suggest	O	O
that	O	O
the	O	O
MSH3	O	O
gene	O	O
encodes	O	O
a	O	O
product	O	O
that	O	O
functions	O	O
in	O	O
repair	O	O
of	O	O
some	O	O
but	O	O
not	O	O
all	O	O
pre	O	O
-	O	O
mutational	O	O
intermediates	O	O
,	O	O
its	O	O
mutation	O	O
in	O	O
tumours	B-Disease	D009369
can	O	O
result	O	O
in	O	O
genomic	O	O
instability	O	O
and	O	O
,	O	O
as	O	O
in	O	O
yeast	O	O
,	O	O
MSH3	O	O
and	O	O
MSH6	O	O
are	O	O
partially	O	O
redundant	O	O
for	O	O
mismatch	O	O
repair	O	O
.	O	O

.	O	O

Kniest	B-Disease	C537207
dysplasia	I-Disease	C537207
:	O	O
Dr	O	O
.	O	O

W	O	O
.	O	O

Kniest	O	O
,	O	O
his	O	O
patient	O	O
,	O	O
the	O	O
molecular	O	O
defect	O	O
.	O	O

Kniest	B-Disease	C537207
dysplasia	I-Disease	C537207
is	O	O
a	O	O
severe	O	O
chondrodysplasia	B-Disease	D010009
caused	O	O
by	O	O
the	O	O
defective	B-Disease	D003095
formation	I-Disease	D003095
of	I-Disease	D003095
type	I-Disease	D003095
II	I-Disease	D003095
collagen	I-Disease	D003095
.	O	O

We	O	O
report	O	O
about	O	O
Dr	O	O
.	O	O

Kniest	O	O
,	O	O
who	O	O
first	O	O
described	O	O
the	O	O
condition	O	O
in	O	O
1952	O	O
,	O	O
and	O	O
his	O	O
patient	O	O
,	O	O
who	O	O
,	O	O
at	O	O
the	O	O
age	O	O
of	O	O
50	O	O
years	O	O
is	O	O
severely	B-Disease	D008607
handicapped	I-Disease	D008607
with	O	O
short	B-Disease	D006130
stature	I-Disease	D006130
,	O	O
restricted	B-Disease	D007592
joint	I-Disease	D007592
mobility	I-Disease	D007592
,	O	O
and	O	O
blindness	B-Disease	D001766
but	O	O
is	O	O
mentally	O	O
alert	O	O
and	O	O
leads	O	O
an	O	O
active	O	O
life	O	O
.	O	O

Molecular	O	O
analysis	O	O
of	O	O
the	O	O
patients	O	O
DNA	O	O
showed	O	O
a	O	O
single	O	O
base	O	O
(	O	O
G	O	O
)	O	O
deletion	O	O
involving	O	O
the	O	O
GT	O	O
dinucleotide	O	O
at	O	O
the	O	O
start	O	O
of	O	O
intron	O	O
18	O	O
destroying	O	O
a	O	O
splice	O	O
site	O	O
of	O	O
the	O	O
COL2A1	O	O
gene	O	O
.	O	O

This	O	O
is	O	O
in	O	O
accordance	O	O
with	O	O
molecular	O	O
findings	O	O
in	O	O
other	O	O
patients	O	O
with	O	O
Kniest	B-Disease	C537207
dysplasia	I-Disease	C537207
and	O	O
confirms	O	O
,	O	O
in	O	O
the	O	O
original	O	O
patient	O	O
,	O	O
that	O	O
the	O	O
disorder	O	O
is	O	O
caused	O	O
by	O	O
small	O	O
inframe	O	O
deletions	O	O
often	O	O
due	O	O
to	O	O
exon	O	O
skipping	O	O
as	O	O
a	O	O
result	O	O
of	O	O
COL2A1	O	O
splice	O	O
site	O	O
mutations	O	O
.	O	O

.	O	O

Ashkenazi	O	O
Jewish	O	O
population	O	O
frequencies	O	O
for	O	O
common	O	O
mutations	O	O
in	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
.	O	O

BRCA1	O	O
and	O	O
BRCA2	O	O
are	O	O
the	O	O
two	O	O
major	O	O
identified	O	O
causes	O	O
of	O	O
inherited	B-Disease	D001943
breast	I-Disease	D001943
cancer	I-Disease	D001943
,	O	O
with	O	O
mutations	O	O
in	O	O
either	O	O
gene	O	O
conferring	O	O
up	O	O
to	O	O
80	O	O
-	O	O
90	O	O
%	O	O
lifetime	O	O
risk	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
in	O	O
carrier	O	O
females	O	O
.	O	O

Mutations	O	O
in	O	O
BRCA1	O	O
account	O	O
for	O	O
approximately	O	O
45	O	O
%	O	O
of	O	O
familial	B-Disease	D001943
breast	I-Disease	D001943
cancer	I-Disease	D001943
and	O	O
90	O	O
%	O	O
of	O	O
inherited	B-Disease	D061325
breast	I-Disease	D061325
/	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
,	O	O
whereas	O	O
mutations	O	O
in	O	O
BRCA2	O	O
account	O	O
for	O	O
a	O	O
comparable	O	O
percentage	O	O
of	O	O
inherited	B-Disease	D001943
breast	I-Disease	D001943
cancer	I-Disease	D001943
cases	O	O
.	O	O

Over	O	O
85	O	O
distinct	O	O
BRCA1	O	O
mutations	O	O
and	O	O
a	O	O
growing	O	O
list	O	O
of	O	O
BRCA2	O	O
mutations	O	O
have	O	O
been	O	O
identified	O	O
,	O	O
with	O	O
the	O	O
majority	O	O
resulting	O	O
in	O	O
protein	O	O
truncation	O	O
.	O	O

A	O	O
specific	O	O
BRCA1	O	O
mutation	O	O
,	O	O
185delAG	O	O
,	O	O
has	O	O
a	O	O
reported	O	O
increased	O	O
carrier	O	O
frequency	O	O
of	O	O
approximately	O	O
0	O	O
.	O	O

9	O	O
%	O	O
in	O	O
the	O	O
Ashkenazi	O	O
Jewish	O	O
population	O	O
,	O	O
but	O	O
is	O	O
also	O	O
found	O	O
in	O	O
rare	O	O
non	O	O
-	O	O
Jewish	O	O
patients	O	O
with	O	O
a	O	O
different	O	O
haplotype	O	O
.	O	O

The	O	O
6174delT	O	O
mutation	O	O
in	O	O
BRCA2	O	O
was	O	O
recently	O	O
identified	O	O
as	O	O
a	O	O
frequent	O	O
mutation	O	O
in	O	O
8	O	O
out	O	O
of	O	O
107	O	O
Ashkenazi	O	O
Jewish	O	O
women	O	O
diagnosed	O	O
with	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
by	O	O
age	O	O
50	O	O
(	O	O
ref	O	O
.	O	O

8	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
in	O	O
three	O	O
Ashkenazi	O	O
male	B-Disease	D018567
breast	I-Disease	D018567
cancer	I-Disease	D018567
patients	O	O
.	O	O

We	O	O
have	O	O
conducted	O	O
a	O	O
large	O	O
-	O	O
scale	O	O
population	O	O
study	O	O
to	O	O
investigate	O	O
the	O	O
prevalence	O	O
of	O	O
specific	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
mutations	O	O
in	O	O
Ashkenazi	O	O
Jewish	O	O
individuals	O	O
who	O	O
were	O	O
unselected	O	O
for	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

BRCA1	O	O
mutation	O	O
screening	O	O
on	O	O
approximately	O	O
3	O	O
,	O	O
000	O	O
Ashkenazi	O	O
Jewish	O	O
samples	O	O
determined	O	O
a	O	O
carrier	O	O
frequency	O	O
of	O	O
1	O	O
.	O	O

09	O	O
%	O	O
for	O	O
the	O	O
185delAG	O	O
mutation	O	O
and	O	O
0	O	O
.	O	O

13	O	O
%	O	O
for	O	O
the	O	O
5382insC	O	O
mutation	O	O
.	O	O

BRCA2	O	O
analysis	O	O
on	O	O
3	O	O
,	O	O
085	O	O
individuals	O	O
from	O	O
the	O	O
same	O	O
population	O	O
showed	O	O
a	O	O
carrier	O	O
frequency	O	O
of	O	O
1	O	O
.	O	O

52	O	O
%	O	O
for	O	O
the	O	O
6174delT	O	O
mutation	O	O
.	O	O

This	O	O
expanded	O	O
population	O	O
-	O	O
based	O	O
study	O	O
confirms	O	O
that	O	O
the	O	O
BRCA1	O	O
185delAG	O	O
mutation	O	O
and	O	O
the	O	O
BRCA2	O	O
6174delT	O	O
mutation	O	O
constitute	O	O
the	O	O
two	O	O
most	O	O
frequent	O	O
mutation	O	O
alleles	O	O
predisposing	O	O
to	O	O
hereditary	B-Disease	D001943
breast	I-Disease	D001943
cancer	I-Disease	D001943
among	O	O
the	O	O
Ashkenazim	O	O
,	O	O
and	O	O
suggests	O	O
a	O	O
relatively	O	O
lower	O	O
penetrance	O	O
for	O	O
the	O	O
6174delT	O	O
mutation	O	O
in	O	O
BRCA2	O	O
Mapping	O	O
the	O	O
homolog	O	O
of	O	O
the	O	O
human	O	O
Rb1	O	O
gene	O	O
to	O	O
chromosome	O	O
14	O	O
of	O	O
higher	O	O
primates	O	O
.	O	O

The	O	O
Rb1	O	O
gene	O	O
has	O	O
been	O	O
implicated	O	O
with	O	O
retinoblastoma	B-Disease	D012175
and	O	O
is	O	O
located	O	O
on	O	O
human	O	O
Chromosome	O	O
(	O	O
Chr	O	O
)	O	O
13q14	O	O
.	O	O

2	O	O
2	O	O
.	O	O

A	O	O
unique	O	O
sequence	O	O
human	O	O
Rb1	O	O
cosmid	O	O
DNA	O	O
probe	O	O
has	O	O
been	O	O
used	O	O
to	O	O
localize	O	O
this	O	O
region	O	O
on	O	O
apes	O	O
Chr	O	O
14	O	O
by	O	O
the	O	O
FISH	O	O
technique	O	O
.	O	O

The	O	O
conservation	O	O
of	O	O
the	O	O
Rb1	O	O
gene	O	O
in	O	O
higher	O	O
primates	O	O
at	O	O
the	O	O
corresponding	O	O
equivalent	O	O
chromosome	O	O
locus	O	O
(	O	O
14q14	O	O
)	O	O
of	O	O
the	O	O
human	O	O
may	O	O
serve	O	O
as	O	O
a	O	O
phylogenetic	O	O
marker	O	O
to	O	O
further	O	O
trace	O	O
the	O	O
evolutionary	O	O
pathway	O	O
of	O	O
human	O	O
descent	O	O
.	O	O

Difficulties	O	O
in	O	O
the	O	O
ascertainment	O	O
of	O	O
C9	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
:	O	O
lessons	O	O
to	O	O
be	O	O
drawn	O	O
from	O	O
a	O	O
compound	O	O
heterozygote	O	O
C9	B-Disease	OMIM:613825
-	I-Disease	OMIM:613825
deficient	I-Disease	OMIM:613825
subject	O	O
.	O	O

A	O	O
group	O	O
of	O	O
patients	O	O
with	O	O
long	O	O
-	O	O
surviving	O	O
mismatched	O	O
kidney	O	O
allografts	O	O
were	O	O
investigated	O	O
for	O	O
complement	O	O
function	O	O
using	O	O
haemolytic	O	O
assays	O	O
in	O	O
agarose	O	O
gels	O	O
.	O	O

One	O	O
patient	O	O
was	O	O
found	O	O
to	O	O
have	O	O
no	O	O
alternative	O	O
pathway	O	O
activity	O	O
but	O	O
a	O	O
low	O	O
normal	O	O
classical	O	O
pathway	O	O
.	O	O

Surprisingly	O	O
,	O	O
investigation	O	O
revealed	O	O
that	O	O
the	O	O
patients	O	O
complement	O	O
was	O	O
normal	O	O
for	O	O
all	O	O
components	O	O
except	O	O
C9	O	O
,	O	O
which	O	O
was	O	O
functionally	O	O
absent	O	O
.	O	O

The	O	O
patient	O	O
was	O	O
shown	O	O
to	O	O
be	O	O
heterozygous	O	O
for	O	O
DNA	O	O
markers	O	O
in	O	O
the	O	O
C6	O	O
,	O	O
C7	O	O
and	O	O
C9	O	O
region	O	O
of	O	O
chromosome	O	O
5	O	O
and	O	O
therefore	O	O
appears	O	O
to	O	O
be	O	O
a	O	O
compound	O	O
heterozygote	O	O
for	O	O
two	O	O
uncharacterized	O	O
C9	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
genes	O	O
.	O	O

Serological	O	O
analysis	O	O
by	O	O
ELISA	O	O
revealed	O	O
that	O	O
he	O	O
has	O	O
trace	O	O
concentrations	O	O
of	O	O
a	O	O
non	O	O
-	O	O
functional	O	O
C9	O	O
molecule	O	O
.	O	O

Western	O	O
blot	O	O
analysis	O	O
was	O	O
not	O	O
sufficiently	O	O
sensitive	O	O
to	O	O
permit	O	O
detection	O	O
of	O	O
this	O	O
molecule	O	O
.	O	O

We	O	O
hypothesize	O	O
that	O	O
the	O	O
patient	O	O
is	O	O
heterozygous	O	O
for	O	O
a	O	O
complete	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
of	I-Disease	OMIM:613825
C9	I-Disease	OMIM:613825
and	O	O
for	O	O
a	O	O
gene	O	O
directing	O	O
hyposynthesis	O	O
of	O	O
a	O	O
defective	O	O
C9	O	O
.	O	O

We	O	O
also	O	O
suggest	O	O
that	O	O
C9	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
may	O	O
be	O	O
more	O	O
common	O	O
among	O	O
Caucasians	O	O
than	O	O
has	O	O
been	O	O
reported	O	O
.	O	O

.	O	O

Moderate	O	O
intergenerational	O	O
and	O	O
somatic	O	O
instability	O	O
of	O	O
a	O	O
55	O	O
-	O	O
CTG	O	O
repeat	O	O
in	O	O
transgenic	O	O
mice	O	O
.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
is	O	O
associated	O	O
with	O	O
the	O	O
expansion	O	O
of	O	O
a	O	O
(	O	O
CTG	O	O
)	O	O
n	O	O
trinucleotide	O	O
repeat	O	O
in	O	O
the	O	O
3	O	O
untranslated	O	O
region	O	O
(	O	O
UTR	O	O
)	O	O
of	O	O
the	O	O
DM	B-Disease	D009223
protein	O	O
kinase	O	O
gene	O	O
(	O	O
DMPK	O	O
)	O	O
.	O	O

The	O	O
(	O	O
CTG	O	O
)	O	O
n	O	O
repeat	O	O
is	O	O
polymorphic	O	O
and	O	O
varies	O	O
in	O	O
size	O	O
between	O	O
5	O	O
and	O	O
37	O	O
repeats	O	O
in	O	O
unaffected	O	O
individuals	O	O
whereas	O	O
in	O	O
affected	O	O
patients	O	O
there	O	O
are	O	O
between	O	O
50	O	O
and	O	O
4	O	O
,	O	O
000	O	O
CTGs	O	O
.	O	O

The	O	O
size	O	O
of	O	O
the	O	O
(	O	O
CTG	O	O
)	O	O
n	O	O
repeat	O	O
,	O	O
which	O	O
increases	O	O
through	O	O
generations	O	O
,	O	O
generally	O	O
correlates	O	O
with	O	O
clinical	O	O
severity	O	O
and	O	O
age	O	O
of	O	O
onset	O	O
.	O	O

The	O	O
instability	O	O
of	O	O
the	O	O
CTG	O	O
repeat	O	O
appears	O	O
to	O	O
depend	O	O
on	O	O
its	O	O
size	O	O
as	O	O
well	O	O
as	O	O
on	O	O
the	O	O
sex	O	O
of	O	O
the	O	O
transmitting	O	O
parent	O	O
.	O	O

Moreover	O	O
,	O	O
mitotic	O	O
instability	O	O
analysis	O	O
of	O	O
different	O	O
human	O	O
DM	B-Disease	D009223
tissues	O	O
shows	O	O
length	O	O
mosaicism	O	O
between	O	O
different	O	O
cell	O	O
lineages	O	O
.	O	O

The	O	O
molecular	O	O
mechanisms	O	O
of	O	O
triplet	O	O
instability	O	O
remain	O	O
elusive	O	O
.	O	O

To	O	O
investigate	O	O
the	O	O
role	O	O
of	O	O
genomic	O	O
sequences	O	O
in	O	O
instability	O	O
,	O	O
we	O	O
produced	O	O
transgenic	O	O
mice	O	O
containing	O	O
a	O	O
45	O	O
-	O	O
kb	O	O
genomic	O	O
segment	O	O
with	O	O
a	O	O
55	O	O
-	O	O
CTG	O	O
repeat	O	O
cloned	O	O
from	O	O
a	O	O
mildly	O	O
affected	O	O
patient	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
other	O	O
mouse	O	O
models	O	O
containing	O	O
CAG	O	O
repeats	O	O
within	O	O
cDNAs	O	O
,	O	O
these	O	O
mice	O	O
showed	O	O
both	O	O
intergenerational	O	O
and	O	O
somatic	O	O
repeat	O	O
instability	O	O
.	O	O

.	O	O

Mutations	O	O
in	O	O
the	O	O
arginine	O	O
-	O	O
rich	O	O
protein	O	O
gene	O	O
(	O	O
ARP	O	O
)	O	O
in	O	O
pancreatic	B-Disease	D010190
cancer	I-Disease	D010190
.	O	O

The	O	O
ARP	O	O
gene	O	O
encodes	O	O
a	O	O
highly	O	O
conserved	O	O
arginine	O	O
-	O	O
rich	O	O
protein	O	O
from	O	O
chromosomal	O	O
band	O	O
3p21	O	O
.	O	O

1	O	O
1	O	O
.	O	O

At	O	O
the	O	O
cytogenetic	O	O
level	O	O
this	O	O
region	O	O
is	O	O
frequently	O	O
deleted	O	O
in	O	O
a	O	O
variety	O	O
of	O	O
different	O	O
solid	B-Disease	D009369
tumors	I-Disease	D009369
,	O	O
although	O	O
not	O	O
in	O	O
pancreatic	B-Disease	D010190
cancer	I-Disease	D010190
.	O	O

We	O	O
have	O	O
reported	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
specific	O	O
mutation	O	O
(	O	O
ATG50	O	O
-	O	O
-	O	O
>	O	O
AGG	O	O
)	O	O
or	O	O
deletion	O	O
of	O	O
codon	O	O
50	O	O
of	O	O
the	O	O
ARP	O	O
gene	O	O
in	O	O
different	O	O
tumor	B-Disease	D009369
types	I-Disease	D009369
(	O	O
Shridhar	O	O
et	O	O
al	O	O
.	O	O

,	O	O
1996	O	O
,	O	O
1996a	O	O
)	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
have	O	O
observed	O	O
mutations	O	O
involving	O	O
codon	O	O
50	O	O
in	O	O
11	O	O
of	O	O
37	O	O
pancreatic	B-Disease	D010190
tumors	I-Disease	D010190
.	O	O

The	O	O
frequency	O	O
of	O	O
codon	O	O
50	O	O
mutation	O	O
is	O	O
roughly	O	O
the	O	O
same	O	O
in	O	O
pancreatic	B-Disease	D010190
tumors	I-Disease	D010190
as	O	O
in	O	O
the	O	O
other	O	O
types	O	O
of	O	O
tumors	B-Disease	D009369
previously	O	O
examined	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
have	O	O
detected	O	O
mutations	O	O
at	O	O
codon	O	O
51	O	O
in	O	O
multiple	O	O
PCR	O	O
subclones	O	O
in	O	O
two	O	O
other	O	O
pancreatic	B-Disease	D010190
tumors	I-Disease	D010190
.	O	O

Mutations	O	O
in	O	O
the	O	O
ARP	O	O
gene	O	O
are	O	O
thus	O	O
commonly	O	O
observed	O	O
in	O	O
pancreatic	B-Disease	D010190
cancer	I-Disease	D010190
,	O	O
as	O	O
well	O	O
as	O	O
many	O	O
other	O	O
cancers	B-Disease	D009369
.	O	O

Heterogeneity	O	O
in	O	O
Schwartz	B-Disease	OMIM:255800
-	I-Disease	OMIM:255800
Jampel	I-Disease	OMIM:255800
chondrodystrophic	I-Disease	OMIM:255800
myotonia	I-Disease	OMIM:255800
.	O	O

The	O	O
Schwartz	B-Disease	OMIM:255800
-	I-Disease	OMIM:255800
Jampel	I-Disease	OMIM:255800
syndrome	I-Disease	OMIM:255800
(	O	O
SJS	B-Disease	OMIM:255800
;	O	O
chondrodystrophic	B-Disease	OMIM:255800
myotonia	I-Disease	OMIM:255800
;	O	O
McK	O	O
255	O	O
,	O	O
800	O	O
)	O	O
is	O	O
a	O	O
recessively	B-Disease	D030342
inherited	I-Disease	D030342
condition	I-Disease	D030342
defined	O	O
by	O	O
myotonia	B-Disease	D009222
,	O	O
short	B-Disease	D006130
stature	I-Disease	D006130
,	O	O
and	O	O
bone	B-Disease	D001848
dysplasia	I-Disease	D001848
.	O	O

Genetic	O	O
linkage	O	O
between	O	O
SJS	B-Disease	OMIM:255800
and	O	O
chromosomal	O	O
region	O	O
1q36	O	O
-	O	O
34	O	O
has	O	O
been	O	O
observed	O	O
in	O	O
several	O	O
families	O	O
,	O	O
but	O	O
the	O	O
gene	O	O
has	O	O
not	O	O
yet	O	O
been	O	O
identified	O	O
.	O	O

We	O	O
studied	O	O
the	O	O
clinical	O	O
and	O	O
radiological	O	O
features	O	O
in	O	O
81	O	O
patients	O	O
from	O	O
the	O	O
literature	O	O
and	O	O
5	O	O
own	O	O
patients	O	O
trying	O	O
to	O	O
identify	O	O
distinct	O	O
subgroups	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
tested	O	O
genetic	O	O
linkage	O	O
to	O	O
the	O	O
SJS	B-Disease	OMIM:255800
locus	O	O
on	O	O
chromosome	O	O
1	O	O
in	O	O
one	O	O
family	O	O
with	O	O
two	O	O
affected	O	O
sibs	O	O
.	O	O

We	O	O
found	O	O
that	O	O
a	O	O
group	O	O
of	O	O
patients	O	O
have	O	O
mild	O	O
skeletal	O	O
changes	O	O
which	O	O
may	O	O
be	O	O
secondary	O	O
consequences	O	O
of	O	O
myotonia	B-Disease	D009222
,	O	O
while	O	O
another	O	O
group	O	O
of	O	O
patients	O	O
appear	O	O
to	O	O
have	O	O
primary	O	O
bone	B-Disease	D001848
dysplasia	I-Disease	D001848
with	O	O
myotonia	B-Disease	D009222
.	O	O

Within	O	O
this	O	O
latter	O	O
group	O	O
,	O	O
there	O	O
are	O	O
differences	O	O
in	O	O
age	O	O
of	O	O
manifestation	O	O
,	O	O
clinical	O	O
course	O	O
and	O	O
pattern	O	O
of	O	O
bone	O	O
changes	O	O
.	O	O

We	O	O
tentatively	O	O
isolate	O	O
three	O	O
different	O	O
types	O	O
of	O	O
SJS	B-Disease	OMIM:255800
type	O	O
1A	O	O
,	O	O
usually	O	O
recognized	O	O
in	O	O
childhood	O	O
,	O	O
with	O	O
moderate	O	O
bone	B-Disease	D001848
dysplasia	I-Disease	D001848
,	O	O
corresponding	O	O
to	O	O
the	O	O
original	O	O
descriptions	O	O
of	O	O
Schwartz	O	O
,	O	O
Jampel	O	O
and	O	O
Aberfeld	O	O
;	O	O
type	O	O
1B	O	O
,	O	O
similar	O	O
to	O	O
type	O	O
1A	O	O
but	O	O
recognizable	O	O
at	O	O
birth	O	O
,	O	O
with	O	O
more	O	O
pronounced	O	O
bone	B-Disease	D001848
dysplasia	I-Disease	D001848
resembling	O	O
Kniest	B-Disease	C537207
dysplasia	I-Disease	C537207
;	O	O
and	O	O
type	O	O
2	O	O
,	O	O
manifest	O	O
at	O	O
birth	O	O
,	O	O
with	O	O
increased	O	O
mortality	O	O
and	O	O
bone	B-Disease	D001848
dysplasia	I-Disease	D001848
resembling	O	O
Pyle	B-Disease	C536252
disease	I-Disease	C536252
.	O	O

Genetic	O	O
analysis	O	O
of	O	O
the	O	O
family	O	O
with	O	O
two	O	O
sibs	O	O
affected	O	O
by	O	O
SJS	B-Disease	OMIM:255800
type	O	O
2	O	O
showed	O	O
evidence	O	O
against	O	O
linkage	O	O
to	O	O
chromosome	O	O
1p36	O	O
-	O	O
34	O	O
.	O	O

CONCLUSIONS	O	O
SJS	B-Disease	OMIM:255800
is	O	O
clinically	O	O
and	O	O
radiologically	O	O
heterogeneous	O	O
.	O	O

The	O	O
causes	O	O
of	O	O
heterogeneity	O	O
are	O	O
not	O	O
known	O	O
yet	O	O
but	O	O
are	O	O
likely	O	O
to	O	O
include	O	O
both	O	O
different	O	O
mutations	O	O
at	O	O
the	O	O
SJS	B-Disease	OMIM:255800
locus	O	O
on	O	O
chromosome	O	O
1	O	O
and	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
second	O	O
SJS	B-Disease	OMIM:255800
locus	O	O
.	O	O

A	O	O
tentative	O	O
clinico	O	O
-	O	O
radiological	O	O
classification	O	O
can	O	O
be	O	O
useful	O	O
for	O	O
the	O	O
characterization	O	O
of	O	O
patients	O	O
and	O	O
the	O	O
development	O	O
of	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
.	O	O

.	O	O

X	B-Disease	D000326
-	I-Disease	D000326
linked	I-Disease	D000326
adrenoleukodystrophy	I-Disease	D000326
is	O	O
a	O	O
frequent	O	O
cause	O	O
of	O	O
idiopathic	O	O
Addison	B-Disease	D000224
'	I-Disease	D000224
s	I-Disease	D000224
disease	I-Disease	D000224
in	O	O
young	O	O
adult	O	O
male	O	O
patients	O	O
.	O	O

X	B-Disease	D000326
-	I-Disease	D000326
Linked	I-Disease	D000326
adrenoleukodystrophy	I-Disease	D000326
(	O	O
ALD	B-Disease	D000326
)	O	O
is	O	O
a	O	O
genetic	B-Disease	D030342
disease	I-Disease	D030342
associated	O	O
with	O	O
demyelination	B-Disease	D020279
of	I-Disease	D020279
the	I-Disease	D020279
central	I-Disease	D020279
nervous	I-Disease	D020279
system	I-Disease	D020279
,	O	O
adrenal	B-Disease	D000309
insufficiency	I-Disease	D000309
,	O	O
and	O	O
accumulation	O	O
of	O	O
very	O	O
long	O	O
chain	O	O
fatty	O	O
acids	O	O
in	O	O
tissue	O	O
and	O	O
body	O	O
fluids	O	O
.	O	O

ALD	B-Disease	D000326
is	O	O
due	O	O
to	O	O
mutation	O	O
of	O	O
a	O	O
gene	O	O
located	O	O
in	O	O
Xq28	O	O
that	O	O
encodes	O	O
a	O	O
peroxisomal	O	O
transporter	O	O
protein	O	O
of	O	O
unknown	O	O
function	O	O
.	O	O

The	O	O
most	O	O
common	O	O
phenotype	O	O
of	O	O
ALD	B-Disease	D000326
is	O	O
the	O	O
cerebral	O	O
form	O	O
(	O	O
45	O	O
%	O	O
)	O	O
that	O	O
develops	O	O
in	O	O
boys	O	O
between	O	O
5	O	O
-	O	O
12	O	O
yr	O	O
.	O	O

Adrenomyeloneuropathy	B-Disease	D000326
(	O	O
AMN	B-Disease	D000326
)	O	O
involves	O	O
the	O	O
spinal	O	O
cord	O	O
and	O	O
peripheral	O	O
nerves	O	O
in	O	O
young	O	O
adults	O	O
(	O	O
35	O	O
%	O	O
)	O	O
.	O	O

Adrenal	B-Disease	D000309
insufficiency	I-Disease	D000309
(	O	O
Addisons	B-Disease	D000224
disease	I-Disease	D000224
)	O	O
is	O	O
frequently	O	O
associated	O	O
with	O	O
AMN	B-Disease	D000326
or	O	O
cerebral	B-Disease	D000326
ALD	I-Disease	D000326
and	O	O
may	O	O
remain	O	O
the	O	O
only	O	O
clinical	O	O
expression	O	O
of	O	O
ALD	B-Disease	D000326
(	O	O
8	O	O
%	O	O
of	O	O
cases	O	O
)	O	O
.	O	O

The	O	O
prevalence	O	O
of	O	O
ALD	B-Disease	D000326
among	O	O
adults	O	O
with	O	O
Addisons	B-Disease	D000224
disease	I-Disease	D000224
remains	O	O
unknown	O	O
.	O	O

To	O	O
evaluate	O	O
this	O	O
prevalence	O	O
,	O	O
we	O	O
performed	O	O
biochemical	O	O
analysis	O	O
of	O	O
very	O	O
long	O	O
chain	O	O
fatty	O	O
acids	O	O
in	O	O
14	O	O
male	O	O
patients	O	O
(	O	O
age	O	O
ranging	O	O
from	O	O
12	O	O
-	O	O
45	O	O
yr	O	O
at	O	O
diagnosis	O	O
)	O	O
previously	O	O
diagnosed	O	O
as	O	O
having	O	O
primary	O	O
idiopathic	O	O
adrenocortical	B-Disease	D000224
insufficiency	I-Disease	D000224
.	O	O

In	O	O
5	O	O
of	O	O
14	O	O
patients	O	O
(	O	O
35	O	O
%	O	O
)	O	O
,	O	O
elevated	O	O
plasma	O	O
concentrations	O	O
of	O	O
very	O	O
long	O	O
chain	O	O
fatty	O	O
acids	O	O
were	O	O
detected	O	O
.	O	O

None	O	O
of	O	O
these	O	O
patients	O	O
had	O	O
adrenocortical	O	O
antibodies	O	O
.	O	O

By	O	O
electrophysiological	O	O
tests	O	O
and	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
it	O	O
was	O	O
determined	O	O
that	O	O
two	O	O
patients	O	O
had	O	O
cerebral	B-Disease	D000326
ALD	I-Disease	D000326
,	O	O
one	O	O
had	O	O
adrenomyeloneuropathy	B-Disease	D000326
with	O	O
cerebral	O	O
involvement	O	O
,	O	O
and	O	O
two	O	O
had	O	O
preclinical	O	O
AMN	B-Disease	D000326
.	O	O

Our	O	O
data	O	O
support	O	O
the	O	O
hypothesis	O	O
that	O	O
ALD	B-Disease	D000326
is	O	O
a	O	O
frequent	O	O
cause	O	O
of	O	O
idiopathic	O	O
Addisons	B-Disease	D000224
disease	I-Disease	D000224
in	O	O
children	O	O
and	O	O
adults	O	O
.	O	O

.	O	O

Low	O	O
incidence	O	O
of	O	O
BRCA2	O	O
mutations	O	O
in	O	O
breast	B-Disease	D001943
carcinoma	I-Disease	D001943
and	O	O
other	O	O
cancers	B-Disease	D009369
.	O	O

Inherited	O	O
mutant	O	O
alleles	O	O
of	O	O
familial	O	O
tumour	B-Disease	D009369
suppressor	O	O
genes	O	O
predispose	O	O
individuals	O	O
to	O	O
particular	O	O
types	O	O
of	O	O
cancer	B-Disease	D009369
.	O	O

In	O	O
addition	O	O
to	O	O
an	O	O
involvement	O	O
in	O	O
inherited	O	O
susceptibility	O	O
to	O	O
cancer	B-Disease	D009369
,	O	O
these	O	O
tumour	B-Disease	D009369
suppressor	O	O
genes	O	O
are	O	O
targets	O	O
for	O	O
somatic	O	O
mutations	O	O
in	O	O
sporadic	B-Disease	D009369
cancers	I-Disease	D009369
of	O	O
the	O	O
same	O	O
type	O	O
found	O	O
in	O	O
the	O	O
familial	O	O
forms	O	O
.	O	O

An	O	O
exception	O	O
is	O	O
BRCA1	O	O
,	O	O
which	O	O
contributes	O	O
to	O	O
a	O	O
significant	O	O
fraction	O	O
of	O	O
familial	B-Disease	D061325
breast	I-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
,	O	O
but	O	O
undergoes	O	O
mutation	O	O
at	O	O
very	O	O
low	O	O
rates	O	O
in	O	O
sporadic	B-Disease	D001943
breast	I-Disease	D001943
and	I-Disease	D001943
ovarian	I-Disease	D001943
cancers	I-Disease	D001943
.	O	O

This	O	O
finding	O	O
suggests	O	O
that	O	O
other	O	O
genes	O	O
may	O	O
be	O	O
the	O	O
principal	O	O
targets	O	O
for	O	O
somatic	O	O
mutation	O	O
in	O	O
breast	B-Disease	D001943
carcinoma	I-Disease	D001943
.	O	O

A	O	O
second	O	O
,	O	O
recently	O	O
identified	O	O
familial	B-Disease	D001943
breast	I-Disease	D001943
cancer	I-Disease	D001943
gene	O	O
,	O	O
BRCA2	O	O
(	O	O
refs	O	O
5	O	O
-	O	O
8	O	O
)	O	O
,	O	O
accounts	O	O
for	O	O
a	O	O
proportion	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
roughly	O	O
equal	O	O
to	O	O
BRCA1	O	O
.	O	O

Like	O	O
BRCA1	O	O
,	O	O
BRCA2	O	O
behaves	O	O
as	O	O
a	O	O
dominantly	O	O
inherited	O	O
tumour	B-Disease	D009369
suppressor	O	O
gene	O	O
.	O	O

Individuals	O	O
who	O	O
inherit	O	O
one	O	O
mutant	O	O
allele	O	O
are	O	O
at	O	O
increased	O	O
risk	O	O
for	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
,	O	O
and	O	O
the	O	O
tumours	B-Disease	D009369
they	O	O
develop	O	O
lose	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
allele	O	O
by	O	O
heterozygous	O	O
deletion	O	O
.	O	O

The	O	O
BRCA2	O	O
coding	O	O
sequence	O	O
is	O	O
huge	O	O
,	O	O
composed	O	O
of	O	O
26	O	O
exons	O	O
that	O	O
span	O	O
10	O	O
,	O	O
443	O	O
bp	O	O
.	O	O

Here	O	O
we	O	O
investigate	O	O
the	O	O
rate	O	O
of	O	O
BRCA2	O	O
mutation	O	O
in	O	O
sporadic	B-Disease	D001943
breast	I-Disease	D001943
cancers	I-Disease	D001943
and	O	O
in	O	O
a	O	O
set	O	O
of	O	O
cell	O	O
lines	O	O
that	O	O
represent	O	O
twelve	O	O
other	O	O
tumour	B-Disease	D009369
types	O	O
.	O	O

Surprisingly	O	O
,	O	O
mutations	O	O
in	O	O
BRCA2	O	O
are	O	O
infrequent	O	O
in	O	O
cancers	B-Disease	D009369
including	O	O
breast	B-Disease	D001943
carcinoma	I-Disease	D001943
.	O	O

However	O	O
,	O	O
a	O	O
probable	O	O
germline	O	O
mutation	O	O
in	O	O
a	O	O
pancreatic	B-Disease	D010190
tumour	I-Disease	D010190
cell	O	O
line	O	O
suggests	O	O
a	O	O
role	O	O
for	O	O
BRCA2	O	O
in	O	O
susceptibility	O	O
to	O	O
pancreatic	B-Disease	D010190
cancer	I-Disease	D010190
.	O	O

.	O	O

Type	O	O
III	O	O
collagen	O	O
is	O	O
crucial	O	O
for	O	O
collagen	O	O
I	O	O
fibrillogenesis	O	O
and	O	O
for	O	O
normal	O	O
cardiovascular	O	O
development	O	O
.	O	O

Type	O	O
III	O	O
collagen	O	O
is	O	O
a	O	O
fibrillar	O	O
forming	O	O
collagen	O	O
comprising	O	O
three	O	O
alpha1	O	O
(	O	O
III	O	O
)	O	O
chains	O	O
and	O	O
is	O	O
expressed	O	O
in	O	O
early	O	O
embryos	O	O
and	O	O
throughout	O	O
embryogenesis	O	O
.	O	O

In	O	O
the	O	O
adult	O	O
,	O	O
type	O	O
III	O	O
collagen	O	O
is	O	O
a	O	O
major	O	O
component	O	O
of	O	O
the	O	O
extracellular	O	O
matrix	O	O
in	O	O
a	O	O
variety	O	O
of	O	O
internal	O	O
organs	O	O
and	O	O
skin	O	O
.	O	O

Mutations	O	O
in	O	O
the	O	O
COL3A1	O	O
gene	O	O
have	O	O
been	O	O
implicated	O	O
as	O	O
a	O	O
cause	O	O
of	O	O
type	B-Disease	D004535
IV	I-Disease	D004535
Ehlers	I-Disease	D004535
-	I-Disease	D004535
Danlos	I-Disease	D004535
syndrome	I-Disease	D004535
,	O	O
a	O	O
disease	O	O
leading	O	O
to	O	O
aortic	B-Disease	D001019
rupture	I-Disease	D001019
in	O	O
early	O	O
adult	O	O
life	O	O
.	O	O

To	O	O
directly	O	O
study	O	O
the	O	O
role	O	O
of	O	O
Col3a1	O	O
in	O	O
development	O	O
and	O	O
disease	O	O
,	O	O
we	O	O
have	O	O
inactivated	O	O
the	O	O
Col3a1	O	O
gene	O	O
in	O	O
embryonic	O	O
stem	O	O
cells	O	O
by	O	O
homologous	O	O
recombination	O	O
.	O	O

The	O	O
mutated	O	O
allele	O	O
was	O	O
transmitted	O	O
through	O	O
the	O	O
mouse	O	O
germ	O	O
line	O	O
and	O	O
homozygous	O	O
mutant	O	O
animals	O	O
were	O	O
derived	O	O
from	O	O
heterozygous	O	O
intercrosses	O	O
.	O	O

About	O	O
10	O	O
%	O	O
of	O	O
the	O	O
homozygous	O	O
mutant	O	O
animals	O	O
survived	O	O
to	O	O
adulthood	O	O
but	O	O
have	O	O
a	O	O
much	O	O
shorter	O	O
life	O	O
span	O	O
compared	O	O
with	O	O
wild	O	O
-	O	O
type	O	O
mice	O	O
.	O	O

The	O	O
major	O	O
cause	O	O
of	O	O
death	O	O
of	O	O
mutant	O	O
mice	O	O
was	O	O
rupture	O	O
of	O	O
the	O	O
major	O	O
blood	O	O
vessels	O	O
,	O	O
similar	O	O
to	O	O
patients	O	O
with	O	O
type	B-Disease	D004535
IV	I-Disease	D004535
Ehlers	I-Disease	D004535
-	I-Disease	D004535
Danlos	I-Disease	D004535
syndrome	I-Disease	D004535
.	O	O

Ultrastructural	O	O
analysis	O	O
of	O	O
tissues	O	O
from	O	O
mutant	O	O
mice	O	O
revealed	O	O
that	O	O
type	O	O
III	O	O
collagen	O	O
is	O	O
essential	O	O
for	O	O
normal	O	O
collagen	O	O
I	O	O
fibrillogenesis	O	O
in	O	O
the	O	O
cardiovascular	O	O
system	O	O
and	O	O
other	O	O
organs	O	O
.	O	O

.	O	O

The	O	O
incidence	O	O
of	O	O
PAX6	O	O
mutation	O	O
in	O	O
patients	O	O
with	O	O
simple	O	O
aniridia	B-Disease	D015783
:	O	O
an	O	O
evaluation	O	O
of	O	O
mutation	O	O
detection	O	O
in	O	O
12	O	O
cases	O	O
.	O	O

Twelve	O	O
aniridia	B-Disease	D015783
patients	O	O
,	O	O
five	O	O
with	O	O
a	O	O
family	O	O
history	O	O
and	O	O
seven	O	O
presumed	O	O
to	O	O
be	O	O
sporadic	O	O
,	O	O
were	O	O
exhaustively	O	O
screened	O	O
in	O	O
order	O	O
to	O	O
test	O	O
what	O	O
proportion	O	O
of	O	O
people	O	O
with	O	O
aniridia	B-Disease	D015783
,	O	O
uncomplicated	O	O
by	O	O
associated	O	O
anomalies	O	O
,	O	O
carry	O	O
mutations	O	O
in	O	O
the	O	O
human	O	O
PAX6	O	O
gene	O	O
.	O	O

Mutations	O	O
were	O	O
detected	O	O
in	O	O
90	O	O
%	O	O
of	O	O
the	O	O
cases	O	O
.	O	O

Three	O	O
mutation	O	O
detection	O	O
techniques	O	O
were	O	O
used	O	O
to	O	O
determine	O	O
if	O	O
one	O	O
method	O	O
was	O	O
superior	O	O
for	O	O
this	O	O
gene	O	O
.	O	O

The	O	O
protein	O	O
truncation	O	O
test	O	O
(	O	O
PTT	O	O
)	O	O
was	O	O
used	O	O
on	O	O
RT	O	O
-	O	O
PCR	O	O
products	O	O
,	O	O
SSCP	O	O
on	O	O
genomic	O	O
PCR	O	O
amplifications	O	O
,	O	O
and	O	O
chemical	O	O
cleavage	O	O
of	O	O
mismatch	O	O
on	O	O
both	O	O
RT	O	O
-	O	O
PCR	O	O
and	O	O
genomic	O	O
amplifications	O	O
.	O	O

For	O	O
RT	O	O
-	O	O
PCR	O	O
products	O	O
,	O	O
only	O	O
the	O	O
translated	O	O
portion	O	O
of	O	O
the	O	O
gene	O	O
was	O	O
screened	O	O
.	O	O

On	O	O
genomic	O	O
products	O	O
exons	O	O
1	O	O
to	O	O
13	O	O
(	O	O
including	O	O
740	O	O
bp	O	O
of	O	O
the	O	O
3	O	O
untranslated	O	O
sequence	O	O
and	O	O
all	O	O
intron	O	O
/	O	O
exon	O	O
boundaries	O	O
)	O	O
were	O	O
screened	O	O
,	O	O
as	O	O
was	O	O
a	O	O
neuroretina	O	O
specific	O	O
enhancer	O	O
in	O	O
intron	O	O
4	O	O
.	O	O

Ten	O	O
of	O	O
the	O	O
possible	O	O
12	O	O
mutations	O	O
in	O	O
the	O	O
five	O	O
familial	O	O
cases	O	O
and	O	O
five	O	O
of	O	O
the	O	O
sporadic	O	O
patients	O	O
were	O	O
found	O	O
,	O	O
all	O	O
of	O	O
which	O	O
conformed	O	O
to	O	O
a	O	O
functional	O	O
outcome	O	O
of	O	O
haploinsufficiency	O	O
.	O	O

Five	O	O
were	O	O
splice	O	O
site	O	O
mutations	O	O
(	O	O
one	O	O
in	O	O
the	O	O
donor	O	O
site	O	O
of	O	O
intron	O	O
4	O	O
,	O	O
two	O	O
in	O	O
the	O	O
donor	O	O
site	O	O
of	O	O
intron	O	O
6	O	O
,	O	O
one	O	O
in	O	O
each	O	O
of	O	O
the	O	O
acceptor	O	O
sites	O	O
of	O	O
introns	O	O
8	O	O
and	O	O
9	O	O
)	O	O
and	O	O
five	O	O
were	O	O
nonsense	O	O
mutations	O	O
in	O	O
exons	O	O
8	O	O
,	O	O
9	O	O
,	O	O
10	O	O
,	O	O
11	O	O
,	O	O
and	O	O
12	O	O
.	O	O

SSCP	O	O
analysis	O	O
of	O	O
individually	O	O
amplified	O	O
exons	O	O
,	O	O
with	O	O
which	O	O
nine	O	O
of	O	O
the	O	O
10	O	O
mutations	O	O
were	O	O
seen	O	O
,	O	O
was	O	O
the	O	O
most	O	O
useful	O	O
detection	O	O
method	O	O
for	O	O
PAX6	O	O
.	O	O

.	O	O

Germline	O	O
mutations	O	O
in	O	O
the	O	O
3	O	O
'	O	O
part	O	O
of	O	O
APC	B-Disease	D011125
exon	O	O
15	O	O
do	O	O
not	O	O
result	O	O
in	O	O
truncated	O	O
proteins	O	O
and	O	O
are	O	O
associated	O	O
with	O	O
attenuated	B-Disease	C538265
adenomatous	I-Disease	C538265
polyposis	I-Disease	C538265
coli	I-Disease	C538265
.	O	O

Familial	B-Disease	D011125
adenomatous	I-Disease	D011125
polyposis	I-Disease	D011125
(	O	O
FAP	B-Disease	D011125
)	O	O
is	O	O
an	O	O
inherited	O	O
predisposition	O	O
to	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
characterized	O	O
by	O	O
the	O	O
development	O	O
of	O	O
numerous	O	O
adenomatous	B-Disease	D018256
polyps	I-Disease	D018256
predominantly	O	O
in	O	O
the	O	O
colorectal	O	O
region	O	O
.	O	O

Germline	O	O
mutations	O	O
in	O	O
the	O	O
adenomatous	B-Disease	D011125
polyposis	I-Disease	D011125
coli	I-Disease	D011125
(	O	O
APC	B-Disease	D011125
)	O	O
gene	O	O
are	O	O
responsible	O	O
for	O	O
most	O	O
cases	O	O
of	O	O
FAP	B-Disease	D011125
.	O	O

Mutations	O	O
at	O	O
the	O	O
5	O	O
end	O	O
of	O	O
APC	B-Disease	D011125
are	O	O
known	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
a	O	O
relatively	O	O
mild	O	O
form	O	O
of	O	O
the	O	O
disease	O	O
,	O	O
called	O	O
attenuated	B-Disease	C538265
adenomatous	I-Disease	C538265
polyposis	I-Disease	C538265
coli	I-Disease	C538265
(	O	O
AAPC	B-Disease	C538265
)	O	O
.	O	O

We	O	O
identified	O	O
a	O	O
frameshift	O	O
mutation	O	O
in	O	O
the	O	O
3	O	O
part	O	O
of	O	O
exon	O	O
15	O	O
,	O	O
resulting	O	O
in	O	O
a	O	O
stop	O	O
codon	O	O
at	O	O
1862	O	O
,	O	O
in	O	O
a	O	O
large	O	O
Dutch	O	O
kindred	O	O
with	O	O
AAPC	B-Disease	C538265
.	O	O

Western	O	O
blot	O	O
analysis	O	O
of	O	O
lymphoblastoid	O	O
cell	O	O
lines	O	O
derived	O	O
from	O	O
affected	O	O
family	O	O
members	O	O
from	O	O
this	O	O
kindred	O	O
,	O	O
as	O	O
well	O	O
as	O	O
from	O	O
a	O	O
previously	O	O
reported	O	O
Swiss	O	O
family	O	O
carrying	O	O
a	O	O
frameshift	O	O
mutation	O	O
at	O	O
codon	O	O
1987	O	O
and	O	O
displaying	O	O
a	O	O
similar	O	O
attenuated	O	O
phenotype	O	O
,	O	O
showed	O	O
only	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
APC	B-Disease	D011125
protein	O	O
.	O	O

Our	O	O
study	O	O
indicates	O	O
that	O	O
chain	O	O
-	O	O
terminating	O	O
mutations	O	O
located	O	O
in	O	O
the	O	O
3	O	O
part	O	O
of	O	O
APC	B-Disease	D011125
do	O	O
not	O	O
result	O	O
in	O	O
detectable	O	O
truncated	O	O
polypeptides	O	O
and	O	O
we	O	O
hypothesize	O	O
that	O	O
this	O	O
is	O	O
likely	O	O
to	O	O
be	O	O
the	O	O
basis	O	O
for	O	O
the	O	O
observed	O	O
AAPC	B-Disease	C538265
phenotype	O	O
.	O	O

.	O	O

Absence	O	O
of	O	O
disease	O	O
phenotype	O	O
and	O	O
intergenerational	O	O
stability	O	O
of	O	O
the	O	O
CAG	O	O
repeat	O	O
in	O	O
transgenic	O	O
mice	O	O
expressing	O	O
the	O	O
human	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
transcript	O	O
.	O	O

The	O	O
mutation	O	O
underlying	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
(	O	O
HD	B-Disease	D006816
)	O	O
is	O	O
CAG	O	O
expansion	O	O
in	O	O
the	O	O
first	O	O
exon	O	O
of	O	O
the	O	O
HD	B-Disease	D006816
gene	O	O
.	O	O

In	O	O
order	O	O
to	O	O
investigate	O	O
the	O	O
role	O	O
of	O	O
CAG	O	O
expansion	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
HD	B-Disease	D006816
,	O	O
we	O	O
have	O	O
produced	O	O
transgenic	O	O
mice	O	O
containing	O	O
the	O	O
full	O	O
length	O	O
human	O	O
HD	B-Disease	D006816
cDNA	O	O
with	O	O
44	O	O
CAG	O	O
repeats	O	O
.	O	O

By	O	O
1	O	O
year	O	O
,	O	O
these	O	O
mice	O	O
have	O	O
no	O	O
behavioral	B-Disease	D001523
abnormalities	I-Disease	D001523
and	O	O
morphometric	O	O
analysis	O	O
at	O	O
6	O	O
(	O	O
one	O	O
animal	O	O
)	O	O
and	O	O
9	O	O
(	O	O
two	O	O
animals	O	O
)	O	O
months	O	O
age	O	O
revealed	O	O
no	O	O
changes	O	O
.	O	O

Despite	O	O
high	O	O
levels	O	O
of	O	O
mRNA	O	O
expression	O	O
,	O	O
there	O	O
was	O	O
no	O	O
evidence	O	O
of	O	O
the	O	O
HD	B-Disease	D006816
gene	O	O
product	O	O
in	O	O
any	O	O
of	O	O
these	O	O
transgenic	O	O
mice	O	O
.	O	O

In	O	O
vitro	O	O
transfection	O	O
studies	O	O
indicated	O	O
that	O	O
the	O	O
inclusion	O	O
of	O	O
120	O	O
bp	O	O
of	O	O
the	O	O
5	O	O
UTR	O	O
in	O	O
the	O	O
cDNA	O	O
construct	O	O
and	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
frameshift	O	O
mutation	O	O
at	O	O
nucleotide	O	O
2349	O	O
prevented	O	O
expression	O	O
of	O	O
the	O	O
HD	B-Disease	D006816
cDNA	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
the	O	O
pathogenesis	O	O
of	O	O
HD	B-Disease	D006816
is	O	O
not	O	O
mediated	O	O
through	O	O
DNA	O	O
-	O	O
protein	O	O
interaction	O	O
and	O	O
that	O	O
presence	O	O
of	O	O
the	O	O
RNA	O	O
transcript	O	O
with	O	O
an	O	O
expanded	O	O
CAG	O	O
repeat	O	O
is	O	O
insufficient	O	O
to	O	O
cause	O	O
the	O	O
disease	O	O
.	O	O

Rather	O	O
,	O	O
translation	O	O
of	O	O
the	O	O
CAG	O	O
is	O	O
crucial	O	O
for	O	O
the	O	O
pathogenesis	O	O
of	O	O
HD	B-Disease	D006816
.	O	O

In	O	O
contrast	O	O
to	O	O
that	O	O
seen	O	O
in	O	O
humans	O	O
,	O	O
the	O	O
CAG	O	O
repeat	O	O
in	O	O
these	O	O
mice	O	O
was	O	O
remarkably	O	O
stable	O	O
in	O	O
97	O	O
meioses	O	O
.	O	O

This	O	O
suggests	O	O
that	O	O
genomic	O	O
sequences	O	O
may	O	O
play	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
influencing	O	O
repeat	O	O
instability	O	O
.	O	O

.	O	O

Detection	O	O
of	O	O
heterozygous	O	O
mutations	O	O
in	O	O
BRCA1	O	O
using	O	O
high	O	O
density	O	O
oligonucleotide	O	O
arrays	O	O
and	O	O
two	O	O
-	O	O
colour	O	O
fluorescence	O	O
analysis	O	O
.	O	O

The	O	O
ability	O	O
to	O	O
scan	O	O
a	O	O
large	O	O
gene	O	O
rapidly	O	O
and	O	O
accurately	O	O
for	O	O
all	O	O
possible	O	O
heterozygous	O	O
mutations	O	O
in	O	O
large	O	O
numbers	O	O
of	O	O
patient	O	O
samples	O	O
will	O	O
be	O	O
critical	O	O
for	O	O
the	O	O
future	O	O
of	O	O
medicine	O	O
.	O	O

We	O	O
have	O	O
designed	O	O
high	O	O
-	O	O
density	O	O
arrays	O	O
consisting	O	O
of	O	O
over	O	O
96	O	O
,	O	O
600	O	O
oligonucleotides	O	O
20	O	O
-	O	O
nucleotides	O	O
(	O	O
nt	O	O
)	O	O
in	O	O
length	O	O
to	O	O
screen	O	O
for	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
heterozygous	O	O
mutations	O	O
in	O	O
the	O	O
3	O	O
.	O	O

45	O	O
-	O	O
kilobases	O	O
(	O	O
kb	O	O
)	O	O
exon	O	O
11	O	O
of	O	O
the	O	O
hereditary	B-Disease	D061325
breast	I-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
gene	O	O
BRCA1	O	O
.	O	O

Reference	O	O
and	O	O
test	O	O
samples	O	O
were	O	O
co	O	O
-	O	O
hybridized	O	O
to	O	O
these	O	O
arrays	O	O
and	O	O
differences	O	O
in	O	O
hybridization	O	O
patterns	O	O
quantitated	O	O
by	O	O
two	O	O
-	O	O
colour	O	O
analysis	O	O
.	O	O

Fourteen	O	O
of	O	O
fifteen	O	O
patient	O	O
samples	O	O
with	O	O
known	O	O
mutations	O	O
were	O	O
accurately	O	O
diagnosed	O	O
,	O	O
and	O	O
no	O	O
false	O	O
positive	O	O
mutations	O	O
were	O	O
identified	O	O
in	O	O
20	O	O
control	O	O
samples	O	O
.	O	O

Eight	O	O
single	O	O
nucleotide	O	O
polymorphisms	O	O
were	O	O
also	O	O
readily	O	O
detected	O	O
.	O	O

DNA	O	O
chip	O	O
-	O	O
based	O	O
assays	O	O
may	O	O
provide	O	O
a	O	O
valuable	O	O
new	O	O
technology	O	O
for	O	O
high	O	O
-	O	O
throughput	O	O
cost	O	O
-	O	O
efficient	O	O
detection	O	O
of	O	O
genetic	O	O
alterations	O	O
.	O	O

Colchicine	O	O
in	O	O
breast	O	O
milk	O	O
of	O	O
patients	O	O
with	O	O
familial	B-Disease	D010505
Mediterranean	I-Disease	D010505
fever	I-Disease	D010505
.	O	O

OBJECTIVE	O	O
.	O	O

To	O	O
clarify	O	O
whether	O	O
colchicine	O	O
is	O	O
excreted	O	O
in	O	O
breast	O	O
milk	O	O
,	O	O
and	O	O
to	O	O
compare	O	O
its	O	O
concentrations	O	O
in	O	O
the	O	O
serum	O	O
and	O	O
breast	O	O
milk	O	O
of	O	O
lactating	O	O
women	O	O
who	O	O
have	O	O
familial	B-Disease	D010505
Mediterranean	I-Disease	D010505
fever	I-Disease	D010505
(	O	O
FMF	B-Disease	D010505
)	O	O
.	O	O

METHODS	O	O
.	O	O

Using	O	O
a	O	O
specific	O	O
radioimmunoassay	O	O
,	O	O
we	O	O
determined	O	O
colchicine	O	O
concentrations	O	O
in	O	O
the	O	O
serum	O	O
and	O	O
breast	O	O
milk	O	O
of	O	O
4	O	O
patients	O	O
at	O	O
various	O	O
time	O	O
points	O	O
,	O	O
following	O	O
oral	O	O
administration	O	O
of	O	O
the	O	O
drug	O	O
.	O	O

The	O	O
study	O	O
evaluated	O	O
4	O	O
patients	O	O
with	O	O
FMF	B-Disease	D010505
who	O	O
had	O	O
been	O	O
taking	O	O
colchicine	O	O
on	O	O
a	O	O
long	O	O
-	O	O
term	O	O
basis	O	O
.	O	O

RESULTS	O	O
.	O	O

Colchicine	O	O
was	O	O
found	O	O
to	O	O
be	O	O
excreted	O	O
in	O	O
breast	O	O
milk	O	O
.	O	O

Its	O	O
levels	O	O
ranged	O	O
between	O	O
1	O	O
.	O	O

9	O	O
and	O	O
8	O	O
.	O	O

6	O	O
ng	O	O
/	O	O
ml	O	O
,	O	O
which	O	O
were	O	O
similar	O	O
to	O	O
those	O	O
found	O	O
in	O	O
the	O	O
serum	O	O
(	O	O
parallel	O	O
concentration	O	O
time	O	O
curves	O	O
)	O	O
.	O	O

However	O	O
,	O	O
there	O	O
appeared	O	O
to	O	O
be	O	O
a	O	O
considerable	O	O
variation	O	O
in	O	O
colchicine	O	O
milk	O	O
concentration	O	O
among	O	O
the	O	O
different	O	O
patients	O	O
,	O	O
which	O	O
might	O	O
be	O	O
related	O	O
to	O	O
individual	O	O
breast	O	O
milk	O	O
composition	O	O
and	O	O
,	O	O
possibly	O	O
,	O	O
to	O	O
other	O	O
nutritional	O	O
or	O	O
metabolic	O	O
factors	O	O
.	O	O

CONCLUSION	O	O
.	O	O

The	O	O
extensive	O	O
peripheral	O	O
tissue	O	O
binding	O	O
and	O	O
relatively	O	O
low	O	O
concentration	O	O
of	O	O
colchicine	O	O
in	O	O
breast	O	O
milk	O	O
suggests	O	O
that	O	O
the	O	O
amount	O	O
ingested	O	O
by	O	O
the	O	O
infant	O	O
is	O	O
small	O	O
.	O	O

Furthermore	O	O
,	O	O
based	O	O
on	O	O
our	O	O
clinical	O	O
experience	O	O
,	O	O
nursing	O	O
appears	O	O
to	O	O
be	O	O
safe	O	O
for	O	O
lactating	O	O
women	O	O
with	O	O
FMF	B-Disease	D010505
who	O	O
continue	O	O
to	O	O
take	O	O
colchicine	O	O
.	O	O

The	O	O
human	O	O
complement	O	O
C9	O	O
gene	O	O
:	O	O
identification	O	O
of	O	O
two	O	O
mutations	O	O
causing	O	O
deficiency	O	O
and	O	O
revision	O	O
of	O	O
the	O	O
gene	O	O
structure	O	O
.	O	O

The	O	O
ninth	O	O
component	O	O
of	O	O
human	O	O
complement	O	O
(	O	O
C9	O	O
)	O	O
is	O	O
the	O	O
last	O	O
of	O	O
the	O	O
terminal	O	O
complement	O	O
components	O	O
creating	O	O
the	O	O
membrane	O	O
attack	O	O
complex	O	O
.	O	O

C9	O	O
is	O	O
a	O	O
single	O	O
-	O	O
chain	O	O
serum	O	O
protein	O	O
that	O	O
is	O	O
encoded	O	O
by	O	O
a	O	O
gene	O	O
located	O	O
on	O	O
chromosome	O	O
5p	O	O
.	O	O

Deficiency	B-Disease	D007153
of	I-Disease	D007153
terminal	I-Disease	D007153
complement	I-Disease	D007153
components	I-Disease	D007153
is	O	O
generally	O	O
associated	O	O
with	O	O
recurrent	O	O
neisseria	B-Disease	D016870
infections	I-Disease	D016870
.	O	O

We	O	O
studied	O	O
a	O	O
previously	O	O
described	O	O
Swiss	O	O
family	O	O
with	O	O
inherited	B-Disease	OMIM:613825
C9	I-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
.	O	O

To	O	O
identify	O	O
the	O	O
genetic	O	O
basis	O	O
of	O	O
C9	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
,	O	O
we	O	O
developed	O	O
an	O	O
approach	O	O
using	O	O
exon	O	O
-	O	O
specific	O	O
PCR	O	O
and	O	O
direct	O	O
DNA	O	O
sequencing	O	O
.	O	O

As	O	O
a	O	O
cause	O	O
of	O	O
C9	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
,	O	O
we	O	O
found	O	O
two	O	O
different	O	O
point	O	O
mutations	O	O
,	O	O
both	O	O
generating	O	O
TGA	O	O
stop	O	O
codons	O	O
in	O	O
the	O	O
coding	O	O
sequence	O	O
.	O	O

One	O	O
mutation	O	O
,	O	O
a	O	O
C	O	O
to	O	O
A	O	O
exchange	O	O
,	O	O
was	O	O
detected	O	O
in	O	O
exon	O	O
2	O	O
at	O	O
cDNA	O	O
position	O	O
166	O	O
,	O	O
the	O	O
other	O	O
,	O	O
a	O	O
C	O	O
to	O	O
T	O	O
exchange	O	O
,	O	O
was	O	O
located	O	O
in	O	O
exon	O	O
4	O	O
(	O	O
cDNA	O	O
position	O	O
464	O	O
)	O	O
.	O	O

In	O	O
family	O	O
studies	O	O
of	O	O
three	O	O
first	O	O
-	O	O
degree	O	O
relatives	O	O
with	O	O
heterozygous	O	O
C9	B-Disease	OMIM:613825
deficiency	I-Disease	OMIM:613825
,	O	O
we	O	O
demonstrated	O	O
that	O	O
the	O	O
two	O	O
mutations	O	O
are	O	O
segregating	O	O
independently	O	O
.	O	O

Therefore	O	O
,	O	O
these	O	O
mutations	O	O
are	O	O
sufficient	O	O
to	O	O
explain	O	O
the	O	O
complete	O	O
deficiency	O	O
of	O	O
both	O	O
the	O	O
probands	O	O
studied	O	O
.	O	O

DNA	O	O
sequencing	O	O
of	O	O
the	O	O
exon	O	O
-	O	O
intron	O	O
junctions	O	O
revealed	O	O
a	O	O
number	O	O
of	O	O
revisions	O	O
regarding	O	O
the	O	O
boundaries	O	O
between	O	O
exons	O	O
4	O	O
,	O	O
5	O	O
,	O	O
and	O	O
6	O	O
as	O	O
well	O	O
as	O	O
between	O	O
exons	O	O
10	O	O
and	O	O
11	O	O
.	O	O

No	O	O
additional	O	O
introns	O	O
were	O	O
detected	O	O
in	O	O
exons	O	O
6	O	O
and	O	O
10	O	O
.	O	O

Furthermore	O	O
,	O	O
DNA	O	O
marker	O	O
studies	O	O
were	O	O
conducted	O	O
using	O	O
known	O	O
polymorphisms	O	O
of	O	O
the	O	O
C6	O	O
,	O	O
C7	O	O
,	O	O
and	O	O
C9	O	O
genes	O	O
,	O	O
confirming	O	O
the	O	O
linkage	O	O
of	O	O
the	O	O
observed	O	O
C9	O	O
mutations	O	O
with	O	O
defined	O	O
haplotypes	O	O
.	O	O

.	O	O

Molecular	O	O
heterogeneity	O	O
of	O	O
classical	B-Disease	D005693
and	I-Disease	D005693
Duarte	I-Disease	D005693
galactosemia	I-Disease	D005693
:	O	O
mutation	O	O
analysis	O	O
by	O	O
denaturing	O	O
gradient	O	O
gel	O	O
electrophoresis	O	O
.	O	O

Classical	B-Disease	D005693
galactosemia	I-Disease	D005693
is	O	O
caused	O	O
by	O	O
one	O	O
common	O	O
missense	O	O
mutation	O	O
(	O	O
Q188R	O	O
)	O	O
and	O	O
by	O	O
several	O	O
rare	O	O
mutations	O	O
in	O	O
the	O	O
galactose	O	O
-	O	O
1	O	O
-	O	O
phosphate	O	O
uridyltransferase	O	O
(	O	O
GALT	O	O
)	O	O
gene	O	O
.	O	O

The	O	O
most	O	O
common	O	O
variant	O	O
of	O	O
GALT	O	O
,	O	O
the	O	O
Duarte	O	O
variant	O	O
,	O	O
occurs	O	O
as	O	O
two	O	O
types	O	O
,	O	O
Duarte	O	O
-	O	O
1	O	O
(	O	O
D	O	O
-	O	O
1	O	O
)	O	O
and	O	O
Duarte	O	O
-	O	O
2	O	O
(	O	O
D	O	O
-	O	O
2	O	O
)	O	O
,	O	O
both	O	O
of	O	O
which	O	O
carry	O	O
the	O	O
sequence	O	O
change	O	O
N314D	O	O
.	O	O

D	O	O
-	O	O
1	O	O
increases	O	O
,	O	O
whereas	O	O
D	O	O
-	O	O
2	O	O
decreases	O	O
GALT	O	O
activity	O	O
.	O	O

To	O	O
study	O	O
the	O	O
molecular	O	O
genetics	O	O
of	O	O
classical	B-Disease	D005693
and	I-Disease	D005693
Duarte	I-Disease	D005693
galactosemia	I-Disease	D005693
,	O	O
we	O	O
analyzed	O	O
the	O	O
GALT	O	O
mutations	O	O
in	O	O
30	O	O
families	O	O
with	O	O
classical	B-Disease	D005693
galactosemia	I-Disease	D005693
,	O	O
in	O	O
10	O	O
families	O	O
with	O	O
the	O	O
D	O	O
-	O	O
2	O	O
variant	O	O
and	O	O
in	O	O
3	O	O
individuals	O	O
carrying	O	O
the	O	O
D	O	O
-	O	O
1	O	O
allele	O	O
by	O	O
denaturing	O	O
gradient	O	O
gel	O	O
electrophoresis	O	O
(	O	O
DGGE	O	O
)	O	O
.	O	O

DGGE	O	O
detected	O	O
59	O	O
of	O	O
the	O	O
60	O	O
classical	B-Disease	D005693
galactosemia	I-Disease	D005693
alleles	O	O
.	O	O

Q188R	O	O
accounted	O	O
for	O	O
60	O	O
%	O	O
,	O	O
K285N	O	O
accounted	O	O
for	O	O
28	O	O
%	O	O
of	O	O
these	O	O
alleles	O	O
.	O	O

Eight	O	O
novel	O	O
candidate	O	O
galactosemia	B-Disease	D005693
mutations	O	O
were	O	O
found	O	O
.	O	O

On	O	O
all	O	O
D	O	O
-	O	O
2	O	O
alleles	O	O
N314D	O	O
occurred	O	O
in	O	O
cis	O	O
with	O	O
two	O	O
intronic	O	O
sequence	O	O
changes	O	O
,	O	O
on	O	O
the	O	O
D	O	O
-	O	O
1	O	O
alleles	O	O
in	O	O
cis	O	O
with	O	O
a	O	O
neutral	O	O
mutation	O	O
in	O	O
exon	O	O
7	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
mutations	O	O
causing	O	O
galactosemia	B-Disease	D005693
are	O	O
highly	O	O
heterogeneous	O	O
and	O	O
that	O	O
K285N	O	O
is	O	O
a	O	O
second	O	O
common	O	O
galactosemia	B-Disease	D005693
mutation	O	O
in	O	O
our	O	O
population	O	O
.	O	O

.	O	O

Nonsense	O	O
mutation	O	O
in	O	O
exon	O	O
3	O	O
of	O	O
the	O	O
proteolipid	O	O
protein	O	O
gene	O	O
(	O	O
PLP	O	O
)	O	O
in	O	O
a	O	O
family	O	O
with	O	O
an	O	O
unusual	O	O
form	O	O
of	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
.	O	O

We	O	O
report	O	O
a	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
transition	O	O
at	O	O
nucleotide	O	O
431	O	O
of	O	O
the	O	O
proteolipid	O	O
protein	O	O
gene	O	O
(	O	O
PLP	O	O
)	O	O
results	O	O
in	O	O
a	O	O
nonsense	O	O
codon	O	O
in	O	O
a	O	O
family	O	O
with	O	O
an	O	O
unusual	O	O
form	O	O
of	O	O
Pelizaeus	B-Disease	OMIM:312080
-	I-Disease	OMIM:312080
Merzbacher	I-Disease	OMIM:312080
disease	I-Disease	OMIM:312080
(	O	O
PMD	B-Disease	OMIM:312080
)	O	O
.	O	O

The	O	O
mutation	O	O
,	O	O
which	O	O
creates	O	O
a	O	O
second	O	O
AluI	O	O
restriction	O	O
site	O	O
,	O	O
results	O	O
in	O	O
a	O	O
nonsense	O	O
mutation	O	O
in	O	O
PLP	O	O
.	O	O

The	O	O
clinical	O	O
picture	O	O
resembles	O	O
somewhat	O	O
that	O	O
of	O	O
X	B-Disease	OMIM:312920
-	I-Disease	OMIM:312920
linked	I-Disease	OMIM:312920
spastic	I-Disease	OMIM:312920
paraplegia	I-Disease	OMIM:312920
(	O	O
SPG	B-Disease	OMIM:312920
)	O	O
.	O	O

It	O	O
differs	O	O
from	O	O
this	O	O
and	O	O
both	O	O
the	O	O
classical	O	O
and	O	O
connatal	O	O
forms	O	O
of	O	O
PMD	B-Disease	OMIM:312080
in	O	O
that	O	O
it	O	O
is	O	O
relatively	O	O
mild	O	O
in	O	O
form	O	O
,	O	O
onset	O	O
is	O	O
delayed	O	O
beyond	O	O
age	O	O
2	O	O
years	O	O
,	O	O
nystagmus	B-Disease	D020417
is	O	O
absent	O	O
,	O	O
tremors	B-Disease	D014202
are	O	O
prominent	O	O
,	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
is	O	O
not	O	O
severe	O	O
,	O	O
some	O	O
patients	O	O
show	O	O
dementia	B-Disease	D003704
or	O	O
personality	B-Disease	D010554
disorders	I-Disease	D010554
,	O	O
the	O	O
disease	O	O
is	O	O
progressive	O	O
rather	O	O
than	O	O
static	O	O
in	O	O
some	O	O
,	O	O
and	O	O
several	O	O
females	O	O
show	O	O
signs	O	O
of	O	O
disease	O	O
.	O	O

The	O	O
nonsense	O	O
mutation	O	O
,	O	O
which	O	O
is	O	O
in	O	O
exon	O	O
3B	O	O
,	O	O
should	O	O
block	O	O
the	O	O
synthesis	O	O
of	O	O
normal	O	O
PLP	O	O
but	O	O
spare	O	O
DM20	O	O
,	O	O
the	O	O
isoform	O	O
whose	O	O
persistence	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
mild	O	O
forms	O	O
of	O	O
PLP	B-Disease	OMIM:312080	OMIM:312920
-	I-Disease	OMIM:312080	OMIM:312920
associated	I-Disease	OMIM:312080	OMIM:312920
disease	I-Disease	OMIM:312080	OMIM:312920
in	O	O
both	O	O
humans	O	O
and	O	O
mice	O	O
.	O	O

.	O	O

The	O	O
hybrid	O	O
PAX3	O	O
-	O	O
FKHR	O	O
fusion	O	O
protein	O	O
of	O	O
alveolar	B-Disease	D018232
rhabdomyosarcoma	I-Disease	D018232
transforms	O	O
fibroblasts	O	O
in	O	O
culture	O	O
.	O	O

Pediatric	B-Disease	D018232
alveolar	I-Disease	D018232
rhabdomyosarcoma	I-Disease	D018232
is	O	O
characterized	O	O
by	O	O
a	O	O
chromosomal	O	O
translocation	O	O
that	O	O
fuses	O	O
parts	O	O
of	O	O
the	O	O
PAX3	O	O
and	O	O
FKHR	O	O
genes	O	O
.	O	O

PAX3	O	O
codes	O	O
for	O	O
a	O	O
transcriptional	O	O
regulator	O	O
that	O	O
controls	O	O
developmental	O	O
programs	O	O
,	O	O
and	O	O
FKHR	O	O
codes	O	O
for	O	O
a	O	O
forkhead	O	O
-	O	O
winged	O	O
helix	O	O
protein	O	O
,	O	O
also	O	O
a	O	O
likely	O	O
transcription	O	O
factor	O	O
.	O	O

The	O	O
PAX3	O	O
-	O	O
FKHR	O	O
fusion	O	O
product	O	O
retains	O	O
the	O	O
DNA	O	O
binding	O	O
domains	O	O
of	O	O
the	O	O
PAX3	O	O
protein	O	O
and	O	O
the	O	O
putative	O	O
activator	O	O
domain	O	O
of	O	O
the	O	O
FKHR	O	O
protein	O	O
.	O	O

The	O	O
PAX3	O	O
-	O	O
FKHR	O	O
protein	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
function	O	O
as	O	O
a	O	O
transcriptional	O	O
activator	O	O
.	O	O

Using	O	O
the	O	O
RCAS	O	O
retroviral	O	O
vector	O	O
,	O	O
we	O	O
have	O	O
introduced	O	O
the	O	O
PAX3	O	O
-	O	O
FKHR	O	O
gene	O	O
into	O	O
chicken	O	O
embryo	O	O
fibroblasts	O	O
.	O	O

Expression	O	O
of	O	O
the	O	O
PAX3	O	O
-	O	O
FKHR	O	O
protein	O	O
in	O	O
these	O	O
cells	O	O
leads	O	O
to	O	O
transformation	O	O
the	O	O
cells	O	O
become	O	O
enlarged	O	O
,	O	O
grow	O	O
tightly	O	O
packed	O	O
and	O	O
in	O	O
multiple	O	O
layers	O	O
,	O	O
and	O	O
acquire	O	O
the	O	O
ability	O	O
for	O	O
anchorage	O	O
-	O	O
independent	O	O
growth	O	O
.	O	O

This	O	O
cellular	O	O
transformation	O	O
in	O	O
vitro	O	O
will	O	O
facilitate	O	O
studies	O	O
on	O	O
the	O	O
mechanism	O	O
of	O	O
PAX3	O	O
-	O	O
FKHR	O	O
-	O	O
induced	O	O
oncogenesis	O	O
.	O	O

.	O	O

A	O	O
clinical	O	O
overview	O	O
of	O	O
WT1	O	O
gene	O	O
mutations	O	O
.	O	O

Mutations	O	O
in	O	O
the	O	O
WT1	O	O
gene	O	O
were	O	O
anticipated	O	O
to	O	O
explain	O	O
the	O	O
genetic	O	O
basis	O	O
of	O	O
the	O	O
childhood	O	O
kidney	B-Disease	D007680
cancer	I-Disease	D007680
,	O	O
Wilms	B-Disease	D009396
tumour	I-Disease	D009396
(	O	O
WT	B-Disease	D009396
)	O	O
.	O	O

Six	O	O
years	O	O
on	O	O
,	O	O
we	O	O
review	O	O
100	O	O
reports	O	O
of	O	O
intragenic	O	O
WT1	O	O
mutations	O	O
and	O	O
examine	O	O
the	O	O
accompanying	O	O
clinical	O	O
phenotypes	O	O
.	O	O

While	O	O
only	O	O
5	O	O
%	O	O
of	O	O
sporadic	B-Disease	D009396
Wilms	I-Disease	D009396
tumours	I-Disease	D009396
have	O	O
intragenic	O	O
WT1	O	O
mutations	O	O
,	O	O
>	O	O
90	O	O
%	O	O
of	O	O
patients	O	O
with	O	O
the	O	O
Denys	B-Disease	D030321
-	I-Disease	D030321
Drash	I-Disease	D030321
syndrome	I-Disease	D030321
(	O	O
renal	B-Disease	D007674
nephropathy	I-Disease	D007674
,	O	O
gonadal	B-Disease	D006059
anomaly	I-Disease	D006059
,	O	O
predisposition	B-Disease	D020022
to	I-Disease	D020022
WT	I-Disease	D020022
)	O	O
carry	O	O
constitutional	O	O
intragenic	O	O
WT1	O	O
mutations	O	O
.	O	O

WT1	O	O
mutations	O	O
have	O	O
also	O	O
been	O	O
reported	O	O
in	O	O
juvenile	B-Disease	D006106
granulosa	I-Disease	D006106
cell	I-Disease	D006106
tumour	I-Disease	D006106
,	O	O
non	B-Disease	D008654
-	I-Disease	D008654
asbestos	I-Disease	D008654
related	I-Disease	D008654
mesothelioma	I-Disease	D008654
,	O	O
desmoplastic	B-Disease	D058405
small	I-Disease	D058405
round	I-Disease	D058405
cell	I-Disease	D058405
tumour	I-Disease	D058405
and	O	O
,	O	O
most	O	O
recently	O	O
,	O	O
acute	B-Disease	D015470
myeloid	I-Disease	D015470
leukemia	I-Disease	D015470
.	O	O

.	O	O

Dual	O	O
roles	O	O
of	O	O
ATM	O	O
in	O	O
the	O	O
cellular	O	O
response	O	O
to	O	O
radiation	O	O
and	O	O
in	O	O
cell	O	O
growth	O	O
control	O	O
.	O	O

The	O	O
gene	O	O
mutated	O	O
in	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
AT	B-Disease	D001260
)	O	O
patients	O	O
,	O	O
denoted	O	O
ATM	O	O
,	O	O
encodes	O	O
a	O	O
putative	O	O
protein	O	O
or	O	O
lipid	O	O
kinase	O	O
.	O	O

To	O	O
elucidate	O	O
the	O	O
functions	O	O
of	O	O
ATM	O	O
,	O	O
we	O	O
disrupted	O	O
the	O	O
mouse	O	O
ATM	O	O
gene	O	O
through	O	O
homologous	O	O
recombination	O	O
in	O	O
mice	O	O
.	O	O

Consistent	O	O
with	O	O
cellular	O	O
defects	O	O
of	O	O
AT	B-Disease	D001260
patients	O	O
,	O	O
the	O	O
ATM	O	O
-	O	O
/	O	O
-	O	O
cells	O	O
are	O	O
hypersensitive	O	O
to	O	O
gamma	O	O
-	O	O
irradiation	O	O
and	O	O
defective	O	O
in	O	O
cell	O	O
-	O	O
cycle	O	O
arrest	O	O
following	O	O
radiation	O	O
,	O	O
correlating	O	O
with	O	O
a	O	O
defective	O	O
up	O	O
-	O	O
regulation	O	O
of	O	O
p53	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
ATM	O	O
-	O	O
/	O	O
-	O	O
mouse	O	O
thymocytes	O	O
are	O	O
more	O	O
resistant	O	O
to	O	O
apoptosis	O	O
induced	O	O
by	O	O
gamma	O	O
-	O	O
irradiation	O	O
than	O	O
normal	O	O
thymocytes	O	O
.	O	O

ATM	O	O
-	O	O
/	O	O
-	O	O
fibroblasts	O	O
are	O	O
inefficient	O	O
in	O	O
G1	O	O
to	O	O
S	O	O
-	O	O
phase	O	O
progression	O	O
following	O	O
serum	O	O
stimulation	O	O
and	O	O
senesce	O	O
after	O	O
only	O	O
a	O	O
few	O	O
passages	O	O
in	O	O
culture	O	O
.	O	O

They	O	O
have	O	O
an	O	O
increased	O	O
constitutive	O	O
level	O	O
of	O	O
p21CP1	O	O
/	O	O
WAF1	O	O
.	O	O

The	O	O
ATM	O	O
protein	O	O
is	O	O
therefore	O	O
critical	O	O
both	O	O
for	O	O
cellular	O	O
responses	O	O
to	O	O
ionizing	O	O
radiation	O	O
and	O	O
for	O	O
normal	O	O
cell	O	O
-	O	O
cycle	O	O
progression	O	O
.	O	O

ATM	O	O
+	O	O
/	O	O
-	O	O
fibroblasts	O	O
and	O	O
thymocytes	O	O
showed	O	O
intermediately	O	O
defective	O	O
responses	O	O
to	O	O
irradiation	O	O
but	O	O
no	O	O
growth	O	O
defect	O	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
increased	O	O
cancer	B-Disease	D009369
risk	O	O
of	O	O
AT	B-Disease	D001260
heterozygotes	O	O
could	O	O
be	O	O
attributable	O	O
to	O	O
poor	O	O
checkpoint	O	O
function	O	O
.	O	O

.	O	O

Identification	O	O
and	O	O
expression	O	O
of	O	O
eight	O	O
novel	O	O
mutations	O	O
among	O	O
non	O	O
-	O	O
Jewish	O	O
patients	O	O
with	O	O
Canavan	B-Disease	D017825
disease	I-Disease	D017825
.	O	O

Canavan	B-Disease	D017825
disease	I-Disease	D017825
is	O	O
inherited	O	O
as	O	O
an	O	O
autosomal	O	O
recessive	O	O
trait	O	O
that	O	O
is	O	O
caused	O	O
by	O	O
the	O	O
deficiency	B-Disease	D017825
of	I-Disease	D017825
aspartoacylase	I-Disease	D017825
(	O	O
ASPA	O	O
)	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
patients	O	O
with	O	O
Canavan	B-Disease	D017825
disease	I-Disease	D017825
are	O	O
from	O	O
an	O	O
Ashkenazi	O	O
Jewish	O	O
background	O	O
.	O	O

Mutations	O	O
in	O	O
ASPA	O	O
that	O	O
lead	O	O
to	O	O
loss	O	O
of	O	O
enzymatic	O	O
activity	O	O
have	O	O
been	O	O
identified	O	O
,	O	O
and	O	O
E285A	O	O
and	O	O
Y231X	O	O
are	O	O
the	O	O
two	O	O
predominant	O	O
mutations	O	O
that	O	O
account	O	O
for	O	O
97	O	O
%	O	O
of	O	O
the	O	O
mutant	O	O
chromosomes	O	O
in	O	O
Ashkenazi	O	O
Jewish	O	O
patients	O	O
.	O	O

The	O	O
current	O	O
study	O	O
was	O	O
aimed	O	O
at	O	O
finding	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
Canavan	B-Disease	D017825
disease	I-Disease	D017825
in	O	O
25	O	O
independent	O	O
patients	O	O
of	O	O
non	O	O
-	O	O
Jewish	O	O
background	O	O
.	O	O

Eight	O	O
novel	O	O
and	O	O
three	O	O
previously	O	O
characterized	O	O
mutations	O	O
accounted	O	O
for	O	O
80	O	O
%	O	O
(	O	O
40	O	O
/	O	O
50	O	O
)	O	O
of	O	O
mutant	O	O
chromosomes	O	O
.	O	O

The	O	O
A305E	O	O
missense	O	O
mutation	O	O
accounted	O	O
for	O	O
48	O	O
%	O	O
(	O	O
24	O	O
/	O	O
50	O	O
)	O	O
of	O	O
mutant	O	O
chromosomes	O	O
in	O	O
patients	O	O
of	O	O
western	O	O
European	O	O
descent	O	O
,	O	O
while	O	O
the	O	O
two	O	O
predominant	O	O
Jewish	O	O
mutations	O	O
each	O	O
accounted	O	O
for	O	O
a	O	O
single	O	O
mutant	O	O
chromosome	O	O
.	O	O

The	O	O
eight	O	O
novel	O	O
mutations	O	O
identified	O	O
included	O	O
1	O	O
-	O	O
and	O	O
4	O	O
-	O	O
bp	O	O
deletions	O	O
(	O	O
32	O	O
deltaT	O	O
and	O	O
876	O	O
deltaAGAA	O	O
,	O	O
respectively	O	O
)	O	O
and	O	O
I16T	O	O
,	O	O
G27R	O	O
,	O	O
D114E	O	O
,	O	O
G123E	O	O
,	O	O
C152Y	O	O
,	O	O
and	O	O
R168C	O	O
missense	O	O
mutations	O	O
.	O	O

The	O	O
homozygous	O	O
32	O	O
deltaT	O	O
deletion	O	O
was	O	O
identified	O	O
in	O	O
the	O	O
only	O	O
known	O	O
patient	O	O
of	O	O
African	O	O
-	O	O
American	O	O
origin	O	O
with	O	O
Canavan	B-Disease	D017825
disease	I-Disease	D017825
.	O	O

The	O	O
heterozygosity	O	O
for	O	O
876	O	O
deltaAGAA	O	O
mutation	O	O
was	O	O
identified	O	O
in	O	O
three	O	O
independent	O	O
patients	O	O
from	O	O
England	O	O
.	O	O

Six	O	O
single	O	O
-	O	O
base	O	O
changes	O	O
leading	O	O
to	O	O
missense	O	O
mutations	O	O
were	O	O
identified	O	O
in	O	O
patients	O	O
from	O	O
Turkey	O	O
(	O	O
D114E	O	O
,	O	O
R168C	O	O
)	O	O
,	O	O
The	O	O
Netherlands	O	O
(	O	O
I16T	O	O
)	O	O
,	O	O
Germany	O	O
(	O	O
G27R	O	O
)	O	O
,	O	O
Ireland	O	O
(	O	O
C152Y	O	O
)	O	O
,	O	O
and	O	O
Canada	O	O
(	O	O
G123E	O	O
)	O	O
.	O	O

A	O	O
PCR	O	O
-	O	O
based	O	O
protocol	O	O
is	O	O
described	O	O
that	O	O
was	O	O
used	O	O
to	O	O
introduce	O	O
mutations	O	O
in	O	O
wild	O	O
-	O	O
type	O	O
cDNA	O	O
.	O	O

In	O	O
vitro	O	O
expression	O	O
of	O	O
mutant	O	O
cDNA	O	O
clones	O	O
demonstrated	O	O
that	O	O
all	O	O
of	O	O
these	O	O
mutations	O	O
led	O	O
to	O	O
a	O	O
deficiency	B-Disease	D017825
of	I-Disease	D017825
ASPA	I-Disease	D017825
and	O	O
should	O	O
therefore	O	O
result	O	O
in	O	O
Canavan	B-Disease	D017825
disease	I-Disease	D017825
.	O	O

.	O	O

BRCA1	O	O
mutations	O	O
in	O	O
women	O	O
attending	O	O
clinics	O	O
that	O	O
evaluate	O	O
the	O	O
risk	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

BACKGROUND	O	O
To	O	O
define	O	O
the	O	O
incidence	O	O
of	O	O
BRCA1	O	O
mutations	O	O
among	O	O
patients	O	O
seen	O	O
in	O	O
clinics	O	O
that	O	O
evaluate	O	O
the	O	O
risk	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
,	O	O
we	O	O
analyzed	O	O
DNA	O	O
samples	O	O
from	O	O
women	O	O
seen	O	O
in	O	O
this	O	O
setting	O	O
and	O	O
constructed	O	O
probability	O	O
tables	O	O
to	O	O
provide	O	O
estimates	O	O
of	O	O
the	O	O
likelihood	O	O
of	O	O
finding	O	O
a	O	O
BRCA1	O	O
mutation	O	O
in	O	O
individual	O	O
families	O	O
.	O	O

METHODS	O	O
Clinical	O	O
information	O	O
,	O	O
family	O	O
histories	O	O
,	O	O
and	O	O
blood	O	O
for	O	O
DNA	O	O
analysis	O	O
were	O	O
obtained	O	O
from	O	O
263	O	O
women	O	O
with	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

Conformation	O	O
-	O	O
sensitive	O	O
gel	O	O
electrophoresis	O	O
and	O	O
DNA	O	O
sequencing	O	O
were	O	O
used	O	O
to	O	O
identify	O	O
BRCA1	O	O
mutations	O	O
.	O	O

RESULTS	O	O
BRCA1	O	O
mutations	O	O
were	O	O
identified	O	O
in	O	O
16	O	O
percent	O	O
of	O	O
women	O	O
with	O	O
a	O	O
family	O	O
history	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

Only	O	O
7	O	O
percent	O	O
of	O	O
women	O	O
from	O	O
families	O	O
with	O	O
a	O	O
history	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
but	O	O
not	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
had	O	O
BRCA1	O	O
mutations	O	O
.	O	O

The	O	O
rates	O	O
were	O	O
higher	O	O
among	O	O
women	O	O
from	O	O
families	O	O
with	O	O
a	O	O
history	O	O
of	O	O
both	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
.	O	O

Among	O	O
family	O	O
members	O	O
,	O	O
an	O	O
average	O	O
age	O	O
of	O	O
less	O	O
than	O	O
55	O	O
years	O	O
at	O	O
the	O	O
diagnosis	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
,	O	O
the	O	O
presence	O	O
of	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
,	O	O
the	O	O
presence	O	O
of	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
in	O	O
the	O	O
same	O	O
woman	O	O
,	O	O
and	O	O
Ashkenazi	O	O
Jewish	O	O
ancestry	O	O
were	O	O
all	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
detecting	O	O
a	O	O
BRCA1	O	O
mutation	O	O
.	O	O

No	O	O
association	O	O
was	O	O
found	O	O
between	O	O
the	O	O
presence	O	O
of	O	O
bilateral	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
or	O	O
the	O	O
number	O	O
of	O	O
breast	B-Disease	D001943
cancers	I-Disease	D001943
in	O	O
a	O	O
family	O	O
and	O	O
the	O	O
detection	O	O
of	O	O
a	O	O
BRCA1	O	O
mutation	O	O
,	O	O
or	O	O
between	O	O
the	O	O
position	O	O
of	O	O
the	O	O
mutation	O	O
in	O	O
the	O	O
BRCA1	O	O
gene	O	O
and	O	O
the	O	O
presence	O	O
of	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
in	O	O
a	O	O
family	O	O
.	O	O

CONCLUSIONS	O	O
Among	O	O
women	O	O
with	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
and	O	O
a	O	O
family	O	O
history	O	O
of	O	O
the	O	O
disease	O	O
,	O	O
the	O	O
percentage	O	O
with	O	O
BRCA1	O	O
coding	O	O
-	O	O
region	O	O
mutations	O	O
is	O	O
less	O	O
than	O	O
the	O	O
45	O	O
percent	O	O
predicted	O	O
by	O	O
genetic	O	O
-	O	O
linkage	O	O
analysis	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
even	O	O
in	O	O
a	O	O
referral	O	O
clinic	O	O
specializing	O	O
in	O	O
screening	O	O
women	O	O
from	O	O
high	O	O
-	O	O
risk	O	O
families	O	O
,	O	O
the	O	O
majority	O	O
of	O	O
tests	O	O
for	O	O
BRCA1	O	O
mutations	O	O
will	O	O
be	O	O
negative	O	O
and	O	O
therefore	O	O
uninformative	O	O
.	O	O

.	O	O

The	O	O
von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
tumor	I-Disease	D006623
suppressor	O	O
gene	O	O
product	O	O
interacts	O	O
with	O	O
Sp1	O	O
to	O	O
repress	O	O
vascular	O	O
endothelial	O	O
growth	O	O
factor	O	O
promoter	O	O
activity	O	O
.	O	O

The	O	O
von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
tumor	I-Disease	D006623
suppressor	O	O
gene	O	O
(	O	O
VHL	O	O
)	O	O
has	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
clear	B-Disease	C538445
-	I-Disease	C538445
cell	I-Disease	C538445
renal	I-Disease	C538445
cell	I-Disease	C538445
carcinoma	I-Disease	C538445
(	O	O
RCC	B-Disease	D002292
)	O	O
,	O	O
as	O	O
VHL	O	O
mutations	O	O
have	O	O
been	O	O
found	O	O
in	O	O
both	O	O
von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
disease	I-Disease	D006623
-	I-Disease	D006623
associated	I-Disease	D006623
and	I-Disease	D006623
sporadic	I-Disease	D006623
RCCs	I-Disease	D006623
.	O	O

Recent	O	O
studies	O	O
suggest	O	O
that	O	O
vascular	O	O
endothelial	O	O
growth	O	O
factor	O	O
(	O	O
VEGF	O	O
)	O	O
mRNA	O	O
is	O	O
upregulated	O	O
in	O	O
RCC	B-Disease	D002292
-	O	O
and	O	O
von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
disease	I-Disease	D006623
-	O	O
associated	O	O
tumors	O	O
.	O	O

We	O	O
have	O	O
therefore	O	O
assessed	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
VHL	O	O
gene	O	O
product	O	O
on	O	O
VEGF	O	O
expression	O	O
.	O	O

VEGF	O	O
promoter	O	O
-	O	O
luciferase	O	O
constructs	O	O
were	O	O
transiently	O	O
cotransfected	O	O
with	O	O
a	O	O
wild	O	O
-	O	O
type	O	O
VHL	O	O
(	O	O
wt	O	O
-	O	O
VHL	O	O
)	O	O
vector	O	O
in	O	O
several	O	O
cell	O	O
lines	O	O
,	O	O
including	O	O
293	O	O
embryonic	O	O
kidney	O	O
and	O	O
RCC	B-Disease	D002292
cell	O	O
lines	O	O
.	O	O

wt	O	O
-	O	O
VHL	O	O
protein	O	O
inhibited	O	O
VEGF	O	O
promoter	O	O
activity	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
up	O	O
to	O	O
5	O	O
-	O	O
to	O	O
10	O	O
-	O	O
fold	O	O
.	O	O

Deletion	O	O
analysis	O	O
defined	O	O
a	O	O
144	O	O
-	O	O
bp	O	O
region	O	O
of	O	O
the	O	O
VEGF	O	O
promoter	O	O
necessary	O	O
for	O	O
VHL	O	O
repression	O	O
.	O	O

This	O	O
VHL	O	O
-	O	O
responsive	O	O
element	O	O
is	O	O
GC	O	O
rich	O	O
and	O	O
specifically	O	O
binds	O	O
the	O	O
transcription	O	O
factor	O	O
Sp1	O	O
in	O	O
crude	O	O
nuclear	O	O
extracts	O	O
.	O	O

In	O	O
Drosophila	O	O
cells	O	O
,	O	O
cotransfected	O	O
VHL	O	O
represses	O	O
Sp1	O	O
-	O	O
mediated	O	O
activation	O	O
but	O	O
not	O	O
basal	O	O
activity	O	O
of	O	O
the	O	O
VEGF	O	O
promoter	O	O
.	O	O

We	O	O
next	O	O
demonstrated	O	O
in	O	O
coimmunoprecipitates	O	O
that	O	O
VHL	O	O
and	O	O
Sp1	O	O
were	O	O
part	O	O
of	O	O
the	O	O
same	O	O
complex	O	O
and	O	O
,	O	O
by	O	O
using	O	O
a	O	O
glutathione	O	O
-	O	O
S	O	O
-	O	O
transferase	O	O
-	O	O
VHL	O	O
fusion	O	O
protein	O	O
and	O	O
purified	O	O
Sp1	O	O
,	O	O
that	O	O
VHL	O	O
and	O	O
Sp1	O	O
directly	O	O
interact	O	O
.	O	O

Furthermore	O	O
,	O	O
endogenous	O	O
VEGF	O	O
mRNA	O	O
levels	O	O
were	O	O
suppressed	O	O
in	O	O
permanent	O	O
RCC	B-Disease	D002292
cell	O	O
lines	O	O
expressing	O	O
wt	O	O
-	O	O
VHL	O	O
,	O	O
and	O	O
nuclear	O	O
run	O	O
-	O	O
on	O	O
studies	O	O
indicated	O	O
that	O	O
VHL	O	O
regulation	O	O
of	O	O
VEGF	O	O
occurs	O	O
at	O	O
least	O	O
partly	O	O
at	O	O
the	O	O
transcriptional	O	O
level	O	O
.	O	O

These	O	O
observations	O	O
support	O	O
a	O	O
new	O	O
mechanism	O	O
for	O	O
VHL	O	O
-	O	O
mediated	O	O
transcriptional	O	O
repression	O	O
via	O	O
a	O	O
direct	O	O
inhibitory	O	O
action	O	O
on	O	O
Sp1	O	O
and	O	O
suggest	O	O
that	O	O
loss	O	O
of	O	O
Sp1	O	O
inhibition	O	O
may	O	O
be	O	O
important	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
disease	I-Disease	D006623
and	O	O
RCC	B-Disease	D002292
.	O	O

.	O	O

Germline	O	O
mutations	O	O
in	O	O
the	O	O
RB1	O	O
gene	O	O
in	O	O
patients	O	O
with	O	O
hereditary	B-Disease	D012175
retinoblastoma	I-Disease	D012175
.	O	O

We	O	O
have	O	O
analyzed	O	O
the	O	O
27	O	O
exons	O	O
and	O	O
the	O	O
promoter	O	O
region	O	O
of	O	O
the	O	O
RB1	O	O
gene	O	O
in	O	O
familial	B-Disease	D012175
or	I-Disease	D012175
sporadic	I-Disease	D012175
bilateral	I-Disease	D012175
retinoblastoma	I-Disease	D012175
by	O	O
using	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
analysis	O	O
.	O	O

For	O	O
improvement	O	O
over	O	O
previous	O	O
studies	O	O
,	O	O
a	O	O
new	O	O
set	O	O
of	O	O
primers	O	O
has	O	O
been	O	O
designed	O	O
,	O	O
which	O	O
allow	O	O
for	O	O
amplification	O	O
of	O	O
the	O	O
coding	O	O
and	O	O
splicing	O	O
sequences	O	O
only	O	O
.	O	O

The	O	O
positioning	O	O
of	O	O
the	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
primers	O	O
was	O	O
such	O	O
that	O	O
the	O	O
resulting	O	O
PCR	O	O
products	O	O
were	O	O
of	O	O
different	O	O
sizes	O	O
,	O	O
which	O	O
enabled	O	O
us	O	O
to	O	O
analyze	O	O
two	O	O
different	O	O
exons	O	O
simultaneously	O	O
and	O	O
still	O	O
distinguish	O	O
between	O	O
the	O	O
banding	O	O
profiles	O	O
for	O	O
both	O	O
(	O	O
biplex	O	O
analysis	O	O
)	O	O
.	O	O

By	O	O
using	O	O
this	O	O
approach	O	O
,	O	O
we	O	O
were	O	O
able	O	O
to	O	O
identify	O	O
mutation	O	O
in	O	O
22	O	O
new	O	O
patients	O	O
,	O	O
but	O	O
the	O	O
overall	O	O
efficiency	O	O
of	O	O
the	O	O
procedure	O	O
when	O	O
we	O	O
used	O	O
a	O	O
single	O	O
-	O	O
pass	O	O
regimen	O	O
was	O	O
only	O	O
48	O	O
%	O	O
.	O	O

The	O	O
mutations	O	O
were	O	O
small	O	O
insertions	O	O
and	O	O
deletions	O	O
and	O	O
point	O	O
mutations	O	O
in	O	O
roughly	O	O
equal	O	O
proportions	O	O
.	O	O

.	O	O

Deletion	O	O
of	O	O
small	O	O
nuclear	O	O
ribonucleoprotein	O	O
polypeptide	O	O
N	O	O
(	O	O
SNRPN	O	O
)	O	O
in	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
detected	O	O
by	O	O
fluorescence	O	O
in	O	O
situ	O	O
hybridization	O	O
:	O	O
two	O	O
sibs	O	O
with	O	O
the	O	O
typical	O	O
phenotype	O	O
without	O	O
a	O	O
cytogenetic	O	O
deletion	O	O
in	O	O
chromosome	O	O
15q	O	O
.	O	O

The	O	O
small	O	O
nuclear	O	O
ribonucleoprotein	O	O
polypeptide	O	O
N	O	O
(	O	O
SNRPN	O	O
)	O	O
gene	O	O
is	O	O
regarded	O	O
as	O	O
one	O	O
of	O	O
the	O	O
candidates	O	O
for	O	O
Prader	B-Disease	D011218
-	I-Disease	D011218
Willi	I-Disease	D011218
syndrome	I-Disease	D011218
(	O	O
PWS	B-Disease	D011218
)	O	O
.	O	O

We	O	O
describe	O	O
two	O	O
sibs	O	O
with	O	O
typical	O	O
PWS	B-Disease	D011218
presenting	O	O
deletion	O	O
of	O	O
SNRPN	O	O
detected	O	O
by	O	O
fluorescence	O	O
in	O	O
situ	O	O
hybridization	O	O
(	O	O
FISH	O	O
)	O	O
.	O	O

Neither	O	O
a	O	O
cytogenetically	O	O
detectable	O	O
15q12	O	O
deletion	O	O
nor	O	O
a	O	O
deletion	O	O
for	O	O
the	O	O
D15S11	O	O
,	O	O
D15S10	O	O
,	O	O
and	O	O
GABRB3	O	O
cosmid	O	O
probes	O	O
were	O	O
found	O	O
in	O	O
either	O	O
patient	O	O
.	O	O

This	O	O
implies	O	O
a	O	O
smaller	O	O
deletion	O	O
limited	O	O
to	O	O
the	O	O
PWS	B-Disease	D011218
critical	O	O
region	O	O
.	O	O

FISH	O	O
with	O	O
a	O	O
SNRPN	O	O
probe	O	O
will	O	O
permit	O	O
analysis	O	O
of	O	O
PWS	B-Disease	D011218
patients	O	O
with	O	O
limited	O	O
deletions	O	O
not	O	O
detectable	O	O
with	O	O
other	O	O
probes	O	O
.	O	O

.	O	O

The	O	O
mouse	O	O
homolog	O	O
of	O	O
the	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
protein	O	O
(	O	O
WASP	O	O
)	O	O
gene	O	O
is	O	O
highly	O	O
conserved	O	O
and	O	O
maps	O	O
near	O	O
the	O	O
scurfy	O	O
(	O	O
sf	O	O
)	O	O
mutation	O	O
on	O	O
the	O	O
X	O	O
chromosome	O	O
.	O	O

The	O	O
mouse	O	O
WASP	O	O
gene	O	O
,	O	O
the	O	O
homolog	O	O
of	O	O
the	O	O
gene	O	O
mutated	O	O
in	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
,	O	O
has	O	O
been	O	O
isolated	O	O
and	O	O
sequenced	O	O
.	O	O

the	O	O
predicted	O	O
amino	O	O
acid	O	O
sequence	O	O
is	O	O
86	O	O
%	O	O
identical	O	O
to	O	O
the	O	O
human	O	O
WASP	O	O
sequence	O	O
.	O	O

A	O	O
distinct	O	O
feature	O	O
of	O	O
the	O	O
mouse	O	O
gene	O	O
is	O	O
an	O	O
expanded	O	O
polymorphic	O	O
GGA	O	O
trinucleotide	O	O
repeat	O	O
that	O	O
codes	O	O
for	O	O
polyglycine	O	O
and	O	O
varies	O	O
from	O	O
15	O	O
to	O	O
17	O	O
triplets	O	O
in	O	O
different	O	O
Mus	O	O
musculus	O	O
strains	O	O
.	O	O

The	O	O
genomic	O	O
structure	O	O
of	O	O
the	O	O
mouse	O	O
WASP	O	O
gene	O	O
is	O	O
expressed	O	O
as	O	O
an	O	O
approximately	O	O
2	O	O
.	O	O

4	O	O
-	O	O
kb	O	O
mRNA	O	O
in	O	O
thymus	O	O
and	O	O
spleen	O	O
.	O	O

Chromosomal	O	O
mapping	O	O
in	O	O
an	O	O
interspecific	O	O
M	O	O
.	O	O

Musculus	O	O
/	O	O
M	O	O
.	O	O

spretus	O	O
backcross	O	O
placed	O	O
the	O	O
Wasp	O	O
locus	O	O
near	O	O
the	O	O
centromere	O	O
of	O	O
the	O	O
mouse	O	O
X	O	O
chromosome	O	O
,	O	O
inseparable	O	O
from	O	O
Gata1	O	O
,	O	O
Tcfe3	O	O
,	O	O
and	O	O
scurfy	O	O
(	O	O
sf	O	O
)	O	O
.	O	O

This	O	O
localization	O	O
makes	O	O
Wasp	O	O
a	O	O
candidate	O	O
for	O	O
involvement	O	O
in	O	O
scurfy	O	O
,	O	O
a	O	O
T	O	O
cell	O	O
-	O	O
mediated	O	O
fatal	B-Disease	D008206
lymphoreticular	I-Disease	D008206
disease	I-Disease	D008206
of	O	O
mice	O	O
that	O	O
has	O	O
previously	O	O
been	O	O
proposed	O	O
as	O	O
a	O	O
mouse	O	O
homolog	O	O
of	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
.	O	O

Northern	O	O
analysis	O	O
of	O	O
sf	O	O
tissue	O	O
samples	O	O
indicated	O	O
the	O	O
presence	O	O
of	O	O
WASP	O	O
mRNA	O	O
in	O	O
liver	O	O
and	O	O
skin	O	O
,	O	O
presumably	O	O
as	O	O
a	O	O
consequence	O	O
of	O	O
lymphocytic	O	O
infiltration	O	O
,	O	O
but	O	O
non	O	O
abnormalities	O	O
in	O	O
the	O	O
amount	O	O
or	O	O
size	O	O
of	O	O
mRNA	O	O
present	O	O
.	O	O

An	O	O
animal	O	O
model	O	O
for	O	O
Norrie	B-Disease	C537849
disease	I-Disease	C537849
(	O	O
ND	B-Disease	C537849
)	O	O
:	O	O
gene	O	O
targeting	O	O
of	O	O
the	O	O
mouse	O	O
ND	B-Disease	C537849
gene	O	O
.	O	O

In	O	O
order	O	O
to	O	O
elucidate	O	O
the	O	O
cellular	O	O
and	O	O
molecular	O	O
processes	O	O
which	O	O
are	O	O
involved	O	O
in	O	O
Norrie	B-Disease	C537849
disease	I-Disease	C537849
(	O	O
ND	B-Disease	C537849
)	O	O
,	O	O
we	O	O
have	O	O
used	O	O
gene	O	O
targeting	O	O
technology	O	O
to	O	O
generate	O	O
ND	B-Disease	C537849
mutant	O	O
mice	O	O
.	O	O

The	O	O
murine	O	O
homologue	O	O
of	O	O
the	O	O
ND	B-Disease	C537849
gene	O	O
was	O	O
cloned	O	O
and	O	O
shown	O	O
to	O	O
encode	O	O
a	O	O
polypeptide	O	O
that	O	O
shares	O	O
94	O	O
%	O	O
of	O	O
the	O	O
amino	O	O
acid	O	O
sequence	O	O
with	O	O
its	O	O
human	O	O
counterpart	O	O
.	O	O

RNA	O	O
in	O	O
situ	O	O
hybridization	O	O
revealed	O	O
expression	O	O
in	O	O
retina	O	O
,	O	O
brain	O	O
and	O	O
the	O	O
olfactory	O	O
bulb	O	O
and	O	O
epithelium	O	O
of	O	O
2	O	O
week	O	O
old	O	O
mice	O	O
.	O	O

Hemizygous	O	O
mice	O	O
carrying	O	O
a	O	O
replacement	O	O
mutation	O	O
in	O	O
exon	O	O
2	O	O
of	O	O
the	O	O
ND	B-Disease	C537849
gene	O	O
developed	O	O
retrolental	O	O
structures	O	O
in	O	O
the	O	O
vitreous	O	O
body	O	O
and	O	O
showed	O	O
an	O	O
overall	O	O
disorganization	O	O
of	O	O
the	O	O
retinal	O	O
ganglion	O	O
cell	O	O
layer	O	O
.	O	O

The	O	O
outer	O	O
plexiform	O	O
layer	O	O
disappears	O	O
occasionally	O	O
,	O	O
resulting	O	O
in	O	O
a	O	O
juxtaposed	O	O
inner	O	O
and	O	O
outer	O	O
nuclear	O	O
layer	O	O
.	O	O

At	O	O
the	O	O
same	O	O
regions	O	O
,	O	O
the	O	O
outer	O	O
segments	O	O
of	O	O
the	O	O
photoreceptor	O	O
cell	O	O
layer	O	O
are	O	O
no	O	O
longer	O	O
present	O	O
.	O	O

These	O	O
ocular	O	O
findings	O	O
are	O	O
consistent	O	O
with	O	O
observations	O	O
in	O	O
ND	B-Disease	C537849
patients	O	O
and	O	O
the	O	O
generated	O	O
mouse	O	O
line	O	O
provides	O	O
a	O	O
faithful	O	O
model	O	O
for	O	O
study	O	O
of	O	O
early	O	O
pathogenic	O	O
events	O	O
in	O	O
this	O	O
severe	O	O
X	B-Disease	D020271
-	I-Disease	D020271
linked	I-Disease	D020271
recessive	I-Disease	D020271
neurological	I-Disease	D020271
disorder	I-Disease	D020271
.	O	O

.	O	O

Phenotypic	O	O
characterization	O	O
of	O	O
individuals	O	O
with	O	O
30	O	O
-	O	O
40	O	O
CAG	O	O
repeats	O	O
in	O	O
the	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
(	O	O
HD	B-Disease	D006816
)	O	O
gene	O	O
reveals	O	O
HD	B-Disease	D006816
cases	O	O
with	O	O
36	O	O
repeats	O	O
and	O	O
apparently	O	O
normal	O	O
elderly	O	O
individuals	O	O
with	O	O
36	O	O
-	O	O
39	O	O
repeats	O	O
.	O	O

Abnormal	O	O
CAG	O	O
expansions	O	O
in	O	O
the	O	O
IT	O	O
-	O	O
15	O	O
gene	O	O
are	O	O
associated	O	O
with	O	O
Huntington	B-Disease	D006816
disease	I-Disease	D006816
(	O	O
HD	B-Disease	D006816
)	O	O
.	O	O

In	O	O
the	O	O
diagnostic	O	O
setting	O	O
it	O	O
is	O	O
necessary	O	O
to	O	O
define	O	O
the	O	O
limits	O	O
of	O	O
the	O	O
CAG	O	O
size	O	O
ranges	O	O
on	O	O
normal	O	O
and	O	O
HD	B-Disease	D006816
-	O	O
associated	O	O
chromosomes	O	O
.	O	O

Most	O	O
large	O	O
analyses	O	O
that	O	O
defined	O	O
the	O	O
limits	O	O
of	O	O
the	O	O
normal	O	O
and	O	O
pathological	O	O
size	O	O
ranges	O	O
employed	O	O
PCR	O	O
assays	O	O
,	O	O
which	O	O
included	O	O
the	O	O
CAG	O	O
repeats	O	O
and	O	O
a	O	O
CCG	O	O
repeat	O	O
tract	O	O
that	O	O
was	O	O
thought	O	O
to	O	O
be	O	O
invariant	O	O
.	O	O

Many	O	O
of	O	O
these	O	O
experiments	O	O
found	O	O
an	O	O
overlap	O	O
between	O	O
the	O	O
normal	O	O
and	O	O
disease	O	O
size	O	O
ranges	O	O
.	O	O

Subsequent	O	O
findings	O	O
that	O	O
the	O	O
CCG	O	O
repeats	O	O
vary	O	O
by	O	O
8	O	O
trinucleotide	O	O
lengths	O	O
suggested	O	O
that	O	O
the	O	O
limits	O	O
of	O	O
the	O	O
normal	O	O
and	O	O
disease	O	O
size	O	O
ranges	O	O
should	O	O
be	O	O
reevaluated	O	O
with	O	O
assays	O	O
that	O	O
exclude	O	O
the	O	O
CCG	O	O
polymorphism	O	O
.	O	O

Since	O	O
patients	O	O
with	O	O
between	O	O
30	O	O
and	O	O
40	O	O
repeats	O	O
are	O	O
rare	O	O
,	O	O
a	O	O
consortium	O	O
was	O	O
assembled	O	O
to	O	O
collect	O	O
such	O	O
individuals	O	O
.	O	O

All	O	O
178	O	O
samples	O	O
were	O	O
reanalyzed	O	O
in	O	O
Cambridge	O	O
by	O	O
using	O	O
assays	O	O
specific	O	O
for	O	O
the	O	O
CAG	O	O
repeats	O	O
.	O	O

We	O	O
have	O	O
optimized	O	O
methods	O	O
for	O	O
reliable	O	O
sizing	O	O
of	O	O
CAG	O	O
repeats	O	O
and	O	O
show	O	O
cases	O	O
that	O	O
demonstrate	O	O
the	O	O
dangers	O	O
of	O	O
using	O	O
PCR	O	O
assays	O	O
that	O	O
include	O	O
both	O	O
the	O	O
CAG	O	O
and	O	O
CCG	O	O
polymorphisms	O	O
.	O	O

Seven	O	O
HD	B-Disease	D006816
patients	O	O
had	O	O
36	O	O
repeats	O	O
,	O	O
which	O	O
confirms	O	O
that	O	O
this	O	O
allele	O	O
is	O	O
associated	O	O
with	O	O
disease	O	O
.	O	O

Individuals	O	O
without	O	O
apparent	O	O
symptoms	O	O
or	O	O
signs	O	O
of	O	O
HD	B-Disease	D006816
were	O	O
found	O	O
at	O	O
36	O	O
repeats	O	O
(	O	O
aged	O	O
74	O	O
,	O	O
78	O	O
,	O	O
79	O	O
,	O	O
and	O	O
87	O	O
years	O	O
)	O	O
,	O	O
37	O	O
repeats	O	O
(	O	O
aged	O	O
69	O	O
years	O	O
)	O	O
,	O	O
38	O	O
repeats	O	O
(	O	O
aged	O	O
69	O	O
and	O	O
90	O	O
years	O	O
)	O	O
,	O	O
and	O	O
39	O	O
repeats	O	O
(	O	O
aged	O	O
67	O	O
,	O	O
90	O	O
,	O	O
and	O	O
95	O	O
years	O	O
)	O	O
.	O	O

The	O	O
detailed	O	O
case	O	O
histories	O	O
of	O	O
an	O	O
exceptional	O	O
case	O	O
from	O	O
this	O	O
series	O	O
will	O	O
be	O	O
presented	O	O
a	O	O
95	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
39	O	O
repeats	O	O
who	O	O
did	O	O
not	O	O
have	O	O
classical	O	O
features	O	O
of	O	O
HD	B-Disease	D006816
.	O	O

The	O	O
apparently	O	O
healthy	O	O
survival	O	O
into	O	O
old	O	O
age	O	O
of	O	O
some	O	O
individuals	O	O
with	O	O
36	O	O
-	O	O
39	O	O
repeats	O	O
suggests	O	O
that	O	O
the	O	O
HD	B-Disease	D006816
mutation	O	O
may	O	O
not	O	O
always	O	O
be	O	O
fully	O	O
penetrant	O	O
.	O	O

.	O	O

HPRT	B-Disease	OMIM:300322	OMIM:102600
-	I-Disease	OMIM:300322	OMIM:102600
APRT	I-Disease	OMIM:300322	OMIM:102600
-	I-Disease	OMIM:300322	OMIM:102600
deficient	I-Disease	OMIM:300322	OMIM:102600
mice	O	O
are	O	O
not	O	O
a	O	O
model	O	O
for	O	O
lesch	B-Disease	D007926
-	I-Disease	D007926
nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
.	O	O

Complete	B-Disease	D007926
hypoxanthine	I-Disease	D007926
-	I-Disease	D007926
guanine	I-Disease	D007926
phosphoribosyl	I-Disease	D007926
-	I-Disease	D007926
transferase	I-Disease	D007926
(	I-Disease	D007926
HPRT	I-Disease	D007926
)	I-Disease	D007926
deficiency	I-Disease	D007926
in	O	O
humans	O	O
results	O	O
in	O	O
the	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
which	O	O
is	O	O
characterized	O	O
,	O	O
among	O	O
other	O	O
features	O	O
,	O	O
by	O	O
compulsive	O	O
self	O	O
-	O	O
injurious	O	O
behavior	O	O
.	O	O

HPRT	B-Disease	D007926
-	I-Disease	D007926
deficient	I-Disease	D007926
mice	O	O
generated	O	O
using	O	O
mouse	O	O
embryonic	O	O
stem	O	O
cells	O	O
exhibit	O	O
none	O	O
of	O	O
the	O	O
behavioral	O	O
symptoms	O	O
associated	O	O
with	O	O
the	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
.	O	O

Administration	O	O
of	O	O
drugs	O	O
that	O	O
inhibit	O	O
adenine	O	O
phosphoribosyltransferase	O	O
(	O	O
APRT	O	O
)	O	O
in	O	O
HPRT	B-Disease	D007926
-	I-Disease	D007926
deficient	I-Disease	D007926
mice	O	O
has	O	O
produced	O	O
the	O	O
suggestion	O	O
that	O	O
deficiency	B-Disease	OMIM:102600
of	I-Disease	OMIM:102600
APRT	I-Disease	OMIM:102600
in	O	O
combination	O	O
with	O	O
HPRT	B-Disease	D007926
-	I-Disease	D007926
deficiency	I-Disease	D007926
in	O	O
mice	O	O
may	O	O
lead	O	O
to	O	O
self	O	O
-	O	O
mutilation	O	O
behavior	O	O
[	O	O
C	O	O
.	O	O

L	O	O
.	O	O

Wu	O	O
and	O	O
D	O	O
.	O	O

W	O	O
.	O	O

Melton	O	O
(	O	O
1993	O	O
)	O	O
Nature	O	O
Genet	O	O
.	O	O

3	O	O
,	O	O
235	O	O
-	O	O
240	O	O
]	O	O
.	O	O

To	O	O
test	O	O
this	O	O
proposition	O	O
,	O	O
we	O	O
bred	O	O
HPRT	B-Disease	OMIM:300322	OMIM:102600
-	I-Disease	OMIM:300322	OMIM:102600
APRT	I-Disease	OMIM:300322	OMIM:102600
-	I-Disease	OMIM:300322	OMIM:102600
deficient	I-Disease	OMIM:300322	OMIM:102600
mice	O	O
.	O	O

Although	O	O
the	O	O
doubly	O	O
-	O	O
deficient	O	O
mice	O	O
excrete	O	O
adenine	O	O
and	O	O
its	O	O
highly	O	O
insoluble	O	O
derivative	O	O
,	O	O
2	O	O
,	O	O
8	O	O
-	O	O
dihydroxyadenine	O	O
,	O	O
which	O	O
are	O	O
also	O	O
associated	O	O
with	O	O
human	O	O
APRT	B-Disease	OMIM:102600
deficiency	I-Disease	OMIM:102600
,	O	O
additional	O	O
abnormalities	O	O
or	O	O
any	O	O
self	O	O
-	O	O
injurious	O	O
behavior	O	O
were	O	O
not	O	O
detected	O	O
.	O	O

Thus	O	O
,	O	O
APRT	B-Disease	OMIM:300322	OMIM:102600
-	I-Disease	OMIM:300322	OMIM:102600
HPRT	I-Disease	OMIM:300322	OMIM:102600
-	I-Disease	OMIM:300322	OMIM:102600
deficient	I-Disease	OMIM:300322	OMIM:102600
mice	O	O
,	O	O
which	O	O
are	O	O
devoid	O	O
of	O	O
any	O	O
purine	O	O
salvage	O	O
pathways	O	O
,	O	O
show	O	O
no	O	O
novel	O	O
phenotype	O	O
and	O	O
are	O	O
not	O	O
a	O	O
model	O	O
for	O	O
the	O	O
behavioral	B-Disease	D001523
abnormalities	I-Disease	D001523
associated	O	O
with	O	O
the	O	O
Lesch	B-Disease	D007926
-	I-Disease	D007926
Nyhan	I-Disease	D007926
syndrome	I-Disease	D007926
as	O	O
previously	O	O
suggested	O	O
Mice	O	O
lacking	O	O
the	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
protein	O	O
kinase	O	O
develop	O	O
a	O	O
late	O	O
onset	O	O
progressive	O	O
myopathy	B-Disease	D009135
.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
dominant	I-Disease	D030342
disorder	I-Disease	D030342
resulting	O	O
from	O	O
the	O	O
expansion	O	O
of	O	O
a	O	O
CTG	O	O
repeat	O	O
in	O	O
the	O	O
3	O	O
untranslated	O	O
region	O	O
of	O	O
a	O	O
putative	O	O
protein	O	O
kinase	O	O
(	O	O
DMPK	O	O
)	O	O
.	O	O

To	O	O
elucidate	O	O
the	O	O
role	O	O
of	O	O
DMPK	O	O
in	O	O
DM	B-Disease	D009223
pathogenesis	O	O
we	O	O
have	O	O
developed	O	O
Dmpk	B-Disease	OMIM:160900
deficient	I-Disease	OMIM:160900
(	O	O
Dmpk	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
.	O	O

Dmpk	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
develop	O	O
a	O	O
late	O	O
-	O	O
onset	O	O
,	O	O
progressive	B-Disease	D009135
skeletal	I-Disease	D009135
myopathy	I-Disease	D009135
that	O	O
shares	O	O
some	O	O
pathological	O	O
features	O	O
with	O	O
DM	B-Disease	D009223
.	O	O

Muscles	O	O
from	O	O
mature	O	O
mice	O	O
show	O	O
variation	O	O
in	O	O
fibre	O	O
size	O	O
,	O	O
increased	O	O
fibre	B-Disease	D020966
degeneration	I-Disease	D020966
and	O	O
fibrosis	B-Disease	D005355
.	O	O

Adult	O	O
Dmpk	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
show	O	O
ultrastructural	O	O
changes	O	O
in	O	O
muscle	O	O
and	O	O
a	O	O
50	O	O
%	O	O
decrease	O	O
in	O	O
force	O	O
generation	O	O
compared	O	O
to	O	O
young	O	O
mice	O	O
.	O	O

Our	O	O
results	O	O
indicate	O	O
that	O	O
DMPK	O	O
may	O	O
be	O	O
necessary	O	O
for	O	O
the	O	O
maintenance	O	O
of	O	O
skeletal	O	O
muscle	O	O
structure	O	O
and	O	O
function	O	O
and	O	O
suggest	O	O
that	O	O
a	O	O
decrease	O	O
in	O	O
DMPK	O	O
levels	O	O
may	O	O
contribute	O	O
to	O	O
DM	B-Disease	D009223
pathology	O	O
.	O	O

.	O	O

Rapid	O	O
detection	O	O
of	O	O
regionally	O	O
clustered	O	O
germ	O	O
-	O	O
line	O	O
BRCA1	O	O
mutations	O	O
by	O	O
multiplex	O	O
heteroduplex	O	O
analysis	O	O
.	O	O

UKCCCR	O	O
Familial	O	O
Ovarian	B-Disease	D010051
Cancer	I-Disease	D010051
Study	O	O
Group	O	O
.	O	O

Germ	O	O
-	O	O
line	O	O
mutations	O	O
of	O	O
the	O	O
BRCA1	O	O
gene	O	O
are	O	O
responsible	O	O
for	O	O
a	O	O
substantial	O	O
proportion	O	O
of	O	O
families	O	O
with	O	O
multiple	O	O
cases	O	O
of	O	O
early	O	O
-	O	O
onset	O	O
breast	B-Disease	OMIM:604370
and	I-Disease	OMIM:604370
/	I-Disease	OMIM:604370
or	I-Disease	OMIM:604370
ovarian	I-Disease	OMIM:604370
cancer	I-Disease	OMIM:604370
.	O	O

Since	O	O
the	O	O
isolation	O	O
of	O	O
BRCA1	O	O
last	O	O
year	O	O
,	O	O
>	O	O
65	O	O
distinct	O	O
mutations	O	O
scattered	O	O
throughout	O	O
the	O	O
coding	O	O
region	O	O
have	O	O
been	O	O
detected	O	O
,	O	O
making	O	O
analysis	O	O
of	O	O
the	O	O
gene	O	O
time	O	O
consuming	O	O
and	O	O
technically	O	O
challenging	O	O
.	O	O

We	O	O
have	O	O
developed	O	O
a	O	O
multiplex	O	O
heteroduplex	O	O
analysis	O	O
that	O	O
is	O	O
designed	O	O
to	O	O
analyze	O	O
one	O	O
-	O	O
quarter	O	O
of	O	O
the	O	O
coding	O	O
sequence	O	O
in	O	O
a	O	O
single	O	O
-	O	O
step	O	O
screening	O	O
procedure	O	O
and	O	O
that	O	O
will	O	O
detect	O	O
approximately	O	O
50	O	O
%	O	O
of	O	O
all	O	O
BRCA1	O	O
mutations	O	O
so	O	O
far	O	O
reported	O	O
in	O	O
breast	B-Disease	OMIM:604370
/	I-Disease	OMIM:604370
ovarian	I-Disease	OMIM:604370
cancer	I-Disease	OMIM:604370
families	O	O
.	O	O

We	O	O
have	O	O
used	O	O
this	O	O
technique	O	O
to	O	O
analyze	O	O
BRCA1	O	O
in	O	O
162	O	O
families	O	O
with	O	O
a	O	O
history	O	O
of	O	O
breast	B-Disease	OMIM:604370
and	I-Disease	OMIM:604370
/	I-Disease	OMIM:604370
or	I-Disease	OMIM:604370
ovarian	I-Disease	OMIM:604370
cancer	I-Disease	OMIM:604370
and	O	O
identified	O	O
12	O	O
distinct	O	O
mutations	O	O
in	O	O
35	O	O
families	O	O
.	O	O

.	O	O

LPP	O	O
,	O	O
the	O	O
preferred	O	O
fusion	O	O
partner	O	O
gene	O	O
of	O	O
HMGIC	O	O
in	O	O
lipomas	B-Disease	D008067
,	O	O
is	O	O
a	O	O
novel	O	O
member	O	O
of	O	O
the	O	O
LIM	O	O
protein	O	O
gene	O	O
family	O	O
.	O	O

A	O	O
major	O	O
cytogenetic	O	O
subgroup	O	O
of	O	O
lipomas	B-Disease	D008067
is	O	O
characterized	O	O
by	O	O
recurrent	O	O
chromosome	O	O
aberrations	O	O
,	O	O
mainly	O	O
translocations	O	O
,	O	O
that	O	O
involve	O	O
chromosome	O	O
segment	O	O
12q13	O	O
-	O	O
q15	O	O
.	O	O

Multiple	O	O
chromosomes	O	O
have	O	O
been	O	O
found	O	O
as	O	O
the	O	O
translocation	O	O
partners	O	O
of	O	O
chromosome	O	O
12	O	O
but	O	O
3q27	O	O
-	O	O
q28	O	O
is	O	O
preferentially	O	O
involved	O	O
.	O	O

In	O	O
previous	O	O
studies	O	O
,	O	O
it	O	O
has	O	O
been	O	O
shown	O	O
that	O	O
the	O	O
high	O	O
mobility	O	O
group	O	O
(	O	O
HMG	O	O
)	O	O
protein	O	O
gene	O	O
HMGIC	O	O
at	O	O
12q15	O	O
is	O	O
consistently	O	O
rearranged	O	O
as	O	O
a	O	O
consequence	O	O
of	O	O
these	O	O
translocations	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
the	O	O
identification	O	O
and	O	O
characterization	O	O
of	O	O
the	O	O
chromosome	O	O
3	O	O
-	O	O
derived	O	O
translocation	O	O
partner	O	O
gene	O	O
,	O	O
which	O	O
we	O	O
have	O	O
designated	O	O
LPP	O	O
(	O	O
lipoma	B-Disease	D008067
preferred	O	O
partner	O	O
gene	O	O
)	O	O
.	O	O

Using	O	O
3	O	O
-	O	O
RACE	O	O
analysis	O	O
of	O	O
HMGIC	O	O
fusion	O	O
transcripts	O	O
in	O	O
lipoma	B-Disease	D008067
cell	O	O
line	O	O
Li	O	O
-	O	O
501	O	O
/	O	O
SV40	O	O
,	O	O
ectopic	O	O
genetic	O	O
sequences	O	O
were	O	O
obtained	O	O
,	O	O
which	O	O
by	O	O
CASH	O	O
(	O	O
chromosome	O	O
assignment	O	O
using	O	O
somatic	O	O
cell	O	O
hybrids	O	O
)	O	O
and	O	O
FISH	O	O
(	O	O
fluorescence	O	O
in	O	O
situ	O	O
hybridization	O	O
)	O	O
analysis	O	O
were	O	O
found	O	O
to	O	O
originate	O	O
from	O	O
chromosome	O	O
segment	O	O
3q27	O	O
-	O	O
q28	O	O
.	O	O

In	O	O
Northern	O	O
blot	O	O
analysis	O	O
,	O	O
an	O	O
mRNA	O	O
of	O	O
over	O	O
10	O	O
kb	O	O
was	O	O
detected	O	O
by	O	O
these	O	O
ectopic	O	O
sequences	O	O
in	O	O
a	O	O
variety	O	O
of	O	O
human	O	O
tissues	O	O
but	O	O
not	O	O
in	O	O
brain	O	O
and	O	O
peripheral	O	O
blood	O	O
leukocytes	O	O
.	O	O

Upon	O	O
partial	O	O
cDNA	O	O
cloning	O	O
,	O	O
features	O	O
of	O	O
the	O	O
genetic	O	O
organization	O	O
of	O	O
LPP	O	O
were	O	O
established	O	O
.	O	O

The	O	O
gene	O	O
was	O	O
found	O	O
to	O	O
span	O	O
a	O	O
genomic	O	O
region	O	O
of	O	O
over	O	O
400	O	O
kb	O	O
.	O	O

Nucleotide	O	O
sequence	O	O
analysis	O	O
of	O	O
a	O	O
composite	O	O
cDNA	O	O
of	O	O
LPP	O	O
revealed	O	O
an	O	O
open	O	O
reading	O	O
frame	O	O
of	O	O
1836	O	O
nucleotides	O	O
encoding	O	O
a	O	O
proline	O	O
-	O	O
rich	O	O
protein	O	O
containing	O	O
a	O	O
leucine	O	O
-	O	O
zipper	O	O
motif	O	O
in	O	O
its	O	O
amino	O	O
-	O	O
terminal	O	O
region	O	O
and	O	O
three	O	O
LIM	O	O
domains	O	O
in	O	O
its	O	O
carboxy	O	O
-	O	O
terminal	O	O
region	O	O
.	O	O

The	O	O
LPP	O	O
-	O	O
encoded	O	O
protein	O	O
should	O	O
be	O	O
classified	O	O
as	O	O
a	O	O
novel	O	O
member	O	O
of	O	O
the	O	O
group	O	O
3	O	O
proteins	O	O
of	O	O
the	O	O
LIM	O	O
protein	O	O
gene	O	O
family	O	O
.	O	O

Using	O	O
reverse	O	O
transcriptase	O	O
combined	O	O
with	O	O
polymerase	O	O
chain	O	O
reactions	O	O
in	O	O
the	O	O
analysis	O	O
of	O	O
a	O	O
number	O	O
of	O	O
lipoma	B-Disease	D008067
cell	O	O
lines	O	O
and	O	O
primary	B-Disease	D008067
lipomas	I-Disease	D008067
,	O	O
it	O	O
appeared	O	O
that	O	O
LPP	O	O
is	O	O
frequently	O	O
rearranged	O	O
also	O	O
in	O	O
cases	O	O
without	O	O
a	O	O
cytogenetically	O	O
detectable	O	O
involvement	O	O
of	O	O
3q27	O	O
-	O	O
q28	O	O
.	O	O

Two	O	O
alternative	O	O
HMGIC	O	O
/	O	O
LPP	O	O
hybrid	O	O
transcripts	O	O
have	O	O
been	O	O
detected	O	O
;	O	O
the	O	O
difference	O	O
between	O	O
them	O	O
is	O	O
mainly	O	O
the	O	O
presence	O	O
of	O	O
either	O	O
two	O	O
or	O	O
three	O	O
LIM	O	O
domains	O	O
in	O	O
the	O	O
predicted	O	O
HMGI	O	O
-	O	O
C	O	O
/	O	O
LPP	O	O
fusion	O	O
proteins	O	O
.	O	O

.	O	O

Exon	O	O
-	O	O
intron	O	O
structure	O	O
of	O	O
the	O	O
human	O	O
neuronal	O	O
nicotinic	O	O
acetylcholine	O	O
receptor	O	O
alpha	O	O
4	O	O
subunit	O	O
(	O	O
CHRNA4	O	O
)	O	O
.	O	O

The	O	O
human	O	O
neuronal	O	O
nicotinic	O	O
acetylcholine	O	O
receptor	O	O
alpha	O	O
4	O	O
subunit	O	O
gene	O	O
(	O	O
CHRNA4	O	O
)	O	O
is	O	O
located	O	O
in	O	O
the	O	O
candidate	O	O
region	O	O
for	O	O
three	O	O
different	O	O
phenotypes	O	O
benign	B-Disease	D020936
familial	I-Disease	D020936
neonatal	I-Disease	D020936
convulsions	I-Disease	D020936
,	O	O
autosomal	B-Disease	D017034
dominant	I-Disease	D017034
nocturnal	I-Disease	D017034
frontal	I-Disease	D017034
lobe	I-Disease	D017034
epilepsy	I-Disease	D017034
,	O	O
and	O	O
low	O	O
-	O	O
voltage	O	O
EEG	O	O
.	O	O

Recently	O	O
,	O	O
a	O	O
missense	O	O
mutation	O	O
in	O	O
transmembrane	O	O
domain	O	O
2	O	O
of	O	O
CHRNA4	O	O
was	O	O
found	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
autosomal	B-Disease	D017034
dominant	I-Disease	D017034
nocturnal	I-Disease	D017034
frontal	I-Disease	D017034
lobe	I-Disease	D017034
epilepsy	I-Disease	D017034
in	O	O
one	O	O
extended	O	O
pedigree	O	O
.	O	O

We	O	O
have	O	O
determined	O	O
the	O	O
genomic	O	O
organization	O	O
of	O	O
CHRNA4	O	O
,	O	O
which	O	O
consists	O	O
of	O	O
six	O	O
exons	O	O
distributed	O	O
over	O	O
approximately	O	O
17	O	O
kb	O	O
of	O	O
genomic	O	O
DNA	O	O
.	O	O

The	O	O
nucleotide	O	O
sequence	O	O
obtained	O	O
from	O	O
the	O	O
genomic	O	O
regions	O	O
adjacent	O	O
to	O	O
the	O	O
exon	O	O
boundaries	O	O
enabled	O	O
us	O	O
to	O	O
develop	O	O
a	O	O
set	O	O
of	O	O
primer	O	O
pairs	O	O
for	O	O
PCR	O	O
amplification	O	O
of	O	O
the	O	O
complete	O	O
coding	O	O
region	O	O
.	O	O

The	O	O
sequence	O	O
analysis	O	O
provides	O	O
the	O	O
basis	O	O
for	O	O
a	O	O
comprehensive	O	O
mutation	O	O
screening	O	O
of	O	O
CHRNA4	O	O
in	O	O
the	O	O
above	O	O
-	O	O
mentioned	O	O
phenotypes	O	O
and	O	O
possibly	O	O
in	O	O
other	O	O
types	O	O
of	O	O
idiopathic	B-Disease	D004827
epilepsies	I-Disease	D004827
.	O	O

.	O	O

A	O	O
novel	O	O
homeodomain	O	O
-	O	O
encoding	O	O
gene	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
large	O	O
CpG	O	O
island	O	O
interrupted	O	O
by	O	O
the	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
unstable	O	O
(	O	O
CTG	O	O
)	O	O
n	O	O
repeat	O	O
.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
(	O	O
CTG	O	O
)	O	O
n	O	O
trinucleotide	O	O
repeat	O	O
expansion	O	O
in	O	O
the	O	O
3	O	O
-	O	O
untranslated	O	O
region	O	O
of	O	O
a	O	O
protein	O	O
kinase	O	O
-	O	O
encoding	O	O
gene	O	O
,	O	O
DMPK	O	O
,	O	O
which	O	O
maps	O	O
to	O	O
chromosome	O	O
19q13	O	O
.	O	O

3	O	O
.	O	O

Characterisation	O	O
of	O	O
the	O	O
expression	O	O
of	O	O
this	O	O
gene	O	O
in	O	O
patient	O	O
tissues	O	O
has	O	O
thus	O	O
far	O	O
generated	O	O
conflicting	O	O
data	O	O
on	O	O
alterations	O	O
in	O	O
the	O	O
steady	O	O
state	O	O
levels	O	O
of	O	O
DMPK	O	O
mRNA	O	O
,	O	O
and	O	O
on	O	O
the	O	O
final	O	O
DMPK	O	O
protein	O	O
levels	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
expansion	O	O
.	O	O

The	O	O
DM	B-Disease	D009223
region	O	O
of	O	O
chromosome	O	O
19	O	O
is	O	O
gene	O	O
rich	O	O
,	O	O
and	O	O
it	O	O
is	O	O
possible	O	O
that	O	O
the	O	O
repeat	O	O
expansion	O	O
may	O	O
lead	O	O
to	O	O
dysfunction	O	O
of	O	O
a	O	O
number	O	O
of	O	O
transcription	O	O
units	O	O
in	O	O
the	O	O
vicinity	O	O
,	O	O
perhaps	O	O
as	O	O
a	O	O
consequence	O	O
of	O	O
chromatin	O	O
disruption	O	O
.	O	O

We	O	O
have	O	O
searched	O	O
for	O	O
genes	O	O
associated	O	O
with	O	O
a	O	O
CpG	O	O
island	O	O
at	O	O
the	O	O
3	O	O
end	O	O
of	O	O
DMPK	O	O
.	O	O

Sequencing	O	O
of	O	O
this	O	O
region	O	O
shows	O	O
that	O	O
the	O	O
island	O	O
extends	O	O
over	O	O
3	O	O
.	O	O

5	O	O
kb	O	O
and	O	O
is	O	O
interrupted	O	O
by	O	O
the	O	O
(	O	O
CTG	O	O
)	O	O
n	O	O
repeat	O	O
.	O	O

Comparison	O	O
of	O	O
genomic	O	O
sequences	O	O
downstream	O	O
(	O	O
centromeric	O	O
)	O	O
of	O	O
the	O	O
repeat	O	O
in	O	O
human	O	O
and	O	O
mouse	O	O
identified	O	O
regions	O	O
of	O	O
significant	O	O
homology	O	O
.	O	O

These	O	O
correspond	O	O
to	O	O
exons	O	O
of	O	O
a	O	O
gene	O	O
predicted	O	O
to	O	O
encode	O	O
a	O	O
homeodomain	O	O
protein	O	O
.	O	O

RT	O	O
-	O	O
PCR	O	O
analysis	O	O
shows	O	O
that	O	O
this	O	O
gene	O	O
,	O	O
which	O	O
we	O	O
have	O	O
called	O	O
DM	B-Disease	D009223
locus	O	O
-	O	O
associated	O	O
homeodomain	O	O
protein	O	O
(	O	O
DMAHP	O	O
)	O	O
,	O	O
is	O	O
expressed	O	O
in	O	O
a	O	O
number	O	O
of	O	O
human	O	O
tissues	O	O
,	O	O
including	O	O
skeletal	O	O
muscle	O	O
,	O	O
heart	O	O
and	O	O
brain	O	O
.	O	O

Missense	O	O
mutations	O	O
in	O	O
the	O	O
Fas	O	O
gene	O	O
resulting	O	O
in	O	O
autoimmune	B-Disease	D056735
lymphoproliferative	I-Disease	D056735
syndrome	I-Disease	D056735
:	O	O
a	O	O
molecular	O	O
and	O	O
immunological	O	O
analysis	O	O
.	O	O

Programmed	O	O
cell	O	O
death	O	O
(	O	O
or	O	O
apoptosis	O	O
)	O	O
is	O	O
a	O	O
physiological	O	O
process	O	O
essential	O	O
to	O	O
the	O	O
normal	O	O
development	O	O
and	O	O
homeostatic	O	O
maintenance	O	O
of	O	O
the	O	O
immune	O	O
system	O	O
.	O	O

The	O	O
Fas	O	O
/	O	O
Apo	O	O
-	O	O
1	O	O
receptor	O	O
plays	O	O
a	O	O
crucial	O	O
role	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
apoptosis	O	O
,	O	O
as	O	O
demonstrated	O	O
by	O	O
lymphoproliferation	O	O
in	O	O
MRL	O	O
-	O	O
lpr	O	O
/	O	O
lpr	O	O
mice	O	O
and	O	O
by	O	O
the	O	O
recently	O	O
described	O	O
autoimmune	B-Disease	D056735
lymphoproliferative	I-Disease	D056735
syndrome	I-Disease	D056735
(	O	O
ALPS	B-Disease	D056735
)	O	O
in	O	O
humans	O	O
,	O	O
both	O	O
of	O	O
which	O	O
are	O	O
due	O	O
to	O	O
mutations	O	O
in	O	O
the	O	O
Fas	O	O
gene	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
novel	O	O
family	O	O
with	O	O
ALPS	B-Disease	D056735
in	O	O
which	O	O
three	O	O
affected	O	O
siblings	O	O
carry	O	O
two	O	O
distinct	O	O
missense	O	O
mutations	O	O
on	O	O
both	O	O
the	O	O
Fas	O	O
gene	O	O
alleles	O	O
and	O	O
show	O	O
lack	O	O
of	O	O
Fas	O	O
-	O	O
induced	O	O
apoptosis	O	O
.	O	O

The	O	O
children	O	O
share	O	O
common	O	O
clinical	O	O
features	O	O
including	O	O
splenomegaly	B-Disease	D013163
and	O	O
lymphadenopathy	B-Disease	D008206
,	O	O
but	O	O
only	O	O
one	O	O
developed	O	O
severe	O	O
autoimmune	B-Disease	D001327
manifestations	I-Disease	D001327
.	O	O

In	O	O
all	O	O
three	O	O
siblings	O	O
,	O	O
we	O	O
demonstrated	O	O
the	O	O
presence	O	O
of	O	O
anergic	O	O
CD3	O	O
+	O	O
CD4	O	O
-	O	O
CD8	O	O
-	O	O
(	O	O
double	O	O
negative	O	O
,	O	O
[	O	O
DN	O	O
]	O	O
)	O	O
T	O	O
cells	O	O
;	O	O
moreover	O	O
,	O	O
a	O	O
chronic	O	O
lymphocyte	O	O
activation	O	O
was	O	O
found	O	O
,	O	O
as	O	O
demonstrated	O	O
by	O	O
the	O	O
presence	O	O
of	O	O
high	O	O
levels	O	O
of	O	O
HLA	O	O
-	O	O
DR	O	O
expression	O	O
on	O	O
peripheral	O	O
CD3	O	O
+	O	O
cells	O	O
and	O	O
by	O	O
the	O	O
presence	O	O
of	O	O
high	O	O
levels	O	O
of	O	O
serum	O	O
activation	O	O
markers	O	O
such	O	O
as	O	O
soluble	O	O
interleukin	O	O
-	O	O
2	O	O
receptor	O	O
(	O	O
slL	O	O
-	O	O
2R	O	O
)	O	O
and	O	O
soluble	O	O
CD30	O	O
(	O	O
sCD30	O	O
)	O	O
.	O	O

.	O	O

Common	O	O
BRCA1	O	O
variants	O	O
and	O	O
susceptibility	O	O
to	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
in	O	O
the	O	O
general	O	O
population	O	O
.	O	O

Most	O	O
multiple	O	O
case	O	O
families	O	O
of	O	O
young	O	O
onset	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
and	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
are	O	O
thought	O	O
to	O	O
be	O	O
due	O	O
to	O	O
highly	O	O
penetrant	O	O
mutations	O	O
in	O	O
the	O	O
predisposing	O	O
genes	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
.	O	O

However	O	O
,	O	O
these	O	O
mutations	O	O
are	O	O
uncommon	O	O
in	O	O
the	O	O
population	O	O
and	O	O
they	O	O
probably	O	O
account	O	O
for	O	O
only	O	O
a	O	O
few	O	O
percent	O	O
of	O	O
all	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
incidence	O	O
.	O	O

A	O	O
much	O	O
larger	O	O
fraction	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
might	O	O
,	O	O
in	O	O
principle	O	O
,	O	O
be	O	O
due	O	O
to	O	O
common	O	O
variants	O	O
which	O	O
confer	O	O
more	O	O
modest	O	O
individual	O	O
risks	O	O
.	O	O

There	O	O
are	O	O
several	O	O
common	O	O
polymorphisms	O	O
in	O	O
the	O	O
BRCA1	O	O
gene	O	O
which	O	O
generate	O	O
amino	O	O
acid	O	O
substitutions	O	O
.	O	O

We	O	O
have	O	O
examined	O	O
the	O	O
frequency	O	O
of	O	O
four	O	O
of	O	O
these	O	O
polymorphisms	O	O
Gln356Arg	O	O
,	O	O
Pro871Leu	O	O
,	O	O
Glu1038Gly	O	O
and	O	O
Ser1613Gly	O	O
in	O	O
large	O	O
series	O	O
of	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
cases	O	O
and	O	O
matched	O	O
controls	O	O
.	O	O

Due	O	O
to	O	O
strong	O	O
linkage	O	O
disequilibrium	O	O
,	O	O
these	O	O
four	O	O
sites	O	O
generate	O	O
only	O	O
three	O	O
haplotypes	O	O
with	O	O
a	O	O
frequency	O	O
>	O	O
1	O	O
.	O	O

3	O	O
%	O	O
.	O	O

The	O	O
most	O	O
common	O	O
haplotypes	O	O
,	O	O
defined	O	O
by	O	O
the	O	O
alleles	O	O
Gln356Pro871Glu1038Ser1613	O	O
and	O	O
Gln356Leu871Gly1038Gly1613	O	O
,	O	O
have	O	O
frequencies	O	O
of	O	O
0	O	O
.	O	O

57	O	O
and	O	O
0	O	O
.	O	O

32	O	O
respectively	O	O
,	O	O
and	O	O
these	O	O
frequencies	O	O
do	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
patient	O	O
and	O	O
control	O	O
groups	O	O
.	O	O

Thus	O	O
the	O	O
most	O	O
common	O	O
polymorphisms	O	O
of	O	O
the	O	O
BRCA1	O	O
gene	O	O
do	O	O
not	O	O
make	O	O
a	O	O
significant	O	O
contribution	O	O
to	O	O
breast	B-Disease	D001943
or	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
risk	O	O
.	O	O

However	O	O
,	O	O
our	O	O
data	O	O
suggest	O	O
that	O	O
the	O	O
Arg356	O	O
allele	O	O
may	O	O
have	O	O
a	O	O
different	O	O
genotype	O	O
distribution	O	O
in	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
patients	O	O
from	O	O
that	O	O
in	O	O
controls	O	O
(	O	O
Arg356	O	O
homozygotes	O	O
are	O	O
more	O	O
frequent	O	O
in	O	O
the	O	O
control	O	O
groups	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O

01	O	O
)	O	O
,	O	O
indicating	O	O
that	O	O
it	O	O
may	O	O
be	O	O
protective	O	O
against	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

If	O	O
this	O	O
finding	O	O
can	O	O
be	O	O
confirmed	O	O
,	O	O
it	O	O
may	O	O
provide	O	O
an	O	O
insight	O	O
into	O	O
the	O	O
structural	O	O
features	O	O
of	O	O
the	O	O
BRCA1	O	O
protein	O	O
that	O	O
are	O	O
important	O	O
for	O	O
its	O	O
function	O	O
.	O	O

Mutation	O	O
of	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
is	O	O
associated	O	O
exclusively	O	O
with	O	O
the	O	O
development	O	O
of	O	O
non	B-Disease	D002292
-	I-Disease	D002292
papillary	I-Disease	D002292
renal	I-Disease	D002292
cell	I-Disease	D002292
carcinomas	I-Disease	D002292
.	O	O

To	O	O
define	O	O
the	O	O
possible	O	O
role	O	O
of	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
in	O	O
the	O	O
development	O	O
of	O	O
sporadic	B-Disease	D002292
renal	I-Disease	D002292
cell	I-Disease	D002292
carcinomas	I-Disease	D002292
,	O	O
91	O	O
different	O	O
parenchymal	B-Disease	D007674
tumours	I-Disease	D007674
of	I-Disease	D007674
the	I-Disease	D007674
kidney	I-Disease	D007674
have	O	O
been	O	O
investigated	O	O
for	O	O
mutation	O	O
of	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
by	O	O
single	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
(	O	O
SSCP	O	O
)	O	O
and	O	O
/	O	O
or	O	O
heteroduplex	O	O
(	O	O
HD	O	O
)	O	O
techniques	O	O
.	O	O

Chromosome	O	O
3p	O	O
deletion	O	O
was	O	O
detected	O	O
in	O	O
98	O	O
per	O	O
cent	O	O
of	O	O
non	B-Disease	D002292
-	I-Disease	D002292
papillary	I-Disease	D002292
renal	I-Disease	D002292
cell	I-Disease	D002292
carcinomas	I-Disease	D002292
and	O	O
in	O	O
25	O	O
per	O	O
cent	O	O
of	O	O
chromophobe	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinomas	I-Disease	D002292
.	O	O

In	O	O
22	O	O
of	O	O
the	O	O
43	O	O
non	B-Disease	D002292
-	I-Disease	D002292
papillary	I-Disease	D002292
renal	I-Disease	D002292
cell	I-Disease	D002292
carcinomas	I-Disease	D002292
,	O	O
abnormally	O	O
migrating	O	O
DNA	O	O
bands	O	O
were	O	O
detected	O	O
by	O	O
SSCP	O	O
and	O	O
/	O	O
or	O	O
HD	O	O
analysis	O	O
.	O	O

No	O	O
mobility	O	O
shift	O	O
was	O	O
seen	O	O
in	O	O
any	O	O
of	O	O
the	O	O
23	O	O
chromophobe	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinomas	I-Disease	D002292
.	O	O

In	O	O
addition	O	O
,	O	O
15	O	O
papillary	B-Disease	D002292
renal	I-Disease	D002292
cell	I-Disease	D002292
tumours	I-Disease	D002292
and	O	O
ten	O	O
renal	B-Disease	C537750
oncocytomas	I-Disease	C537750
,	O	O
which	O	O
are	O	O
characterized	O	O
by	O	O
genetic	O	O
changes	O	O
other	O	O
than	O	O
loss	O	O
of	O	O
chromosome	O	O
3p	O	O
sequences	O	O
,	O	O
were	O	O
analysed	O	O
for	O	O
mutation	O	O
of	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
.	O	O

None	O	O
of	O	O
these	O	O
tumours	B-Disease	D009369
showed	O	O
abnormal	O	O
migration	O	O
patterns	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
mutation	O	O
of	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
is	O	O
associated	O	O
exclusively	O	O
with	O	O
the	O	O
development	O	O
of	O	O
non	B-Disease	D002292
-	I-Disease	D002292
papillary	I-Disease	D002292
renal	I-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
.	O	O

.	O	O

Comparative	O	O
genome	O	O
mapping	O	O
of	O	O
the	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
region	O	O
in	O	O
mouse	O	O
,	O	O
rat	O	O
,	O	O
and	O	O
Syrian	O	O
hamster	O	O
.	O	O

Chromosomal	O	O
locations	O	O
of	O	O
the	O	O
Atm	O	O
(	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
AT	B-Disease	D001260
)	O	O
-	O	O
mutated	O	O
)	O	O
and	O	O
Acat1	O	O
(	O	O
mitochondrial	O	O
acetoacetyl	O	O
-	O	O
CoA	O	O
thiolase	O	O
)	O	O
genes	O	O
in	O	O
mouse	O	O
,	O	O
rat	O	O
,	O	O
and	O	O
Syrian	O	O
hamster	O	O
were	O	O
determined	O	O
by	O	O
direct	O	O
R	O	O
-	O	O
banding	O	O
FISH	O	O
.	O	O

Both	O	O
genes	O	O
were	O	O
colocalized	O	O
to	O	O
the	O	O
C	O	O
-	O	O
D	O	O
band	O	O
of	O	O
mouse	O	O
chromosome	O	O
9	O	O
,	O	O
the	O	O
proximal	O	O
end	O	O
of	O	O
q24	O	O
.	O	O

1	O	O
of	O	O
rat	O	O
chromosome	O	O
8	O	O
,	O	O
and	O	O
qa4	O	O
-	O	O
qa5	O	O
of	O	O
Syrian	O	O
hamster	O	O
chromosome	O	O
12	O	O
.	O	O

The	O	O
regions	O	O
in	O	O
the	O	O
mouse	O	O
and	O	O
rat	O	O
were	O	O
homologous	O	O
to	O	O
human	O	O
chromosome	O	O
11q	O	O
.	O	O

Fine	O	O
genetic	O	O
linkage	O	O
mapping	O	O
of	O	O
the	O	O
mouse	O	O
AT	B-Disease	D001260
region	O	O
was	O	O
performed	O	O
using	O	O
the	O	O
interspecific	O	O
backcross	O	O
mice	O	O
.	O	O

Atm	O	O
,	O	O
Acat1	O	O
,	O	O
and	O	O
Npat	O	O
,	O	O
which	O	O
is	O	O
a	O	O
new	O	O
gene	O	O
isolated	O	O
from	O	O
the	O	O
AT	B-Disease	D001260
region	O	O
,	O	O
and	O	O
12	O	O
flanking	O	O
microsatellite	O	O
DNA	O	O
markers	O	O
were	O	O
examined	O	O
.	O	O

No	O	O
recombinations	O	O
were	O	O
found	O	O
among	O	O
the	O	O
Atm	O	O
,	O	O
Npat	O	O
,	O	O
Acat1	O	O
,	O	O
and	O	O
D9Mit6	O	O
loci	O	O
,	O	O
and	O	O
these	O	O
loci	O	O
were	O	O
mapped	O	O
2	O	O
.	O	O

0	O	O
cM	O	O
distal	O	O
to	O	O
D9Mit99	O	O
and	O	O
1	O	O
.	O	O

3	O	O
cM	O	O
proximal	O	O
to	O	O
D9Mit102	O	O
.	O	O

Comparison	O	O
of	O	O
the	O	O
linkage	O	O
map	O	O
of	O	O
mouse	O	O
chromosome	O	O
9	O	O
(	O	O
MMU9	O	O
)	O	O
and	O	O
that	O	O
of	O	O
human	O	O
chromosome	O	O
11	O	O
(	O	O
HSA11	O	O
)	O	O
indicates	O	O
that	O	O
there	O	O
is	O	O
a	O	O
chromosomal	O	O
rearrangement	O	O
due	O	O
to	O	O
an	O	O
inversion	O	O
between	O	O
Ets1	O	O
and	O	O
Atm	O	O
-	O	O
Npat	O	O
-	O	O
Acat1	O	O
and	O	O
that	O	O
the	O	O
inversion	O	O
of	O	O
MMU9	O	O
originated	O	O
from	O	O
the	O	O
chromosomal	O	O
breakage	O	O
at	O	O
the	O	O
boundary	O	O
between	O	O
Gria4	O	O
and	O	O
Atm	O	O
-	O	O
Npat	O	O
-	O	O
Acat1	O	O
on	O	O
HSA11	O	O
.	O	O

This	O	O
type	O	O
of	O	O
inversion	O	O
appeared	O	O
to	O	O
be	O	O
conserved	O	O
in	O	O
the	O	O
three	O	O
rodent	O	O
species	O	O
,	O	O
mouse	O	O
,	O	O
rat	O	O
,	O	O
and	O	O
Syrian	O	O
hamster	O	O
,	O	O
using	O	O
additional	O	O
comparative	O	O
mapping	O	O
data	O	O
with	O	O
the	O	O
Rck	O	O
gene	O	O
Tumor	B-Disease	D009369
suppression	O	O
and	O	O
apoptosis	O	O
of	O	O
human	O	O
prostate	B-Disease	D011471
carcinoma	I-Disease	D011471
mediated	O	O
by	O	O
a	O	O
genetic	O	O
locus	O	O
within	O	O
human	O	O
chromosome	O	O
10pter	O	O
-	O	O
q11	O	O
.	O	O

Prostate	B-Disease	D011471
cancer	I-Disease	D011471
is	O	O
the	O	O
second	O	O
leading	O	O
cause	O	O
of	O	O
male	O	O
cancer	B-Disease	D009369
deaths	O	O
in	O	O
the	O	O
United	O	O
States	O	O
.	O	O

Yet	O	O
,	O	O
despite	O	O
a	O	O
large	O	O
international	O	O
effort	O	O
,	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
molecular	O	O
mechanisms	O	O
that	O	O
underlie	O	O
this	O	O
devastating	O	O
disease	O	O
.	O	O

Prostate	O	O
secretory	O	O
epithelial	O	O
cells	O	O
and	O	O
androgen	O	O
-	O	O
dependent	O	O
prostate	B-Disease	D011471
carcinomas	I-Disease	D011471
undergo	O	O
apoptosis	O	O
in	O	O
response	O	O
to	O	O
androgen	O	O
deprivation	O	O
and	O	O
,	O	O
furthermore	O	O
,	O	O
most	O	O
prostate	B-Disease	D011471
carcinomas	I-Disease	D011471
become	O	O
androgen	O	O
independent	O	O
and	O	O
refractory	O	O
to	O	O
further	O	O
therapeutic	O	O
manipulations	O	O
during	O	O
disease	O	O
progression	O	O
.	O	O

Definition	O	O
of	O	O
the	O	O
genetic	O	O
events	O	O
that	O	O
trigger	O	O
apoptosis	O	O
in	O	O
the	O	O
prostate	O	O
could	O	O
provide	O	O
important	O	O
insights	O	O
into	O	O
critical	O	O
pathways	O	O
in	O	O
normal	O	O
development	O	O
as	O	O
well	O	O
as	O	O
elucidate	O	O
the	O	O
perturbations	O	O
of	O	O
those	O	O
key	O	O
pathways	O	O
in	O	O
neoplastic	O	O
transformation	O	O
.	O	O

We	O	O
report	O	O
the	O	O
functional	O	O
definition	O	O
of	O	O
a	O	O
novel	O	O
genetic	O	O
locus	O	O
within	O	O
human	O	O
chromosome	O	O
10pter	O	O
-	O	O
q11	O	O
that	O	O
mediates	O	O
both	O	O
in	O	O
vivo	O	O
tumor	O	O
suppression	O	O
and	O	O
in	O	O
vitro	O	O
apoptosis	O	O
of	O	O
prostatic	B-Disease	D011471
adenocarcinoma	I-Disease	D011471
cells	O	O
.	O	O

A	O	O
defined	O	O
fragment	O	O
of	O	O
human	O	O
chromosome	O	O
10	O	O
was	O	O
transferred	O	O
via	O	O
microcell	O	O
fusion	O	O
into	O	O
a	O	O
prostate	B-Disease	D011471
adenocarcinoma	I-Disease	D011471
cell	O	O
line	O	O
.	O	O

Microcell	O	O
hybrids	O	O
containing	O	O
only	O	O
the	O	O
region	O	O
10pter	O	O
-	O	O
q11	O	O
were	O	O
suppressed	O	O
for	O	O
tumorigenicity	O	O
following	O	O
injection	O	O
of	O	O
microcell	O	O
hybrids	O	O
into	O	O
nude	O	O
mice	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
complemented	O	O
hybrids	O	O
undergo	O	O
programmed	O	O
cell	O	O
death	O	O
in	O	O
vitro	O	O
via	O	O
a	O	O
mechanism	O	O
that	O	O
does	O	O
not	O	O
require	O	O
nuclear	O	O
localization	O	O
of	O	O
p53	O	O
.	O	O

These	O	O
data	O	O
functionally	O	O
define	O	O
a	O	O
novel	O	O
genetic	O	O
locus	O	O
,	O	O
designated	O	O
PAC1	O	O
,	O	O
for	O	O
prostate	B-Disease	D011471
adenocarcinoma	I-Disease	D011471
1	O	O
,	O	O
involved	O	O
in	O	O
tumor	O	O
suppression	O	O
of	O	O
human	O	O
prostate	B-Disease	D011471
carcinoma	I-Disease	D011471
and	O	O
furthermore	O	O
strongly	O	O
suggest	O	O
that	O	O
the	O	O
cell	O	O
death	O	O
pathway	O	O
can	O	O
be	O	O
functionally	O	O
restored	O	O
in	O	O
prostatic	B-Disease	D011471
adenocarcinoma	I-Disease	D011471
.	O	O

.	O	O

Phenotypic	O	O
and	O	O
genotypic	O	O
overlap	O	O
between	O	O
atelosteogenesis	B-Disease	C535395
type	I-Disease	C535395
2	I-Disease	C535395
and	O	O
diastrophic	B-Disease	C536170
dysplasia	I-Disease	C536170
.	O	O

Mutations	O	O
in	O	O
the	O	O
diastrophic	B-Disease	C536170
dysplasia	I-Disease	C536170
sulfate	O	O
transporter	O	O
gene	O	O
DTDST	O	O
have	O	O
been	O	O
associated	O	O
with	O	O
a	O	O
family	O	O
of	O	O
chondrodysplasias	B-Disease	D010009
that	O	O
comprises	O	O
,	O	O
in	O	O
order	O	O
of	O	O
increasing	O	O
severity	O	O
,	O	O
diastrophic	B-Disease	C536170
dysplasia	I-Disease	C536170
(	O	O
DTD	B-Disease	C536170
)	O	O
,	O	O
atelosteogenesis	B-Disease	C535395
type	I-Disease	C535395
2	I-Disease	C535395
(	O	O
AO2	B-Disease	C535395
)	O	O
,	O	O
and	O	O
achondrogenesis	B-Disease	C536016
type	I-Disease	C536016
1B	I-Disease	C536016
(	O	O
ACG1B	B-Disease	C536016
)	O	O
.	O	O

To	O	O
learn	O	O
more	O	O
about	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
DTDST	B-Disease	OMIM:222600
chondrodysplasias	I-Disease	OMIM:222600
and	O	O
about	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
,	O	O
we	O	O
studied	O	O
fibroblast	O	O
cultures	O	O
of	O	O
three	O	O
new	O	O
patients	O	O
one	O	O
with	O	O
AO	B-Disease	C535395
-	I-Disease	C535395
2	I-Disease	C535395
,	O	O
one	O	O
with	O	O
DTD	B-Disease	C536170
,	O	O
and	O	O
one	O	O
with	O	O
an	O	O
intermediate	O	O
phenotype	O	O
(	O	O
AO2	B-Disease	C535395
/	O	O
DTD	B-Disease	C536170
)	O	O
.	O	O

Reduced	O	O
incorporation	O	O
of	O	O
inorganic	O	O
sulfate	O	O
into	O	O
macromolecules	O	O
was	O	O
found	O	O
in	O	O
all	O	O
three	O	O
.	O	O

Each	O	O
of	O	O
the	O	O
three	O	O
patients	O	O
was	O	O
found	O	O
to	O	O
be	O	O
heterozygous	O	O
for	O	O
a	O	O
c862t	O	O
transition	O	O
predicting	O	O
a	O	O
R279W	O	O
substitution	O	O
in	O	O
the	O	O
third	O	O
extracellular	O	O
loop	O	O
of	O	O
DTDST	O	O
.	O	O

In	O	O
two	O	O
patients	O	O
(	O	O
DTD	B-Disease	C536170
and	O	O
AO2	B-Disease	C535395
/	O	O
DTD	B-Disease	C536170
)	O	O
,	O	O
no	O	O
other	O	O
structural	O	O
mutation	O	O
was	O	O
found	O	O
,	O	O
but	O	O
polymerase	O	O
chain	O	O
reaction	O	O
amplification	O	O
and	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
analysis	O	O
of	O	O
fibroblast	O	O
cDNA	O	O
showed	O	O
reduced	O	O
mRNA	O	O
levels	O	O
of	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
DTDST	O	O
allele	O	O
these	O	O
two	O	O
patients	O	O
may	O	O
be	O	O
compound	O	O
heterozygotes	O	O
for	O	O
the	O	O
"	O	O
Finnish	O	O
"	O	O
mutation	O	O
(	O	O
as	O	O
yet	O	O
uncharacterized	O	O
at	O	O
the	O	O
DNA	O	O
level	O	O
)	O	O
,	O	O
which	O	O
causes	O	O
reduced	O	O
expression	O	O
of	O	O
DTDST	O	O
.	O	O

The	O	O
third	O	O
patient	O	O
(	O	O
with	O	O
AO2	B-Disease	C535395
)	O	O
had	O	O
the	O	O
R279W	O	O
mutation	O	O
compounded	O	O
with	O	O
a	O	O
novel	O	O
mutation	O	O
,	O	O
the	O	O
deletion	O	O
of	O	O
cytosine	O	O
418	O	O
(	O	O
delta	O	O
c418	O	O
)	O	O
,	O	O
predicting	O	O
a	O	O
frameshift	O	O
with	O	O
premature	O	O
termination	O	O
.	O	O

Also	O	O
the	O	O
delta	O	O
c418	O	O
allele	O	O
was	O	O
underrepresented	O	O
in	O	O
the	O	O
cDNA	O	O
,	O	O
in	O	O
accordance	O	O
with	O	O
previous	O	O
observations	O	O
that	O	O
premature	O	O
stop	O	O
codons	O	O
reduce	O	O
mRNA	O	O
levels	O	O
.	O	O

The	O	O
presence	O	O
of	O	O
the	O	O
DTDST	O	O
R279W	O	O
mutation	O	O
in	O	O
a	O	O
total	O	O
of	O	O
11	O	O
patients	O	O
with	O	O
AO2	B-Disease	C535395
or	O	O
DTD	B-Disease	C536170
emphasizes	O	O
the	O	O
overlap	O	O
between	O	O
these	O	O
conditions	O	O
.	O	O

This	O	O
mutation	O	O
has	O	O
not	O	O
been	O	O
found	O	O
so	O	O
far	O	O
in	O	O
8	O	O
analyzed	O	O
ACG1B	B-Disease	C536016
patients	O	O
,	O	O
suggesting	O	O
that	O	O
it	O	O
allows	O	O
some	O	O
residual	O	O
activity	O	O
of	O	O
the	O	O
sulfate	O	O
transporter	O	O
.	O	O

.	O	O

Cloning	O	O
of	O	O
the	O	O
homogentisate	O	O
1	O	O
,	O	O
2	O	O
-	O	O
dioxygenase	O	O
gene	O	O
,	O	O
the	O	O
key	O	O
enzyme	O	O
of	O	O
alkaptonuria	B-Disease	D000474
in	O	O
mouse	O	O
.	O	O

We	O	O
determined	O	O
48	O	O
amino	O	O
acid	O	O
residues	O	O
from	O	O
five	O	O
peptides	O	O
from	O	O
the	O	O
homogeneous	O	O
monomer	O	O
of	O	O
homogentisate	O	O
1	O	O
,	O	O
2	O	O
-	O	O
dioxygenase	O	O
(	O	O
HGO	O	O
;	O	O
E	O	O
.	O	O

C	O	O
.	O	O

1	O	O
.	O	O

13	O	O
.	O	O

11	O	O
.	O	O

15	O	O
)	O	O
of	O	O
mouse	O	O
liver	O	O
.	O	O

After	O	O
digestion	O	O
with	O	O
trypsin	O	O
,	O	O
peptides	O	O
were	O	O
separated	O	O
by	O	O
reversed	O	O
phase	O	O
chromatography	O	O
and	O	O
amino	O	O
acid	O	O
sequenced	O	O
.	O	O

The	O	O
deduced	O	O
codon	O	O
sequence	O	O
of	O	O
three	O	O
peptides	O	O
was	O	O
used	O	O
to	O	O
derive	O	O
degenerated	O	O
oligomeres	O	O
.	O	O

By	O	O
combining	O	O
these	O	O
oligos	O	O
,	O	O
we	O	O
were	O	O
able	O	O
to	O	O
amplify	O	O
fragments	O	O
from	O	O
100	O	O
to	O	O
300	O	O
bases	O	O
(	O	O
b	O	O
)	O	O
from	O	O
mouse	O	O
liver	O	O
cDNA	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
after	O	O
reverse	O	O
transcription	O	O
(	O	O
RT	O	O
-	O	O
PCR	O	O
)	O	O
.	O	O

A	O	O
fragment	O	O
of	O	O
200	O	O
b	O	O
was	O	O
cloned	O	O
and	O	O
used	O	O
as	O	O
a	O	O
probe	O	O
to	O	O
screen	O	O
a	O	O
mouse	O	O
liver	O	O
cDNA	O	O
library	O	O
.	O	O

One	O	O
clone	O	O
from	O	O
this	O	O
library	O	O
contained	O	O
the	O	O
complete	O	O
cDNA	O	O
-	O	O
insert	O	O
for	O	O
HGO	O	O
as	O	O
determined	O	O
by	O	O
sequencing	O	O
.	O	O

The	O	O
cDNA	O	O
encodes	O	O
for	O	O
a	O	O
protein	O	O
of	O	O
50	O	O
kDa	O	O
,	O	O
as	O	O
predicted	O	O
.	O	O

The	O	O
cDNA	O	O
of	O	O
mouse	O	O
HGO	O	O
has	O	O
an	O	O
overall	O	O
identity	O	O
of	O	O
41	O	O
%	O	O
to	O	O
the	O	O
corresponding	O	O
gene	O	O
hmgA	O	O
from	O	O
Aspergillus	O	O
.	O	O

Sequence	O	O
similarities	O	O
to	O	O
human	O	O
expressed	O	O
sequence	O	O
tags	O	O
(	O	O
EST	O	O
)	O	O
clones	O	O
ranged	O	O
from	O	O
70	O	O
%	O	O
to	O	O
20	O	O
%	O	O
.	O	O

The	O	O
positions	O	O
of	O	O
122	O	O
conserved	O	O
amino	O	O
acids	O	O
could	O	O
be	O	O
determined	O	O
by	O	O
multiple	O	O
sequence	O	O
alignment	O	O
.	O	O

We	O	O
identified	O	O
one	O	O
first	O	O
intron	O	O
of	O	O
928	O	O
b	O	O
in	O	O
the	O	O
mouse	O	O
gene	O	O
.	O	O

The	O	O
gene	O	O
for	O	O
HGO	O	O
seems	O	O
to	O	O
be	O	O
expressed	O	O
in	O	O
various	O	O
tissues	O	O
,	O	O
as	O	O
shown	O	O
by	O	O
RT	O	O
-	O	O
PCR	O	O
on	O	O
different	O	O
cDNAs	O	O
.	O	O

FISH	O	O
experiments	O	O
with	O	O
the	O	O
whole	O	O
murine	O	O
cDNA	O	O
as	O	O
probe	O	O
clearly	O	O
revealed	O	O
signals	O	O
at	O	O
the	O	O
human	O	O
chromosomal	O	O
band	O	O
3q13	O	O
.	O	O

3	O	O
-	O	O
q21	O	O
.	O	O

This	O	O
corresponds	O	O
well	O	O
to	O	O
the	O	O
previous	O	O
assignment	O	O
of	O	O
the	O	O
locus	O	O
for	O	O
the	O	O
human	O	O
alkaptonuria	B-Disease	D000474
gene	O	O
(	O	O
AKU	O	O
)	O	O
to	O	O
the	O	O
same	O	O
chromosomal	O	O
region	O	O
by	O	O
multipoint	O	O
linkage	O	O
analysis	O	O
.	O	O

We	O	O
therefore	O	O
conclude	O	O
that	O	O
the	O	O
HGO	O	O
cDNA	O	O
encodes	O	O
the	O	O
gene	O	O
responsible	O	O
for	O	O
alkaptonuria	B-Disease	D000474
.	O	O

Abnormal	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
protein	O	O
kinase	O	O
levels	O	O
produce	O	O
only	O	O
mild	O	O
myopathy	B-Disease	D009135
in	O	O
mice	O	O
.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
is	O	O
commonly	O	O
associated	O	O
with	O	O
CTG	O	O
repeat	O	O
expansions	O	O
within	O	O
the	O	O
gene	O	O
for	O	O
DM	B-Disease	D009223
-	O	O
protein	O	O
kinase	O	O
(	O	O
DMPK	O	O
)	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
altered	O	O
expression	O	O
levels	O	O
of	O	O
DMPK	O	O
,	O	O
which	O	O
is	O	O
ubiquitously	O	O
expressed	O	O
in	O	O
all	O	O
muscle	O	O
cell	O	O
lineages	O	O
during	O	O
development	O	O
,	O	O
was	O	O
examined	O	O
by	O	O
disrupting	O	O
the	O	O
endogenous	O	O
Dmpk	O	O
gene	O	O
and	O	O
overexpressing	O	O
a	O	O
normal	O	O
human	O	O
DMPK	O	O
transgene	O	O
in	O	O
mice	O	O
.	O	O

Nullizygous	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
showed	O	O
only	O	O
inconsistent	O	O
and	O	O
minor	O	O
size	O	O
changes	O	O
in	O	O
head	O	O
and	O	O
neck	O	O
muscle	O	O
fibres	O	O
at	O	O
older	O	O
age	O	O
,	O	O
animals	O	O
with	O	O
the	O	O
highest	O	O
DMPK	O	O
transgene	O	O
expression	O	O
showed	O	O
hypertrophic	B-Disease	D002312
cardiomyopathy	I-Disease	D002312
and	O	O
enhanced	O	O
neonatal	O	O
mortality	O	O
.	O	O

However	O	O
,	O	O
both	O	O
models	O	O
lack	O	O
other	O	O
frequent	O	O
DM	B-Disease	D009223
symptoms	O	O
including	O	O
the	O	O
fibre	O	O
-	O	O
type	O	O
dependent	O	O
atrophy	B-Disease	D001284
,	O	O
myotonia	B-Disease	D009222
,	O	O
cataract	B-Disease	D002386
and	O	O
male	B-Disease	D007248
-	I-Disease	D007248
infertility	I-Disease	D007248
.	O	O

These	O	O
results	O	O
strengthen	O	O
the	O	O
contention	O	O
that	O	O
simple	O	O
loss	O	O
-	O	O
or	O	O
gain	O	O
-	O	O
of	O	O
-	O	O
expression	O	O
of	O	O
DMPK	O	O
is	O	O
not	O	O
the	O	O
only	O	O
crucial	O	O
requirement	O	O
for	O	O
development	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

.	O	O

Molecular	O	O
bases	O	O
of	O	O
combined	B-Disease	OMIM:612446
subtotal	I-Disease	OMIM:612446
deficiencies	I-Disease	OMIM:612446
of	I-Disease	OMIM:612446
C6	I-Disease	OMIM:612446
and	I-Disease	OMIM:612446
C7	I-Disease	OMIM:612446
:	O	O
their	O	O
effects	O	O
in	O	O
combination	O	O
with	O	O
other	O	O
C6	B-Disease	OMIM:612446
and	I-Disease	OMIM:612446
C7	I-Disease	OMIM:612446
deficiencies	I-Disease	OMIM:612446
.	O	O

Combined	B-Disease	OMIM:612446
subtotal	I-Disease	OMIM:612446
deficiency	I-Disease	OMIM:612446
of	I-Disease	OMIM:612446
C6	I-Disease	OMIM:612446
and	I-Disease	OMIM:612446
C7	I-Disease	OMIM:612446
,	O	O
in	O	O
which	O	O
both	O	O
proteins	O	O
are	O	O
expressed	O	O
at	O	O
very	O	O
low	O	O
levels	O	O
,	O	O
has	O	O
been	O	O
observed	O	O
in	O	O
homozygous	O	O
form	O	O
in	O	O
two	O	O
families	O	O
.	O	O

A	O	O
defect	O	O
at	O	O
the	O	O
5	O	O
splice	O	O
donor	O	O
site	O	O
of	O	O
intron	O	O
15	O	O
of	O	O
the	O	O
C6	O	O
gene	O	O
explains	O	O
the	O	O
low	O	O
molecular	O	O
weight	O	O
of	O	O
the	O	O
C6	O	O
protein	O	O
and	O	O
is	O	O
probably	O	O
responsible	O	O
for	O	O
its	O	O
low	O	O
expressed	O	O
concentration	O	O
.	O	O

The	O	O
C7	O	O
defect	O	O
is	O	O
more	O	O
enigmatic	O	O
the	O	O
protein	O	O
is	O	O
of	O	O
normal	O	O
molecular	O	O
weight	O	O
,	O	O
low	O	O
circulating	O	O
concentration	O	O
,	O	O
and	O	O
altered	O	O
isoelectric	O	O
point	O	O
.	O	O

An	O	O
Arg	O	O
>	O	O
Ser	O	O
codon	O	O
substitution	O	O
in	O	O
exon	O	O
11	O	O
is	O	O
the	O	O
only	O	O
molecular	O	O
alteration	O	O
within	O	O
the	O	O
mature	O	O
C7	O	O
protein	O	O
.	O	O

These	O	O
defects	O	O
are	O	O
associated	O	O
with	O	O
a	O	O
characteristic	O	O
set	O	O
of	O	O
polymorphic	O	O
DNA	O	O
markers	O	O
in	O	O
the	O	O
C6	O	O
/	O	O
C7	O	O
region	O	O
,	O	O
forming	O	O
a	O	O
distinct	O	O
haplotype	O	O
.	O	O

The	O	O
haplotype	O	O
has	O	O
been	O	O
found	O	O
in	O	O
combination	O	O
with	O	O
a	O	O
number	O	O
of	O	O
other	O	O
haplotypes	O	O
containing	O	O
defective	O	O
genes	O	O
that	O	O
lead	O	O
either	O	O
to	O	O
C6	B-Disease	OMIM:612446
or	I-Disease	OMIM:612446
C7	I-Disease	OMIM:612446
deficiency	I-Disease	OMIM:612446
,	O	O
but	O	O
with	O	O
different	O	O
consequences	O	O
.	O	O

Where	O	O
it	O	O
is	O	O
combined	O	O
with	O	O
a	O	O
C6	B-Disease	OMIM:612446
-	I-Disease	OMIM:612446
deficient	I-Disease	OMIM:612446
gene	O	O
,	O	O
the	O	O
serum	O	O
C7	O	O
levels	O	O
can	O	O
be	O	O
surprisingly	O	O
high	O	O
,	O	O
possibly	O	O
because	O	O
there	O	O
is	O	O
no	O	O
C6	O	O
generating	O	O
C56	O	O
to	O	O
consume	O	O
the	O	O
C7	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
where	O	O
the	O	O
C7	O	O
genes	O	O
are	O	O
both	O	O
defective	O	O
(	O	O
but	O	O
still	O	O
partially	O	O
functional	O	O
)	O	O
,	O	O
there	O	O
may	O	O
be	O	O
a	O	O
profound	O	O
deficit	O	O
of	O	O
circulating	O	O
C7	O	O
because	O	O
there	O	O
is	O	O
ample	O	O
C6	O	O
to	O	O
produce	O	O
C56	O	O
and	O	O
consume	O	O
the	O	O
already	O	O
small	O	O
amount	O	O
of	O	O
C7	O	O
.	O	O

Each	O	O
molecular	O	O
defect	O	O
has	O	O
also	O	O
been	O	O
found	O	O
in	O	O
isolation	O	O
and	O	O
has	O	O
the	O	O
expected	O	O
effect	O	O
.	O	O

.	O	O

Constitutively	O	O
methylated	O	O
CpG	O	O
dinucleotides	O	O
as	O	O
mutation	O	O
hot	O	O
spots	O	O
in	O	O
the	O	O
retinoblastoma	B-Disease	D012175
gene	O	O
(	O	O
RB1	O	O
)	O	O
.	O	O

A	O	O
wide	O	O
spectrum	O	O
of	O	O
mutations	O	O
,	O	O
ranging	O	O
from	O	O
point	O	O
mutations	O	O
to	O	O
large	O	O
deletions	O	O
,	O	O
have	O	O
been	O	O
described	O	O
in	O	O
the	O	O
retinoblastoma	B-Disease	D012175
gene	O	O
(	O	O
RB1	O	O
)	O	O
.	O	O

Mutations	O	O
have	O	O
been	O	O
found	O	O
throughout	O	O
the	O	O
gene	O	O
;	O	O
however	O	O
,	O	O
these	O	O
genetic	O	O
alterations	O	O
do	O	O
not	O	O
appear	O	O
to	O	O
be	O	O
homogeneously	O	O
distributed	O	O
.	O	O

In	O	O
particular	O	O
,	O	O
a	O	O
significant	O	O
proportion	O	O
of	O	O
disease	O	O
-	O	O
causing	O	O
mutations	O	O
results	O	O
in	O	O
the	O	O
premature	O	O
termination	O	O
of	O	O
protein	O	O
synthesis	O	O
,	O	O
and	O	O
the	O	O
majority	O	O
of	O	O
these	O	O
mutations	O	O
occur	O	O
as	O	O
C	O	O
-	O	O
-	O	O
>	O	O
T	O	O
transitions	O	O
at	O	O
CpG	O	O
dinucleotides	O	O
(	O	O
CpGs	O	O
)	O	O
.	O	O

Such	O	O
recurrent	O	O
CpG	O	O
mutations	O	O
,	O	O
including	O	O
those	O	O
found	O	O
in	O	O
RB1	O	O
,	O	O
are	O	O
likely	O	O
the	O	O
result	O	O
of	O	O
the	O	O
deamination	O	O
of	O	O
5	O	O
-	O	O
methylcytosine	O	O
within	O	O
these	O	O
CpGs	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
used	O	O
the	O	O
sodiumbisulfite	O	O
conversion	O	O
method	O	O
to	O	O
detect	O	O
cytosine	O	O
methylation	O	O
in	O	O
representative	O	O
exons	O	O
of	O	O
RB1	O	O
.	O	O

We	O	O
analyzed	O	O
DNA	O	O
from	O	O
a	O	O
variety	O	O
of	O	O
tissues	O	O
and	O	O
specifically	O	O
targeted	O	O
CGA	O	O
codons	O	O
in	O	O
RB1	O	O
,	O	O
where	O	O
recurrent	O	O
premature	O	O
termination	O	O
mutations	O	O
have	O	O
been	O	O
reported	O	O
.	O	O

We	O	O
found	O	O
that	O	O
DNA	O	O
methylation	O	O
within	O	O
RB1	O	O
exons	O	O
8	O	O
,	O	O
14	O	O
,	O	O
25	O	O
,	O	O
and	O	O
27	O	O
appeared	O	O
to	O	O
be	O	O
restricted	O	O
to	O	O
CpGs	O	O
,	O	O
including	O	O
six	O	O
CGA	O	O
codons	O	O
.	O	O

Other	O	O
codons	O	O
containing	O	O
methylated	O	O
cytosines	O	O
have	O	O
not	O	O
been	O	O
reported	O	O
to	O	O
be	O	O
mutated	O	O
.	O	O

Therefore	O	O
,	O	O
disease	O	O
-	O	O
causing	O	O
mutations	O	O
at	O	O
CpGs	O	O
in	O	O
RB1	O	O
appear	O	O
to	O	O
be	O	O
determined	O	O
by	O	O
several	O	O
factors	O	O
,	O	O
including	O	O
the	O	O
constitutive	O	O
presence	O	O
of	O	O
DNA	O	O
methylation	O	O
at	O	O
cytosines	O	O
within	O	O
CpGs	O	O
,	O	O
the	O	O
specific	O	O
codon	O	O
within	O	O
which	O	O
the	O	O
methylated	O	O
cytosine	O	O
is	O	O
located	O	O
,	O	O
and	O	O
the	O	O
particular	O	O
region	O	O
of	O	O
the	O	O
gene	O	O
within	O	O
which	O	O
that	O	O
codon	O	O
resides	O	O
.	O	O

.	O	O

The	O	O
TSG101	O	O
tumor	B-Disease	D009369
susceptibility	O	O
gene	O	O
is	O	O
located	O	O
in	O	O
chromosome	O	O
11	O	O
band	O	O
p15	O	O
and	O	O
is	O	O
mutated	O	O
in	O	O
human	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

Recent	O	O
work	O	O
has	O	O
identified	O	O
a	O	O
mouse	O	O
gene	O	O
(	O	O
tsg101	O	O
)	O	O
whose	O	O
inactivation	O	O
in	O	O
fibroblasts	O	O
results	O	O
in	O	O
cellular	O	O
transformation	O	O
and	O	O
the	O	O
ability	O	O
to	O	O
produce	O	O
metastatic	B-Disease	D009362
tumors	I-Disease	D009362
in	O	O
nude	O	O
mice	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
that	O	O
the	O	O
human	O	O
homolog	O	O
,	O	O
TSG101	O	O
,	O	O
which	O	O
we	O	O
isolated	O	O
and	O	O
mapped	O	O
to	O	O
chromosome	O	O
11	O	O
,	O	O
bands	O	O
15	O	O
.	O	O

1	O	O
-	O	O
15	O	O
1	O	O
-	O	O
15	O	O
.	O	O

2	O	O
,	O	O
a	O	O
region	O	O
proposed	O	O
to	O	O
contain	O	O
tumor	B-Disease	D009369
suppressor	O	O
gene	O	O
(	O	O
s	O	O
)	O	O
,	O	O
is	O	O
mutated	O	O
at	O	O
high	O	O
frequency	O	O
in	O	O
human	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

In	O	O
7	O	O
of	O	O
15	O	O
uncultured	O	O
primary	O	O
human	O	O
breast	B-Disease	D001943
carcinomas	I-Disease	D001943
,	O	O
intragenic	O	O
deletions	O	O
were	O	O
shown	O	O
in	O	O
TSG101	O	O
genomic	O	O
DNA	O	O
and	O	O
transcripts	O	O
by	O	O
gel	O	O
and	O	O
sequence	O	O
analysis	O	O
,	O	O
and	O	O
mutations	O	O
affecting	O	O
two	O	O
TSG101	O	O
alleles	O	O
were	O	O
identified	O	O
in	O	O
four	O	O
of	O	O
these	O	O
cancers	B-Disease	D009369
.	O	O

No	O	O
TSG101	O	O
defects	O	O
were	O	O
found	O	O
in	O	O
matched	O	O
normal	O	O
breast	O	O
tissue	O	O
from	O	O
the	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
patients	O	O
.	O	O

These	O	O
findings	O	O
strongly	O	O
implicate	O	O
TSG101	O	O
mutations	O	O
in	O	O
human	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
The	O	O
Emery	B-Disease	D020389
-	I-Disease	D020389
Dreifuss	I-Disease	D020389
muscular	I-Disease	D020389
dystrophy	I-Disease	D020389
protein	O	O
,	O	O
emerin	O	O
,	O	O
is	O	O
a	O	O
nuclear	O	O
membrane	O	O
protein	O	O
.	O	O

A	O	O
large	O	O
fragment	O	O
of	O	O
emerin	O	O
cDNA	O	O
was	O	O
prepared	O	O
by	O	O
PCR	O	O
and	O	O
expressed	O	O
as	O	O
a	O	O
recombinant	O	O
protein	O	O
in	O	O
Escherichia	O	O
coli	O	O
.	O	O

Using	O	O
this	O	O
as	O	O
immunogen	O	O
,	O	O
we	O	O
prepared	O	O
a	O	O
panel	O	O
of	O	O
12	O	O
monoclonal	O	O
antibodies	O	O
which	O	O
recognise	O	O
at	O	O
least	O	O
four	O	O
different	O	O
epitopes	O	O
on	O	O
emerin	O	O
in	O	O
order	O	O
to	O	O
ensure	O	O
that	O	O
emerin	O	O
can	O	O
be	O	O
distinguished	O	O
from	O	O
non	O	O
-	O	O
specific	O	O
cross	O	O
-	O	O
reacting	O	O
proteins	O	O
.	O	O

All	O	O
the	O	O
mAbs	O	O
recognised	O	O
a	O	O
34	O	O
kDa	O	O
protein	O	O
in	O	O
all	O	O
tissues	O	O
tested	O	O
,	O	O
though	O	O
minor	O	O
emerin	O	O
-	O	O
related	O	O
bands	O	O
were	O	O
also	O	O
detected	O	O
in	O	O
some	O	O
tissues	O	O
.	O	O

Immunofluorescence	O	O
microscopy	O	O
showed	O	O
that	O	O
emerin	O	O
is	O	O
located	O	O
at	O	O
the	O	O
nuclear	O	O
rim	O	O
in	O	O
all	O	O
tissues	O	O
examined	O	O
.	O	O

A	O	O
muscle	O	O
biopsy	O	O
from	O	O
an	O	O
Emery	B-Disease	D020389
-	I-Disease	D020389
Dreifuss	I-Disease	D020389
muscular	I-Disease	D020389
dystrophy	I-Disease	D020389
(	O	O
EMDM	B-Disease	D020389
)	O	O
patient	O	O
showed	O	O
complete	O	O
absence	O	O
of	O	O
emerin	O	O
by	O	O
both	O	O
Western	O	O
blotting	O	O
and	O	O
immunohistochemistry	O	O
,	O	O
suggesting	O	O
a	O	O
simple	O	O
diagnostic	O	O
antibody	O	O
test	O	O
for	O	O
EDMD	B-Disease	D020389
families	O	O
.	O	O

Biochemical	O	O
fractionation	O	O
of	O	O
brain	O	O
and	O	O
liver	O	O
tissues	O	O
showed	O	O
that	O	O
emerin	O	O
was	O	O
present	O	O
in	O	O
nuclei	O	O
purified	O	O
by	O	O
centrifugation	O	O
through	O	O
65	O	O
%	O	O
sucrose	O	O
and	O	O
was	O	O
absent	O	O
from	O	O
soluble	O	O
fractions	O	O
(	O	O
post	O	O
-	O	O
100	O	O
,	O	O
000	O	O
g	O	O
)	O	O
.	O	O

From	O	O
these	O	O
results	O	O
,	O	O
together	O	O
with	O	O
sequence	O	O
and	O	O
structural	O	O
homologies	O	O
between	O	O
emerin	O	O
,	O	O
thymopoietins	O	O
and	O	O
the	O	O
nuclear	O	O
lamina	O	O
-	O	O
associated	O	O
protein	O	O
,	O	O
LAP2	O	O
,	O	O
we	O	O
suggest	O	O
that	O	O
emerin	O	O
will	O	O
prove	O	O
to	O	O
be	O	O
one	O	O
member	O	O
of	O	O
a	O	O
family	O	O
of	O	O
inner	O	O
nuclear	O	O
membrane	O	O
proteins	O	O
.	O	O

.	O	O

Influence	O	O
of	O	O
PAX6	O	O
gene	O	O
dosage	O	O
on	O	O
development	O	O
:	O	O
overexpression	O	O
causes	O	O
severe	O	O
eye	B-Disease	D005124
abnormalities	I-Disease	D005124
.	O	O

Aniridia	B-Disease	D015783
in	O	O
man	O	O
and	O	O
Small	O	O
eye	O	O
in	O	O
mice	O	O
are	O	O
semidominant	B-Disease	D002658
developmental	I-Disease	D002658
disorders	I-Disease	D002658
caused	O	O
by	O	O
mutations	O	O
within	O	O
the	O	O
paired	O	O
box	O	O
gene	O	O
PAX6	O	O
.	O	O

Whereas	O	O
heterozygotes	O	O
suffer	O	O
from	O	O
iris	B-Disease	D007499
hypoplasia	I-Disease	D007499
,	O	O
homozygous	O	O
mice	O	O
lack	O	O
eyes	O	O
and	O	O
nasal	O	O
cavities	O	O
and	O	O
exhibit	O	O
brain	B-Disease	D001927
abnormalities	I-Disease	D001927
.	O	O

To	O	O
investigate	O	O
the	O	O
role	O	O
of	O	O
gene	O	O
dosage	O	O
in	O	O
more	O	O
detail	O	O
,	O	O
we	O	O
have	O	O
generated	O	O
yeast	O	O
artificial	O	O
chromosome	O	O
transgenic	O	O
mice	O	O
carrying	O	O
the	O	O
human	O	O
PAX6	O	O
locus	O	O
.	O	O

When	O	O
crossed	O	O
onto	O	O
the	O	O
Small	O	O
eye	O	O
background	O	O
,	O	O
the	O	O
transgene	O	O
rescues	O	O
the	O	O
mutant	O	O
phenotype	O	O
.	O	O

Strikingly	O	O
,	O	O
mice	O	O
carrying	O	O
multiple	O	O
copies	O	O
on	O	O
a	O	O
wild	O	O
-	O	O
type	O	O
background	O	O
show	O	O
specific	O	O
developmental	B-Disease	D005124
abnormalities	I-Disease	D005124
of	I-Disease	D005124
the	I-Disease	D005124
eye	I-Disease	D005124
,	O	O
but	O	O
not	O	O
of	O	O
other	O	O
tissues	O	O
expressing	O	O
the	O	O
gene	O	O
.	O	O

Thus	O	O
,	O	O
at	O	O
least	O	O
five	O	O
different	O	O
eye	O	O
phenotypes	O	O
are	O	O
associated	O	O
with	O	O
changes	O	O
in	O	O
PAX6	O	O
expression	O	O
.	O	O

We	O	O
provide	O	O
evidence	O	O
that	O	O
not	O	O
only	O	O
reduced	O	O
,	O	O
but	O	O
also	O	O
increased	O	O
levels	O	O
of	O	O
transcriptional	O	O
regulators	O	O
can	O	O
cause	O	O
developmental	B-Disease	D002658
defects	I-Disease	D002658
.	O	O

.	O	O

Founding	O	O
BRCA1	O	O
mutations	O	O
in	O	O
hereditary	B-Disease	D061325
breast	I-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
in	O	O
southern	O	O
Sweden	O	O
.	O	O

Nine	O	O
different	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
in	O	O
the	O	O
BRCA1	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
susceptibility	O	O
gene	O	O
were	O	O
identified	O	O
in	O	O
15	O	O
of	O	O
47	O	O
kindreds	O	O
from	O	O
southern	O	O
Sweden	O	O
,	O	O
by	O	O
use	O	O
of	O	O
SSCP	O	O
and	O	O
heteroduplex	O	O
analysis	O	O
of	O	O
all	O	O
exons	O	O
and	O	O
flanking	O	O
intron	O	O
region	O	O
and	O	O
by	O	O
a	O	O
protein	O	O
-	O	O
truncation	O	O
test	O	O
for	O	O
exon	O	O
11	O	O
,	O	O
followed	O	O
by	O	O
direct	O	O
sequencing	O	O
.	O	O

All	O	O
but	O	O
one	O	O
of	O	O
the	O	O
mutations	O	O
are	O	O
predicted	O	O
to	O	O
give	O	O
rise	O	O
to	O	O
premature	O	O
translation	O	O
termination	O	O
and	O	O
include	O	O
seven	O	O
frameshift	O	O
insertions	O	O
or	O	O
deletions	O	O
,	O	O
a	O	O
nonsense	O	O
mutation	O	O
,	O	O
and	O	O
a	O	O
splice	O	O
acceptor	O	O
site	O	O
mutation	O	O
.	O	O

The	O	O
remaining	O	O
mutation	O	O
is	O	O
a	O	O
missense	O	O
mutation	O	O
(	O	O
Cys61Gly	O	O
)	O	O
in	O	O
the	O	O
zinc	O	O
-	O	O
binding	O	O
motif	O	O
.	O	O

Four	O	O
novel	O	O
Swedish	O	O
founding	O	O
mutations	O	O
were	O	O
identified	O	O
the	O	O
nucleotide	O	O
2595	O	O
deletion	O	O
A	O	O
was	O	O
found	O	O
in	O	O
five	O	O
families	O	O
,	O	O
the	O	O
C	O	O
1806	O	O
T	O	O
nonsense	O	O
mutation	O	O
in	O	O
three	O	O
families	O	O
,	O	O
the	O	O
3166	O	O
insertion	O	O
TGAGA	O	O
in	O	O
three	O	O
families	O	O
,	O	O
and	O	O
the	O	O
nucleotide	O	O
1201	O	O
deletion	O	O
11	O	O
in	O	O
two	O	O
families	O	O
.	O	O

Analysis	O	O
of	O	O
the	O	O
intragenic	O	O
polymorphism	O	O
D17S855	O	O
supports	O	O
common	O	O
origins	O	O
of	O	O
the	O	O
mutations	O	O
.	O	O

Eleven	O	O
of	O	O
the	O	O
15	O	O
kindreds	O	O
manifesting	O	O
BRCA1	O	O
mutations	O	O
were	O	O
breast	B-Disease	D061325
-	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
families	O	O
,	O	O
several	O	O
of	O	O
them	O	O
with	O	O
a	O	O
predominant	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
phenotype	O	O
.	O	O

The	O	O
set	O	O
of	O	O
32	O	O
families	O	O
in	O	O
which	O	O
no	O	O
BRCA1	O	O
alterations	O	O
were	O	O
detected	O	O
included	O	O
1	O	O
breast	B-Disease	D061325
-	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
kindred	O	O
manifesting	O	O
clear	O	O
linkage	O	O
to	O	O
the	O	O
BRCA1	O	O
region	O	O
and	O	O
loss	O	O
of	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
chromosome	O	O
in	O	O
associated	O	O
tumors	B-Disease	D009369
.	O	O

Other	O	O
tumor	B-Disease	D009369
types	O	O
found	O	O
in	O	O
BRCA1	O	O
mutation	O	O
/	O	O
haplotype	O	O
carriers	O	O
included	O	O
prostatic	B-Disease	D011471
,	I-Disease	D011471
pancreas	I-Disease	D011471
,	I-Disease	D011471
skin	I-Disease	D011471
,	I-Disease	D011471
and	I-Disease	D011471
lung	I-Disease	D011471
cancer	I-Disease	D011471
,	O	O
a	O	O
malignant	B-Disease	D008545
melanoma	I-Disease	D008545
,	O	O
an	O	O
oligodendroglioma	B-Disease	D009837
,	O	O
and	O	O
a	O	O
carcinosarcoma	B-Disease	D002296
.	O	O

In	O	O
all	O	O
,	O	O
12	O	O
of	O	O
16	O	O
kindreds	O	O
manifesting	O	O
BRCA1	O	O
mutation	O	O
or	O	O
linkage	O	O
contained	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
,	O	O
as	O	O
compared	O	O
with	O	O
only	O	O
6	O	O
of	O	O
the	O	O
remaining	O	O
31	O	O
families	O	O
(	O	O
P	O	O
<	O	O
.	O	O

001	O	O
)	O	O
.	O	O

The	O	O
present	O	O
study	O	O
confirms	O	O
the	O	O
involvement	O	O
of	O	O
BRCA1	O	O
in	O	O
disease	O	O
predisposition	O	O
for	O	O
a	O	O
subset	O	O
of	O	O
hereditary	B-Disease	D001943
breast	I-Disease	D001943
cancer	I-Disease	D001943
families	O	O
often	O	O
characterized	O	O
by	O	O
ovarian	B-Disease	D010051
cancers	I-Disease	D010051
.	O	O

The	O	O
DCC	O	O
protein	O	O
and	O	O
prognosis	O	O
in	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
.	O	O

BACKGROUND	O	O
Allelic	O	O
loss	O	O
of	O	O
chromosome	O	O
18q	O	O
predicts	O	O
a	O	O
poor	O	O
outcome	O	O
in	O	O
patients	O	O
with	O	O
stage	B-Disease	D015179
II	I-Disease	D015179
colorectal	I-Disease	D015179
cancer	I-Disease	D015179
.	O	O

Although	O	O
the	O	O
specific	O	O
gene	O	O
inactivated	O	O
by	O	O
this	O	O
allelic	O	O
loss	O	O
has	O	O
not	O	O
been	O	O
elucidated	O	O
,	O	O
the	O	O
DCC	O	O
(	O	O
deleted	O	O
in	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
)	O	O
gene	O	O
is	O	O
a	O	O
candidate	O	O
.	O	O

We	O	O
investigated	O	O
whether	O	O
the	O	O
expression	O	O
of	O	O
the	O	O
DCC	O	O
protein	O	O
in	O	O
tumor	B-Disease	D009369
cells	O	O
is	O	O
a	O	O
prognostic	O	O
marker	O	O
in	O	O
colorectal	B-Disease	D015179
carcinoma	I-Disease	D015179
.	O	O

METHODS	O	O
The	O	O
expression	O	O
of	O	O
DCC	O	O
was	O	O
evaluated	O	O
immunohistochemically	O	O
in	O	O
132	O	O
paraffin	O	O
-	O	O
embedded	O	O
samples	O	O
from	O	O
patients	O	O
with	O	O
curatively	O	O
resected	O	O
stage	B-Disease	D015179
II	I-Disease	D015179
and	I-Disease	D015179
III	I-Disease	D015179
colorectal	I-Disease	D015179
carcinomas	I-Disease	D015179
.	O	O

The	O	O
Cox	O	O
proportional	O	O
-	O	O
hazards	O	O
model	O	O
was	O	O
used	O	O
to	O	O
adjust	O	O
for	O	O
covariates	O	O
including	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
tumor	B-Disease	D009369
site	O	O
,	O	O
degree	O	O
of	O	O
tumor	B-Disease	D009369
differentiation	O	O
,	O	O
and	O	O
use	O	O
of	O	O
adjuvant	O	O
therapy	O	O
.	O	O

RESULTS	O	O
The	O	O
expression	O	O
of	O	O
DCC	O	O
was	O	O
a	O	O
strong	O	O
positive	O	O
predictive	O	O
factor	O	O
for	O	O
survival	O	O
in	O	O
both	O	O
stage	B-Disease	D015179
II	I-Disease	D015179
and	I-Disease	D015179
stage	I-Disease	D015179
III	I-Disease	D015179
colorectal	I-Disease	D015179
carcinomas	I-Disease	D015179
.	O	O

In	O	O
patients	O	O
with	O	O
stage	O	O
II	O	O
disease	O	O
whose	O	O
tumors	B-Disease	D009369
expressed	O	O
DCC	O	O
,	O	O
the	O	O
five	O	O
-	O	O
year	O	O
survival	O	O
rate	O	O
was	O	O
94	O	O
.	O	O

3	O	O
percent	O	O
,	O	O
whereas	O	O
in	O	O
patients	O	O
with	O	O
DCC	B-Disease	D009369
-	I-Disease	D009369
negative	I-Disease	D009369
tumors	I-Disease	D009369
,	O	O
the	O	O
survival	O	O
rate	O	O
was	O	O
61	O	O
.	O	O

6	O	O
percent	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

In	O	O
patients	O	O
with	O	O
stage	B-Disease	D009369
III	I-Disease	D009369
disease	I-Disease	D009369
,	O	O
the	O	O
respective	O	O
survival	O	O
rates	O	O
were	O	O
59	O	O
.	O	O

3	O	O
percent	O	O
and	O	O
33	O	O
.	O	O

2	O	O
percent	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

03	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
DCC	O	O
is	O	O
a	O	O
prognostic	O	O
marker	O	O
in	O	O
patients	O	O
with	O	O
stage	B-Disease	D015179
II	I-Disease	D015179
or	I-Disease	D015179
stage	I-Disease	D015179
III	I-Disease	D015179
colorectal	I-Disease	D015179
cancer	I-Disease	D015179
.	O	O

In	O	O
stage	B-Disease	D015179
II	I-Disease	D015179
colorectal	I-Disease	D015179
carcinomas	I-Disease	D015179
,	O	O
the	O	O
absence	O	O
of	O	O
DCC	O	O
identifies	O	O
a	O	O
subgroup	O	O
of	O	O
patients	O	O
with	O	O
lesions	O	O
that	O	O
behave	O	O
like	O	O
stage	B-Disease	D009369
III	I-Disease	D009369
cancers	I-Disease	D009369
.	O	O

These	O	O
findings	O	O
may	O	O
thus	O	O
have	O	O
therapeutic	O	O
implications	O	O
in	O	O
this	O	O
group	O	O
of	O	O
patients	O	O
Gene	O	O
therapy	O	O
for	O	O
phenylketonuria	B-Disease	D010661
.	O	O

Classical	O	O
phenylketonuria	B-Disease	D010661
(	O	O
PKU	B-Disease	D010661
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
caused	O	O
by	O	O
a	O	O
deficiency	B-Disease	OMIM:261600
of	I-Disease	OMIM:261600
hepatic	I-Disease	OMIM:261600
phenylalanine	I-Disease	OMIM:261600
hydroxylase	I-Disease	OMIM:261600
(	O	O
PAH	O	O
)	O	O
.	O	O

Limitations	O	O
of	O	O
the	O	O
current	O	O
dietary	O	O
treatment	O	O
for	O	O
PKU	B-Disease	D010661
have	O	O
led	O	O
to	O	O
the	O	O
development	O	O
of	O	O
potential	O	O
treatments	O	O
based	O	O
on	O	O
somatic	O	O
gene	O	O
transfer	O	O
.	O	O

Three	O	O
different	O	O
vector	O	O
systems	O	O
have	O	O
been	O	O
examined	O	O
.	O	O

Vectors	O	O
derived	O	O
from	O	O
a	O	O
recombinant	O	O
retrovirus	O	O
or	O	O
a	O	O
DNA	O	O
/	O	O
protein	O	O
complex	O	O
can	O	O
efficiently	O	O
transduce	O	O
the	O	O
PAH	O	O
cDNA	O	O
into	O	O
PAH	B-Disease	OMIM:261600
-	I-Disease	OMIM:261600
deficient	I-Disease	OMIM:261600
hepatocytes	O	O
in	O	O
vitro	O	O
,	O	O
but	O	O
the	O	O
application	O	O
of	O	O
these	O	O
vector	O	O
systems	O	O
is	O	O
presently	O	O
limited	O	O
by	O	O
their	O	O
low	O	O
transduction	O	O
efficiency	O	O
in	O	O
vivo	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
a	O	O
vector	O	O
derived	O	O
from	O	O
a	O	O
recombinant	O	O
adenovirus	O	O
can	O	O
restore	O	O
10	O	O
%	O	O
-	O	O
80	O	O
%	O	O
of	O	O
normal	O	O
hepatic	O	O
PAH	O	O
activity	O	O
into	O	O
PAH	B-Disease	OMIM:261600
-	I-Disease	OMIM:261600
deficient	I-Disease	OMIM:261600
mice	O	O
,	O	O
which	O	O
completely	O	O
normalizes	O	O
serum	O	O
phenylalanine	O	O
levels	O	O
.	O	O

This	O	O
treatment	O	O
is	O	O
transient	O	O
and	O	O
cannot	O	O
be	O	O
effectively	O	O
re	O	O
-	O	O
administered	O	O
due	O	O
to	O	O
the	O	O
presence	O	O
of	O	O
neutralizing	O	O
antibodies	O	O
directed	O	O
against	O	O
the	O	O
recombinant	O	O
adenoviral	O	O
vector	O	O
.	O	O

However	O	O
,	O	O
these	O	O
findings	O	O
suggest	O	O
that	O	O
PKU	B-Disease	D010661
can	O	O
be	O	O
completely	O	O
corrected	O	O
by	O	O
somatic	O	O
gene	O	O
therapy	O	O
,	O	O
and	O	O
provide	O	O
some	O	O
direction	O	O
for	O	O
the	O	O
future	O	O
development	O	O
of	O	O
adenoviral	O	O
vectors	O	O
.	O	O

.	O	O

Identification	O	O
of	O	O
a	O	O
RING	O	O
protein	O	O
that	O	O
can	O	O
interact	O	O
in	O	O
vivo	O	O
with	O	O
the	O	O
BRCA1	O	O
gene	O	O
product	O	O
.	O	O

The	O	O
hereditary	B-Disease	D061325
breast	I-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
gene	O	O
,	O	O
BRCA1	O	O
,	O	O
encodes	O	O
a	O	O
large	O	O
polypeptide	O	O
that	O	O
contains	O	O
the	O	O
cysteine	O	O
-	O	O
rich	O	O
RING	O	O
motif	O	O
,	O	O
a	O	O
zinc	O	O
-	O	O
binding	O	O
domain	O	O
found	O	O
in	O	O
a	O	O
variety	O	O
of	O	O
regulatory	O	O
proteins	O	O
.	O	O

Here	O	O
we	O	O
describe	O	O
a	O	O
novel	O	O
protein	O	O
that	O	O
interacts	O	O
in	O	O
vivo	O	O
with	O	O
the	O	O
N	O	O
-	O	O
terminal	O	O
region	O	O
of	O	O
BRCA1	O	O
.	O	O

This	O	O
BRCA1	O	O
-	O	O
associated	O	O
RING	O	O
domain	O	O
(	O	O
BARD1	O	O
)	O	O
protein	O	O
contains	O	O
an	O	O
N	O	O
-	O	O
terminal	O	O
RING	O	O
motif	O	O
,	O	O
three	O	O
tandem	O	O
ankyrin	O	O
repeats	O	O
,	O	O
and	O	O
a	O	O
C	O	O
-	O	O
terminal	O	O
sequence	O	O
with	O	O
significant	O	O
homology	O	O
to	O	O
the	O	O
phylogenetically	O	O
conserved	O	O
BRCT	O	O
domains	O	O
that	O	O
lie	O	O
near	O	O
the	O	O
C	O	O
terminus	O	O
of	O	O
BRCA1	O	O
.	O	O

The	O	O
BARD1	O	O
/	O	O
BRCA1	O	O
interaction	O	O
is	O	O
disrupted	O	O
by	O	O
BRCA1	O	O
missense	O	O
mutations	O	O
that	O	O
segregate	O	O
with	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
susceptibility	O	O
,	O	O
indicating	O	O
that	O	O
BARD1	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
mediating	O	O
tumour	B-Disease	D009369
suppression	O	O
by	O	O
BRCA1	O	O
.	O	O

.	O	O

Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
:	O	O
no	O	O
strict	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
but	O	O
clustering	O	O
of	O	O
missense	O	O
mutations	O	O
in	O	O
the	O	O
amino	O	O
-	O	O
terminal	O	O
part	O	O
of	O	O
the	O	O
WASP	O	O
gene	O	O
product	O	O
.	O	O

The	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
protein	O	O
(	O	O
WASP	O	O
)	O	O
gene	O	O
was	O	O
found	O	O
to	O	O
be	O	O
mutated	O	O
in	O	O
patients	O	O
presenting	O	O
with	O	O
WAS	B-Disease	D014923
and	O	O
in	O	O
patients	O	O
showing	O	O
X	B-Disease	OMIM:313900
-	I-Disease	OMIM:313900
linked	I-Disease	OMIM:313900
thrombocytopenia	I-Disease	OMIM:313900
.	O	O

Mutation	O	O
analysis	O	O
in	O	O
19	O	O
families	O	O
of	O	O
German	O	O
,	O	O
Swiss	O	O
and	O	O
Turkish	O	O
descent	O	O
by	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
and	O	O
sequencing	O	O
resulted	O	O
in	O	O
the	O	O
detection	O	O
of	O	O
seven	O	O
novel	O	O
and	O	O
10	O	O
known	O	O
mutations	O	O
.	O	O

A	O	O
striking	O	O
clustering	O	O
of	O	O
missense	O	O
mutations	O	O
in	O	O
the	O	O
first	O	O
four	O	O
exons	O	O
contrasted	O	O
with	O	O
a	O	O
random	O	O
distribution	O	O
of	O	O
nonsense	O	O
mutations	O	O
.	O	O

More	O	O
than	O	O
85	O	O
%	O	O
of	O	O
all	O	O
known	O	O
missense	O	O
mutations	O	O
were	O	O
localized	O	O
in	O	O
the	O	O
amino	O	O
-	O	O
terminal	O	O
stretch	O	O
of	O	O
the	O	O
WASP	O	O
gene	O	O
product	O	O
;	O	O
this	O	O
region	O	O
contained	O	O
a	O	O
mutational	O	O
hot	O	O
spot	O	O
at	O	O
codon	O	O
86	O	O
.	O	O

No	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlation	O	O
emerged	O	O
after	O	O
a	O	O
comparison	O	O
of	O	O
the	O	O
identified	O	O
mutations	O	O
with	O	O
the	O	O
resulting	O	O
clinical	O	O
picture	O	O
for	O	O
a	O	O
classical	O	O
WAS	B-Disease	D014923
phenotype	O	O
.	O	O

A	O	O
substitution	O	O
at	O	O
codon	O	O
86	O	O
resulted	O	O
in	O	O
an	O	O
extremely	O	O
variable	O	O
expression	O	O
of	O	O
the	O	O
disease	O	O
in	O	O
a	O	O
large	O	O
Swiss	O	O
family	O	O
.	O	O

An	O	O
extended	O	O
homology	O	O
search	O	O
revealed	O	O
a	O	O
distant	O	O
relationship	O	O
of	O	O
this	O	O
stretch	O	O
to	O	O
the	O	O
vasodilator	O	O
-	O	O
stimulated	O	O
phosphoprotein	O	O
(	O	O
VASP	O	O
)	O	O
,	O	O
which	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
maintenance	O	O
of	O	O
cyto	O	O
-	O	O
architecture	O	O
by	O	O
interacting	O	O
with	O	O
actin	O	O
-	O	O
like	O	O
filaments	O	O
.	O	O

.	O	O

Autosomal	O	O
dominant	O	O
primary	O	O
hyperparathyroidism	B-Disease	OMIM:145001
and	I-Disease	OMIM:145001
jaw	I-Disease	OMIM:145001
tumor	I-Disease	OMIM:145001
syndrome	I-Disease	OMIM:145001
associated	O	O
with	O	O
renal	B-Disease	D007674	D006222
hamartomas	I-Disease	D007674	D006222
and	O	O
cystic	B-Disease	D052177
kidney	I-Disease	D052177
disease	I-Disease	D052177
:	O	O
linkage	O	O
to	O	O
1q21	O	O
-	O	O
q32	O	O
and	O	O
loss	O	O
of	O	O
the	O	O
wild	O	O
type	O	O
allele	O	O
in	O	O
renal	B-Disease	D007674	D006222
hamartomas	I-Disease	D007674	D006222
.	O	O

Hereditary	B-Disease	OMIM:145001
hyperparathyroidism	I-Disease	OMIM:145001
-	I-Disease	OMIM:145001
jaw	I-Disease	OMIM:145001
tumor	I-Disease	OMIM:145001
syndrome	I-Disease	OMIM:145001
(	O	O
HPT	B-Disease	OMIM:145001
-	I-Disease	OMIM:145001
JT	I-Disease	OMIM:145001
)	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
dominant	I-Disease	D030342
disease	I-Disease	D030342
(	O	O
OMIM	O	O
145001	O	O
)	O	O
that	O	O
has	O	O
recently	O	O
been	O	O
mapped	O	O
to	O	O
chromosomal	O	O
region	O	O
1q21	O	O
-	O	O
q32	O	O
(	O	O
HRPT2	O	O
)	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
two	O	O
families	O	O
with	O	O
HPT	B-Disease	OMIM:145001
-	I-Disease	OMIM:145001
JT	I-Disease	OMIM:145001
syndrome	O	O
in	O	O
which	O	O
adult	B-Disease	C536399
renal	I-Disease	C536399
hamartomas	I-Disease	C536399
or	O	O
cystic	B-Disease	D052177
kidney	I-Disease	D052177
disease	I-Disease	D052177
were	O	O
prominent	O	O
associated	O	O
features	O	O
,	O	O
possibly	O	O
representing	O	O
a	O	O
new	O	O
phenotypic	O	O
variant	O	O
of	O	O
the	O	O
HPT	B-Disease	OMIM:145001
-	I-Disease	OMIM:145001
JT	I-Disease	OMIM:145001
syndrome	O	O
.	O	O

In	O	O
the	O	O
first	O	O
family	O	O
,	O	O
renal	B-Disease	D007680
lesions	I-Disease	D007680
were	O	O
present	O	O
in	O	O
five	O	O
out	O	O
of	O	O
six	O	O
affected	O	O
individuals	O	O
,	O	O
whereas	O	O
HPT	B-Disease	D006961
and	O	O
JT	B-Disease	D007573
were	O	O
seen	O	O
in	O	O
four	O	O
and	O	O
two	O	O
cases	O	O
,	O	O
respectively	O	O
.	O	O

In	O	O
the	O	O
second	O	O
family	O	O
,	O	O
JT	B-Disease	D007573
was	O	O
found	O	O
in	O	O
three	O	O
of	O	O
the	O	O
five	O	O
affected	O	O
individuals	O	O
and	O	O
two	O	O
affected	O	O
members	O	O
also	O	O
exhibited	O	O
polycystic	B-Disease	D007690
kidney	I-Disease	D007690
disease	I-Disease	D007690
.	O	O

The	O	O
possibility	O	O
of	O	O
the	O	O
latter	O	O
cosegregating	O	O
as	O	O
a	O	O
separate	O	O
autosomal	O	O
dominant	O	O
gene	O	O
can	O	O
not	O	O
be	O	O
ruled	O	O
out	O	O
.	O	O

A	O	O
sex	O	O
-	O	O
dependent	O	O
penetrance	O	O
of	O	O
primary	B-Disease	D049950
HPT	I-Disease	D049950
,	O	O
resulting	O	O
in	O	O
predominantly	O	O
male	O	O
-	O	O
affected	O	O
cases	O	O
was	O	O
evident	O	O
in	O	O
the	O	O
two	O	O
families	O	O
.	O	O

Twenty	O	O
microsatellite	O	O
markers	O	O
in	O	O
the	O	O
HRPT2	O	O
region	O	O
were	O	O
typed	O	O
,	O	O
in	O	O
addition	O	O
to	O	O
markers	O	O
in	O	O
the	O	O
multiple	B-Disease	D009377
endocrine	I-Disease	D009377
neoplasia	I-Disease	D009377
(	I-Disease	D009377
MEN	I-Disease	D009377
)	I-Disease	D009377
types	I-Disease	D009377
1	I-Disease	D009377
and	I-Disease	D009377
2	I-Disease	D009377
regions	O	O
at	O	O
11q13	O	O
and	O	O
10q11	O	O
.	O	O

The	O	O
disease	O	O
in	O	O
these	O	O
two	O	O
kindreds	O	O
was	O	O
linked	O	O
to	O	O
five	O	O
markers	O	O
in	O	O
the	O	O
1q21	O	O
-	O	O
q32	O	O
region	O	O
(	O	O
logarithm	O	O
-	O	O
of	O	O
-	O	O
odds	O	O
scores	O	O
3	O	O
.	O	O

2	O	O
-	O	O
4	O	O
2	O	O
-	O	O
4	O	O
.	O	O

2	O	O
)	O	O
,	O	O
whereas	O	O
linkage	O	O
to	O	O
the	O	O
MEN1	B-Disease	OMIM:131100
and	O	O
MEN2	B-Disease	D018813
regions	O	O
was	O	O
excluded	O	O
.	O	O

Meiotic	O	O
recombinations	O	O
detected	O	O
in	O	O
affected	O	O
individuals	O	O
placed	O	O
the	O	O
locus	O	O
telomeric	O	O
of	O	O
D1S215	O	O
,	O	O
thus	O	O
narrowing	O	O
the	O	O
HRPT2	O	O
region	O	O
from	O	O
>	O	O
60	O	O
to	O	O
approximately	O	O
34	O	O
centimorgans	O	O
.	O	O

Loss	O	O
of	O	O
heterozygosity	O	O
was	O	O
studied	O	O
in	O	O
seven	O	O
renal	B-Disease	D007674	D006222
hamartomas	I-Disease	D007674	D006222
from	O	O
two	O	O
affected	O	O
individuals	O	O
in	O	O
the	O	O
first	O	O
family	O	O
,	O	O
as	O	O
well	O	O
as	O	O
in	O	O
a	O	O
jaw	B-Disease	D007573
tumor	I-Disease	D007573
and	O	O
a	O	O
parathyroid	B-Disease	D010282
tumor	I-Disease	D010282
from	O	O
the	O	O
second	O	O
family	O	O
.	O	O

All	O	O
renal	B-Disease	D007674	D006222
hamartomas	I-Disease	D007674	D006222
showed	O	O
loss	O	O
of	O	O
heterozygosity	O	O
at	O	O
the	O	O
1q21	O	O
-	O	O
q32	O	O
region	O	O
.	O	O

The	O	O
losses	O	O
invariably	O	O
involved	O	O
the	O	O
wild	O	O
type	O	O
allele	O	O
derived	O	O
from	O	O
the	O	O
unaffected	O	O
parent	O	O
,	O	O
suggesting	O	O
the	O	O
inactivation	O	O
of	O	O
a	O	O
tumor	B-Disease	D009369
suppressor	O	O
gene	O	O
in	O	O
this	O	O
region	O	O
Heterodimer	O	O
formation	O	O
and	O	O
activity	O	O
in	O	O
the	O	O
human	O	O
enzyme	O	O
galactose	O	O
-	O	O
1	O	O
-	O	O
phosphate	O	O
uridylyltransferase	O	O
.	O	O

One	O	O
of	O	O
the	O	O
fundamental	O	O
questions	O	O
concerning	O	O
expression	O	O
and	O	O
function	O	O
of	O	O
dimeric	O	O
enzymes	O	O
involves	O	O
the	O	O
impact	O	O
of	O	O
naturally	O	O
occurring	O	O
mutations	O	O
on	O	O
subunit	O	O
assembly	O	O
and	O	O
heterodimer	O	O
activity	O	O
.	O	O

This	O	O
question	O	O
is	O	O
of	O	O
particular	O	O
interest	O	O
for	O	O
the	O	O
human	O	O
enzyme	O	O
galactose	O	O
-	O	O
l	O	O
-	O	O
phosphate	O	O
uridylyl	O	O
-	O	O
transferase	O	O
(	O	O
GALT	O	O
)	O	O
,	O	O
impairment	O	O
of	O	O
which	O	O
results	O	O
in	O	O
the	O	O
inherited	B-Disease	D008659
metabolic	I-Disease	D008659
disorder	I-Disease	D008659
galactosemia	B-Disease	D005693
,	O	O
because	O	O
many	O	O
if	O	O
not	O	O
most	O	O
patients	O	O
studied	O	O
to	O	O
date	O	O
are	O	O
compound	O	O
heterozygotes	O	O
rather	O	O
than	O	O
true	O	O
molecular	O	O
homozygotes	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
broad	O	O
range	O	O
of	O	O
phenotypic	O	O
severity	O	O
observed	O	O
in	O	O
these	O	O
patients	O	O
raises	O	O
the	O	O
possibility	O	O
that	O	O
allelic	O	O
combination	O	O
,	O	O
not	O	O
just	O	O
allelic	O	O
constitution	O	O
,	O	O
may	O	O
play	O	O
some	O	O
role	O	O
in	O	O
determining	O	O
outcome	O	O
.	O	O

In	O	O
the	O	O
work	O	O
described	O	O
herein	O	O
,	O	O
we	O	O
have	O	O
selected	O	O
two	O	O
distinct	O	O
naturally	O	O
occurring	O	O
null	O	O
mutations	O	O
of	O	O
GALT	O	O
,	O	O
Q188R	O	O
and	O	O
R333W	O	O
,	O	O
and	O	O
asked	O	O
the	O	O
questions	O	O
(	O	O
i	O	O
)	O	O
what	O	O
are	O	O
the	O	O
impacts	O	O
of	O	O
these	O	O
mutations	O	O
on	O	O
subunit	O	O
assembly	O	O
,	O	O
and	O	O
(	O	O
ii	O	O
)	O	O
if	O	O
heterodimers	O	O
do	O	O
form	O	O
,	O	O
are	O	O
they	O	O
active	O	O
?	O	O
To	O	O
answer	O	O
these	O	O
questions	O	O
,	O	O
we	O	O
have	O	O
established	O	O
a	O	O
yeast	O	O
system	O	O
for	O	O
the	O	O
coexpression	O	O
of	O	O
epitope	O	O
-	O	O
tagged	O	O
alleles	O	O
of	O	O
human	O	O
GALT	O	O
and	O	O
investigated	O	O
both	O	O
the	O	O
extent	O	O
of	O	O
specific	O	O
GALT	O	O
subunit	O	O
interactions	O	O
and	O	O
the	O	O
activity	O	O
of	O	O
defined	O	O
heterodimer	O	O
pools	O	O
.	O	O

We	O	O
have	O	O
found	O	O
that	O	O
both	O	O
homodimers	O	O
and	O	O
heterodimers	O	O
do	O	O
form	O	O
involving	O	O
each	O	O
of	O	O
the	O	O
mutant	O	O
subunits	O	O
tested	O	O
and	O	O
that	O	O
both	O	O
heterodimer	O	O
pools	O	O
retain	O	O
substantial	O	O
enzymatic	O	O
activity	O	O
.	O	O

These	O	O
results	O	O
are	O	O
significant	O	O
not	O	O
only	O	O
in	O	O
terms	O	O
of	O	O
their	O	O
implications	O	O
for	O	O
furthering	O	O
our	O	O
understanding	O	O
of	O	O
galactosemia	B-Disease	D005693
and	O	O
GALT	O	O
holoenzyme	O	O
structure	O	O
-	O	O
function	O	O
relationships	O	O
but	O	O
also	O	O
because	O	O
the	O	O
system	O	O
described	O	O
may	O	O
serve	O	O
as	O	O
a	O	O
model	O	O
for	O	O
similar	O	O
studies	O	O
of	O	O
other	O	O
complexes	O	O
composed	O	O
of	O	O
multiple	O	O
subunits	O	O
.	O	O

.	O	O

BRCA1	O	O
R841W	O	O
:	O	O
a	O	O
strong	O	O
candidate	O	O
for	O	O
a	O	O
common	O	O
mutation	O	O
with	O	O
moderate	O	O
phenotype	O	O
.	O	O

BRCA1	O	O
mutations	O	O
cause	O	O
increased	O	O
risk	O	O
for	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
,	O	O
frequently	O	O
of	O	O
early	O	O
onset	O	O
.	O	O

Many	O	O
different	O	O
mutations	O	O
occur	O	O
in	O	O
BRCA1	O	O
,	O	O
including	O	O
several	O	O
examples	O	O
of	O	O
recurrent	O	O
mutations	O	O
,	O	O
each	O	O
of	O	O
which	O	O
accounts	O	O
for	O	O
a	O	O
significant	O	O
number	O	O
of	O	O
families	O	O
with	O	O
heritable	O	O
cancer	B-Disease	D009369
predisposition	O	O
.	O	O

These	O	O
common	O	O
mutations	O	O
have	O	O
an	O	O
etiological	O	O
role	O	O
in	O	O
many	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
cases	O	O
and	O	O
provide	O	O
the	O	O
opportunity	O	O
to	O	O
examine	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
and	O	O
genotype	O	O
-	O	O
environment	O	O
interactions	O	O
in	O	O
individuals	O	O
with	O	O
the	O	O
identical	O	O
BRCA1	O	O
lesion	O	O
.	O	O

We	O	O
report	O	O
a	O	O
novel	O	O
missense	O	O
change	O	O
in	O	O
BRCA1	O	O
,	O	O
2640	O	O
C	O	O
-	O	O
-	O	O
>	O	O
T	O	O
(	O	O
R841W	O	O
)	O	O
,	O	O
found	O	O
in	O	O
3	O	O
cases	O	O
from	O	O
a	O	O
subject	O	O
group	O	O
of	O	O
305	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
79	I-Disease	D001943
ovarian	I-Disease	D001943
cancer	I-Disease	D001943
cases	O	O
from	O	O
Orange	O	O
County	O	O
,	O	O
CA	O	O
.	O	O

These	O	O
are	O	O
consecutive	O	O
,	O	O
population	O	O
-	O	O
based	O	O
cases	O	O
not	O	O
selected	O	O
for	O	O
age	O	O
or	O	O
family	O	O
history	O	O
.	O	O

In	O	O
all	O	O
three	O	O
cases	O	O
,	O	O
there	O	O
is	O	O
a	O	O
strong	O	O
family	O	O
history	O	O
of	O	O
breast	B-Disease	D001943
,	I-Disease	D001943
ovarian	I-Disease	D001943
,	I-Disease	D001943
or	I-Disease	D001943
other	I-Disease	D001943
cancers	I-Disease	D001943
possibly	O	O
related	O	O
to	O	O
a	O	O
BRCA1	O	O
defect	O	O
and	O	O
family	O	O
members	O	O
showed	O	O
a	O	O
high	O	O
concordance	O	O
of	O	O
cancer	B-Disease	D009369
incidence	O	O
with	O	O
the	O	O
presence	O	O
of	O	O
R841W	O	O
.	O	O

The	O	O
age	O	O
of	O	O
cancer	B-Disease	D009369
onset	O	O
was	O	O
not	O	O
always	O	O
distinct	O	O
from	O	O
typical	O	O
sporadic	O	O
cases	O	O
.	O	O

Testing	O	O
of	O	O
a	O	O
sample	O	O
of	O	O
413	O	O
unrelated	O	O
individuals	O	O
to	O	O
examine	O	O
the	O	O
hypothesis	O	O
that	O	O
R841W	O	O
might	O	O
be	O	O
a	O	O
rare	O	O
polymorphism	O	O
detected	O	O
one	O	O
additional	O	O
instance	O	O
in	O	O
a	O	O
woman	O	O
with	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
diagnosed	O	O
at	O	O
age	O	O
77	O	O
years	O	O
,	O	O
and	O	O
cancer	B-Disease	D009369
in	O	O
one	O	O
parent	O	O
.	O	O

R841W	O	O
is	O	O
likely	O	O
to	O	O
be	O	O
an	O	O
etiologically	O	O
significant	O	O
lesion	O	O
with	O	O
involvement	O	O
in	O	O
close	O	O
to	O	O
1	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
of	O	O
0	O	O
-	O	O
1	O	O
.	O	O

7	O	O
%	O	O
)	O	O
of	O	O
all	O	O
breast	B-Disease	D001943
and	I-Disease	D001943
ovarian	I-Disease	D001943
cancers	I-Disease	D001943
in	O	O
this	O	O
population	O	O
.	O	O

Independent	O	O
origin	O	O
of	O	O
single	O	O
and	O	O
double	O	O
mutations	O	O
in	O	O
the	O	O
human	O	O
glucose	O	O
6	O	O
-	O	O
phosphate	O	O
dehydrogenase	O	O
gene	O	O
.	O	O

The	O	O
vast	O	O
majority	O	O
of	O	O
both	O	O
polymorphic	O	O
and	O	O
sporadic	O	O
G6PD	O	O
variants	O	O
are	O	O
due	O	O
to	O	O
single	O	O
missense	O	O
mutations	O	O
.	O	O

In	O	O
the	O	O
four	O	O
polymorphic	O	O
variants	O	O
that	O	O
have	O	O
two	O	O
point	O	O
mutations	O	O
,	O	O
one	O	O
of	O	O
the	O	O
mutations	O	O
is	O	O
always	O	O
376	O	O
A	O	O
-	O	O
-	O	O
>	O	O
G	O	O
(	O	O
126	O	O
Asn	O	O
-	O	O
-	O	O
>	O	O
Asp	O	O
)	O	O
,	O	O
which	O	O
on	O	O
its	O	O
own	O	O
gives	O	O
rise	O	O
to	O	O
the	O	O
nondeficient	O	O
polymorphic	O	O
variant	O	O
,	O	O
G6PD	O	O
A	O	O
.	O	O

In	O	O
a	O	O
study	O	O
of	O	O
G6PD	B-Disease	D005955
deficient	I-Disease	D005955
patients	O	O
who	O	O
presented	O	O
with	O	O
clinical	O	O
favism	B-Disease	D005236
in	O	O
Spain	O	O
,	O	O
we	O	O
have	O	O
found	O	O
a	O	O
new	O	O
polymorphic	O	O
variant	O	O
that	O	O
we	O	O
have	O	O
called	O	O
G6PD	O	O
Malaga	O	O
,	O	O
whose	O	O
only	O	O
abnormality	O	O
is	O	O
a	O	O
542	O	O
A	O	O
-	O	O
-	O	O
>	O	O
T	O	O
(	O	O
181	O	O
Asp	O	O
-	O	O
-	O	O
>	O	O
Val	O	O
)	O	O
mutation	O	O
.	O	O

This	O	O
is	O	O
the	O	O
same	O	O
mutation	O	O
as	O	O
previously	O	O
found	O	O
in	O	O
association	O	O
with	O	O
the	O	O
mutation	O	O
of	O	O
G6PD	O	O
A	O	O
in	O	O
the	O	O
double	O	O
mutant	O	O
,	O	O
G6PD	O	O
Santamaria	O	O
.	O	O

G6PD	O	O
Malaga	O	O
is	O	O
associated	O	O
with	O	O
enzyme	B-Disease	D008661
deficiency	I-Disease	D008661
(	O	O
class	O	O
III	O	O
)	O	O
,	O	O
and	O	O
the	O	O
enzymic	O	O
properties	O	O
of	O	O
G6PD	O	O
Malaga	O	O
and	O	O
G6PD	O	O
Santamaria	O	O
are	O	O
quite	O	O
similar	O	O
,	O	O
indicating	O	O
that	O	O
in	O	O
this	O	O
case	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
two	O	O
mutations	O	O
are	O	O
additive	O	O
rather	O	O
than	O	O
synergistic	O	O
.	O	O

G6PD	O	O
Santamaria	O	O
might	O	O
have	O	O
been	O	O
produced	O	O
by	O	O
recombination	O	O
between	O	O
G6PD	O	O
A	O	O
and	O	O
G6PD	O	O
Malaga	O	O
;	O	O
however	O	O
haplotype	O	O
analysis	O	O
,	O	O
including	O	O
the	O	O
use	O	O
of	O	O
a	O	O
new	O	O
silent	O	O
polymorphism	O	O
,	O	O
suggests	O	O
that	O	O
the	O	O
same	O	O
542	O	O
A	O	O
-	O	O
-	O	O
>	O	O
T	O	O
mutation	O	O
has	O	O
taken	O	O
place	O	O
independently	O	O
in	O	O
a	O	O
G6PD	O	O
B	O	O
gene	O	O
to	O	O
give	O	O
G6PD	O	O
Malaga	O	O
and	O	O
in	O	O
a	O	O
G6PD	O	O
A	O	O
gene	O	O
to	O	O
give	O	O
G6PD	O	O
Santamaria	O	O
.	O	O

These	O	O
findings	O	O
help	O	O
to	O	O
outline	O	O
the	O	O
relationship	O	O
and	O	O
evolution	O	O
of	O	O
mutations	O	O
in	O	O
the	O	O
human	O	O
G6PD	O	O
locus	O	O
.	O	O

.	O	O

FISH	O	O
studies	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
sporadic	B-Disease	D015783
aniridia	I-Disease	D015783
and	O	O
t	O	O
(	O	O
7	O	O
;	O	O
11	O	O
)	O	O
(	O	O
q31	O	O
.	O	O

2	O	O
;	O	O
p13	O	O
)	O	O
.	O	O

A	O	O
2	O	O
year	O	O
old	O	O
female	O	O
presenting	O	O
with	O	O
bilateral	B-Disease	D015783
sporadic	I-Disease	D015783
aniridia	I-Disease	D015783
was	O	O
found	O	O
to	O	O
have	O	O
an	O	O
apparently	O	O
balanced	O	O
reciprocal	O	O
translocation	O	O
with	O	O
a	O	O
chromosome	O	O
11	O	O
breakpoint	O	O
within	O	O
band	O	O
p13	O	O
.	O	O

Fluorescence	O	O
in	O	O
situ	O	O
hybridisation	O	O
(	O	O
FISH	O	O
)	O	O
studies	O	O
with	O	O
distal	O	O
11p13	O	O
specific	O	O
cosmids	O	O
showed	O	O
that	O	O
the	O	O
chromosome	O	O
11	O	O
breakpoint	O	O
lay	O	O
between	O	O
the	O	O
aniridia	B-Disease	D015783
(	O	O
PAX6	O	O
)	O	O
locus	O	O
and	O	O
a	O	O
region	O	O
approximately	O	O
100	O	O
kb	O	O
distal	O	O
to	O	O
PAX6	O	O
defined	O	O
by	O	O
the	O	O
cosmid	O	O
FO2121	O	O
.	O	O

Although	O	O
this	O	O
patient	O	O
did	O	O
not	O	O
have	O	O
a	O	O
detectable	O	O
deletion	O	O
within	O	O
PAX6	O	O
,	O	O
her	O	O
aniridia	B-Disease	D015783
may	O	O
have	O	O
resulted	O	O
from	O	O
a	O	O
disruption	O	O
of	O	O
the	O	O
distal	O	O
chromatin	O	O
domain	O	O
containing	O	O
either	O	O
enhancers	O	O
or	O	O
regulators	O	O
for	O	O
PAX6	O	O
.	O	O

This	O	O
case	O	O
may	O	O
therefore	O	O
be	O	O
another	O	O
example	O	O
of	O	O
aniridia	B-Disease	D015783
caused	O	O
by	O	O
a	O	O
position	O	O
effect	O	O
as	O	O
recently	O	O
described	O	O
in	O	O
two	O	O
familial	B-Disease	D015783
aniridia	I-Disease	D015783
patients	O	O
in	O	O
which	O	O
the	O	O
phenotype	O	O
cosegregated	O	O
with	O	O
chromosome	B-Disease	D002869
abnormalities	I-Disease	D002869
with	O	O
11p13	O	O
breakpoints	O	O
.	O	O

.	O	O

Ovarian	B-Disease	D010051
cancer	I-Disease	D010051
risk	O	O
in	O	O
BRCA1	O	O
carriers	O	O
is	O	O
modified	O	O
by	O	O
the	O	O
HRAS1	O	O
variable	O	O
number	O	O
of	O	O
tandem	O	O
repeat	O	O
(	O	O
VNTR	O	O
)	O	O
locus	O	O
.	O	O

Women	O	O
who	O	O
carry	O	O
a	O	O
mutation	O	O
in	O	O
the	O	O
BRCA1	O	O
gene	O	O
(	O	O
on	O	O
chromosome	O	O
17q21	O	O
)	O	O
,	O	O
have	O	O
an	O	O
80	O	O
%	O	O
risk	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
and	O	O
a	O	O
40	O	O
%	O	O
risk	O	O
of	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
by	O	O
the	O	O
age	O	O
of	O	O
70	O	O
(	O	O
ref	O	O
.	O	O

1	O	O
)	O	O
.	O	O

The	O	O
variable	O	O
penetrance	O	O
of	O	O
BRCA1	O	O
suggests	O	O
that	O	O
other	O	O
genetic	O	O
and	O	O
non	O	O
-	O	O
genetic	O	O
factors	O	O
play	O	O
a	O	O
role	O	O
in	O	O
tumourigenesis	O	O
in	O	O
these	O	O
individuals	O	O
.	O	O

The	O	O
HRAS1	O	O
variable	O	O
number	O	O
of	O	O
tandem	O	O
repeats	O	O
(	O	O
VNTR	O	O
)	O	O
polymorphism	O	O
,	O	O
located	O	O
1	O	O
kilobase	O	O
(	O	O
kb	O	O
)	O	O
downstream	O	O
of	O	O
the	O	O
HRAS1	O	O
proto	O	O
-	O	O
oncogene	O	O
(	O	O
chromosome	O	O
11p15	O	O
.	O	O

5	O	O
)	O	O
is	O	O
one	O	O
possible	O	O
genetic	O	O
modifier	O	O
of	O	O
cancer	B-Disease	D009369
penetrance	O	O
.	O	O

Individuals	O	O
who	O	O
have	O	O
rare	O	O
alleles	O	O
of	O	O
the	O	O
VNTR	O	O
have	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
certain	O	O
types	O	O
of	O	O
cancers	B-Disease	D009369
,	O	O
including	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
(	O	O
2	O	O
-	O	O
4	O	O
)	O	O
.	O	O

To	O	O
investigate	O	O
whether	O	O
the	O	O
presence	O	O
of	O	O
rare	O	O
HRAS1	O	O
alleles	O	O
increases	O	O
susceptibility	O	O
to	O	O
hereditary	B-Disease	D061325
breast	I-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
,	O	O
we	O	O
have	O	O
typed	O	O
a	O	O
panel	O	O
of	O	O
307	O	O
female	O	O
BRCA1	O	O
carriers	O	O
at	O	O
this	O	O
locus	O	O
using	O	O
a	O	O
PCR	O	O
-	O	O
based	O	O
technique	O	O
.	O	O

The	O	O
risk	O	O
for	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
was	O	O
2	O	O
.	O	O

11	O	O
times	O	O
greater	O	O
for	O	O
BRCA1	O	O
carriers	O	O
harbouring	O	O
one	O	O
or	O	O
two	O	O
rare	O	O
HRAS1	O	O
alleles	O	O
,	O	O
compared	O	O
to	O	O
carriers	O	O
with	O	O
only	O	O
common	O	O
alleles	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

015	O	O
)	O	O
.	O	O

The	O	O
magnitude	O	O
of	O	O
the	O	O
relative	O	O
risk	O	O
associated	O	O
with	O	O
a	O	O
rare	O	O
HRAS1	O	O
allele	O	O
was	O	O
not	O	O
altered	O	O
by	O	O
adjusting	O	O
for	O	O
the	O	O
other	O	O
known	O	O
risk	O	O
factors	O	O
for	O	O
hereditary	B-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
(	O	O
5	O	O
)	O	O
.	O	O

Susceptibility	O	O
to	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
did	O	O
not	O	O
appear	O	O
to	O	O
be	O	O
affected	O	O
by	O	O
the	O	O
presence	O	O
of	O	O
rare	O	O
HRAS1	O	O
alleles	O	O
.	O	O

This	O	O
study	O	O
is	O	O
the	O	O
first	O	O
to	O	O
show	O	O
the	O	O
effect	O	O
of	O	O
a	O	O
modifying	O	O
gene	O	O
on	O	O
the	O	O
penetrance	O	O
of	O	O
an	O	O
inherited	B-Disease	D009386
cancer	I-Disease	D009386
syndrome	I-Disease	D009386
A	O	O
previously	O	O
undescribed	O	O
mutation	O	O
within	O	O
the	O	O
tetramerisation	O	O
domain	O	O
of	O	O
TP53	O	O
in	O	O
a	O	O
family	O	O
with	O	O
Li	B-Disease	D016864
-	I-Disease	D016864
Fraumeni	I-Disease	D016864
syndrome	I-Disease	D016864
.	O	O

We	O	O
report	O	O
details	O	O
of	O	O
a	O	O
family	O	O
with	O	O
classic	O	O
Li	B-Disease	D016864
-	I-Disease	D016864
Fraumeni	I-Disease	D016864
syndrome	I-Disease	D016864
in	O	O
which	O	O
there	O	O
is	O	O
a	O	O
mutation	O	O
in	O	O
codon	O	O
344	O	O
of	O	O
the	O	O
tumour	B-Disease	D009369
suppressor	O	O
gene	O	O
TP53	O	O
.	O	O

Codon	O	O
344	O	O
is	O	O
a	O	O
key	O	O
residue	O	O
within	O	O
the	O	O
tetramerisation	O	O
domain	O	O
,	O	O
and	O	O
the	O	O
amino	O	O
acid	O	O
substitution	O	O
of	O	O
a	O	O
proline	O	O
for	O	O
a	O	O
leucine	O	O
is	O	O
predicted	O	O
to	O	O
have	O	O
profound	O	O
implications	O	O
for	O	O
tetramerisation	O	O
and	O	O
potentially	O	O
DNA	O	O
binding	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
report	O	O
of	O	O
a	O	O
mutation	O	O
at	O	O
this	O	O
residue	O	O
in	O	O
either	O	O
sporadic	B-Disease	D009369
tumours	I-Disease	D009369
or	O	O
in	O	O
the	O	O
germline	O	O
and	O	O
the	O	O
first	O	O
report	O	O
of	O	O
a	O	O
germline	O	O
mutation	O	O
within	O	O
the	O	O
tetramerisation	O	O
domain	O	O
.	O	O

The	O	O
family	O	O
does	O	O
not	O	O
appear	O	O
to	O	O
be	O	O
remarkable	O	O
in	O	O
the	O	O
spectrum	O	O
of	O	O
tumours	B-Disease	D009369
,	O	O
and	O	O
there	O	O
is	O	O
loss	O	O
of	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
allele	O	O
in	O	O
a	O	O
leiomyosarcoma	B-Disease	D007890
from	O	O
the	O	O
proband	O	O
.	O	O

A	O	O
cell	O	O
line	O	O
has	O	O
been	O	O
established	O	O
from	O	O
the	O	O
tumour	B-Disease	D009369
of	O	O
the	O	O
proband	O	O
and	O	O
cytogenetic	O	O
and	O	O
molecular	O	O
studies	O	O
carried	O	O
out	O	O
,	O	O
providing	O	O
an	O	O
extensive	O	O
analysis	O	O
in	O	O
this	O	O
family	O	O
.	O	O

.	O	O

Trinucleotide	O	O
repeat	O	O
expansion	O	O
at	O	O
the	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
locus	O	O
reduces	O	O
expression	O	O
of	O	O
DMAHP	O	O
.	O	O

Myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
,	O	O
or	O	O
dystrophia	B-Disease	D009223
myotonica	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
,	O	O
is	O	O
an	O	O
autosomal	B-Disease	D030342
dominant	I-Disease	D030342
multisystem	I-Disease	D030342
disorder	I-Disease	D030342
caused	O	O
by	O	O
the	O	O
expansion	O	O
of	O	O
a	O	O
CTG	O	O
trinucleotide	O	O
repeat	O	O
in	O	O
the	O	O
3	O	O
untranslated	O	O
region	O	O
of	O	O
the	O	O
DMPK	O	O
protein	O	O
kinase	O	O
gene	O	O
on	O	O
chromosome	O	O
19q13	O	O
.	O	O

3	O	O
(	O	O
refs	O	O
1	O	O
-	O	O
3	O	O
)	O	O
.	O	O

Although	O	O
the	O	O
DM	B-Disease	D009223
mutation	O	O
was	O	O
identified	O	O
more	O	O
than	O	O
five	O	O
years	O	O
ago	O	O
,	O	O
the	O	O
pathogenic	O	O
mechanisms	O	O
underlying	O	O
this	O	O
most	O	O
prevalent	O	O
form	O	O
of	O	O
hereditary	O	O
adult	O	O
neuromuscular	B-Disease	D009468
disease	I-Disease	D009468
remain	O	O
elusive	O	O
.	O	O

Previous	O	O
work	O	O
from	O	O
our	O	O
laboratory	O	O
demonstrated	O	O
that	O	O
a	O	O
DNase	O	O
l	O	O
-	O	O
hypersensitive	O	O
site	O	O
located	O	O
adjacent	O	O
to	O	O
the	O	O
repeats	O	O
on	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
allele	O	O
is	O	O
eliminated	O	O
by	O	O
repeat	O	O
expansion	O	O
,	O	O
indicating	O	O
that	O	O
large	O	O
CTG	O	O
-	O	O
repeat	O	O
arrays	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
a	O	O
local	O	O
chromatin	O	O
environment	O	O
that	O	O
represses	O	O
gene	O	O
expression	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
that	O	O
the	O	O
hypersensitive	O	O
site	O	O
contains	O	O
an	O	O
enhancer	O	O
element	O	O
that	O	O
regulates	O	O
transcription	O	O
of	O	O
the	O	O
adjacent	O	O
DMAHP	O	O
homeobox	O	O
gene	O	O
.	O	O

Analysis	O	O
of	O	O
DMAHP	O	O
expression	O	O
in	O	O
the	O	O
cells	O	O
of	O	O
DM	B-Disease	D009223
patients	O	O
with	O	O
loss	O	O
of	O	O
the	O	O
hypersensitive	O	O
site	O	O
revealed	O	O
a	O	O
two	O	O
-	O	O
to	O	O
fourfold	O	O
reduction	O	O
in	O	O
steady	O	O
-	O	O
state	O	O
DMAHP	O	O
transcript	O	O
levels	O	O
relative	O	O
to	O	O
wild	O	O
-	O	O
type	O	O
controls	O	O
.	O	O

Allele	O	O
-	O	O
specific	O	O
analysis	O	O
of	O	O
DMAHP	O	O
expression	O	O
showed	O	O
that	O	O
steady	O	O
-	O	O
state	O	O
transcript	O	O
levels	O	O
from	O	O
the	O	O
expanded	O	O
allele	O	O
were	O	O
greatly	O	O
reduced	O	O
in	O	O
comparison	O	O
to	O	O
those	O	O
from	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
allele	O	O
.	O	O

Together	O	O
,	O	O
these	O	O
results	O	O
demonstrate	O	O
that	O	O
CTG	O	O
-	O	O
repeat	O	O
expansions	O	O
can	O	O
suppress	O	O
local	O	O
gene	O	O
expression	O	O
and	O	O
implicate	O	O
DMAHP	O	O
in	O	O
DM	B-Disease	D009223
pathogenesis	O	O
.	O	O

A	O	O
mutation	O	O
in	O	O
autosomal	B-Disease	OMIM:160800
dominant	I-Disease	OMIM:160800
myotonia	I-Disease	OMIM:160800
congenita	I-Disease	OMIM:160800
affects	O	O
pore	O	O
properties	O	O
of	O	O
the	O	O
muscle	O	O
chloride	O	O
channel	O	O
.	O	O

Autosomal	B-Disease	OMIM:160800
dominant	I-Disease	OMIM:160800
myotonia	I-Disease	OMIM:160800
congenita	I-Disease	OMIM:160800
is	O	O
an	O	O
inherited	B-Disease	D009135	D030342
disorder	I-Disease	D009135	D030342
of	I-Disease	D009135	D030342
skeletal	I-Disease	D009135	D030342
muscle	I-Disease	D009135	D030342
caused	O	O
by	O	O
mutations	O	O
in	O	O
a	O	O
voltage	O	O
-	O	O
gated	O	O
Cl	O	O
-	O	O
channel	O	O
gene	O	O
(	O	O
CLCN1	O	O
,	O	O
7q35	O	O
)	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
that	O	O
a	O	O
mutation	O	O
predicting	O	O
the	O	O
substitution	O	O
of	O	O
Gly	O	O
230	O	O
by	O	O
glutamic	O	O
acid	O	O
(	O	O
G230E	O	O
)	O	O
between	O	O
segments	O	O
D3	O	O
and	O	O
D4	O	O
dramatically	O	O
alters	O	O
the	O	O
pore	O	O
properties	O	O
of	O	O
a	O	O
recombinant	O	O
human	O	O
muscle	O	O
Cl	O	O
-	O	O
channel	O	O
(	O	O
hCIC	O	O
-	O	O
1	O	O
)	O	O
expressed	O	O
in	O	O
a	O	O
mammalian	O	O
cell	O	O
line	O	O
(	O	O
tsA201	O	O
)	O	O
.	O	O

The	O	O
G230E	O	O
mutation	O	O
causes	O	O
substantial	O	O
changes	O	O
in	O	O
anion	O	O
and	O	O
cation	O	O
selectivity	O	O
as	O	O
well	O	O
as	O	O
a	O	O
fundamental	O	O
change	O	O
in	O	O
rectification	O	O
of	O	O
the	O	O
current	O	O
-	O	O
voltage	O	O
relationship	O	O
.	O	O

Whereas	O	O
wild	O	O
-	O	O
type	O	O
channels	O	O
are	O	O
characterized	O	O
by	O	O
pronounced	O	O
inward	O	O
rectification	O	O
and	O	O
a	O	O
Cl	O	O
>	O	O
thiocyanate	O	O
>	O	O
Br	O	O
>	O	O
NO	O	O
(	O	O
3	O	O
)	O	O
>	O	O
I	O	O
>	O	O
CH	O	O
(	O	O
3	O	O
)	O	O
SO	O	O
(	O	O
3	O	O
)	O	O
selectivity	O	O
,	O	O
G230E	O	O
exhibits	O	O
outward	O	O
rectification	O	O
at	O	O
positive	O	O
potentials	O	O
and	O	O
a	O	O
thiocyanate	O	O
>	O	O
NO	O	O
(	O	O
3	O	O
)	O	O
>	O	O
I	O	O
>	O	O
Br	O	O
>	O	O
Cl	O	O
>	O	O
CH	O	O
(	O	O
3	O	O
)	O	O
SO	O	O
(	O	O
3	O	O
)	O	O
selectivity	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
cation	O	O
-	O	O
to	O	O
-	O	O
anion	O	O
permeability	O	O
ratio	O	O
of	O	O
the	O	O
mutant	O	O
is	O	O
much	O	O
greater	O	O
than	O	O
that	O	O
of	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
channel	O	O
.	O	O

Voltage	O	O
-	O	O
dependent	O	O
blocks	O	O
by	O	O
intracellular	O	O
and	O	O
extracellular	O	O
iodide	O	O
help	O	O
to	O	O
distinguish	O	O
two	O	O
distinct	O	O
ion	O	O
binding	O	O
sites	O	O
within	O	O
the	O	O
hClC	O	O
-	O	O
1	O	O
conduction	O	O
pathway	O	O
.	O	O

Both	O	O
binding	O	O
sites	O	O
are	O	O
preserved	O	O
in	O	O
the	O	O
mutant	O	O
but	O	O
have	O	O
decreased	O	O
affinities	O	O
for	O	O
iodide	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
Gly	O	O
230	O	O
is	O	O
critical	O	O
for	O	O
normal	O	O
ion	O	O
conductance	O	O
in	O	O
hClC	O	O
-	O	O
1	O	O
and	O	O
that	O	O
this	O	O
residue	O	O
resides	O	O
within	O	O
the	O	O
channel	O	O
pore	O	O
.	O	O

.	O	O

Mutation	O	O
analysis	O	O
of	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
in	O	O
a	O	O
male	B-Disease	D018567
breast	I-Disease	D018567
cancer	I-Disease	D018567
population	O	O
.	O	O

A	O	O
population	O	O
-	O	O
based	O	O
series	O	O
of	O	O
54	O	O
male	B-Disease	D018567
breast	I-Disease	D018567
cancer	I-Disease	D018567
cases	O	O
from	O	O
Southern	O	O
California	O	O
were	O	O
analyzed	O	O
for	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
in	O	O
the	O	O
inherited	B-Disease	D061325
breast	I-Disease	D061325
/	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
genes	O	O
,	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
.	O	O

Nine	O	O
(	O	O
17	O	O
%	O	O
)	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
a	O	O
family	O	O
history	O	O
of	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
/	I-Disease	D061325
or	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
in	O	O
at	O	O
least	O	O
one	O	O
first	O	O
-	O	O
degree	O	O
relative	O	O
.	O	O

A	O	O
further	O	O
seven	O	O
(	O	O
13	O	O
%	O	O
)	O	O
of	O	O
the	O	O
patients	O	O
reported	O	O
breast	B-Disease	D061325
/	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
in	O	O
at	O	O
least	O	O
one	O	O
second	O	O
-	O	O
degree	O	O
relative	O	O
and	O	O
in	O	O
no	O	O
first	O	O
-	O	O
degree	O	O
relatives	O	O
.	O	O

No	O	O
germ	O	O
-	O	O
line	O	O
BRCA1	O	O
mutations	O	O
were	O	O
found	O	O
.	O	O

Two	O	O
male	B-Disease	D018567
breast	I-Disease	D018567
cancer	I-Disease	D018567
patients	O	O
(	O	O
4	O	O
%	O	O
of	O	O
the	O	O
total	O	O
)	O	O
were	O	O
found	O	O
to	O	O
carry	O	O
novel	O	O
truncating	O	O
mutations	O	O
in	O	O
the	O	O
BRCA2	O	O
gene	O	O
.	O	O

Only	O	O
one	O	O
of	O	O
the	O	O
two	O	O
male	B-Disease	D018567
breast	I-Disease	D018567
cancer	I-Disease	D018567
patients	O	O
carrying	O	O
a	O	O
BRCA2	O	O
mutation	O	O
had	O	O
a	O	O
family	O	O
history	O	O
of	O	O
cancer	B-Disease	D009369
,	O	O
with	O	O
one	O	O
case	O	O
of	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
in	O	O
a	O	O
first	O	O
-	O	O
degree	O	O
relative	O	O
.	O	O

The	O	O
remaining	O	O
eight	O	O
cases	O	O
(	O	O
89	O	O
%	O	O
)	O	O
of	O	O
male	B-Disease	D018567
breast	I-Disease	D018567
cancer	I-Disease	D018567
with	O	O
a	O	O
family	O	O
history	O	O
of	O	O
breast	B-Disease	D061325
/	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
in	O	O
first	O	O
-	O	O
degree	O	O
relatives	O	O
remain	O	O
unaccounted	O	O
for	O	O
by	O	O
mutations	O	O
in	O	O
either	O	O
the	O	O
BRCA1	O	O
gene	O	O
or	O	O
the	O	O
BRCA2	O	O
gene	O	O
.	O	O

.	O	O

Expression	O	O
of	O	O
the	O	O
von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
disease	I-Disease	D006623
tumour	I-Disease	D006623
suppressor	O	O
gene	O	O
during	O	O
human	O	O
embryogenesis	O	O
.	O	O

The	O	O
von	B-Disease	D006623
Hippel	I-Disease	D006623
-	I-Disease	D006623
Lindau	I-Disease	D006623
(	I-Disease	D006623
VHL	I-Disease	D006623
)	I-Disease	D006623
disease	I-Disease	D006623
product	O	O
is	O	O
thought	O	O
to	O	O
down	O	O
-	O	O
regulate	O	O
transcription	O	O
by	O	O
antagonizing	O	O
elongin	O	O
-	O	O
enhanced	O	O
transcriptional	O	O
elongation	O	O
.	O	O

Germline	O	O
VHL	B-Disease	D006623
gene	O	O
mutations	O	O
predispose	O	O
to	O	O
the	O	O
development	O	O
of	O	O
retinal	B-Disease	D012175
,	I-Disease	D012175
cerebellar	I-Disease	D012175
and	I-Disease	D012175
spinal	I-Disease	D012175
haemangioblastomas	I-Disease	D012175
,	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
and	O	O
phaeochromocytoma	B-Disease	D010673
.	O	O

In	O	O
addition	O	O
,	O	O
somatic	O	O
Inactivation	O	O
of	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
is	O	O
frequent	O	O
in	O	O
sporadic	B-Disease	D002292
renal	I-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
and	O	O
haemangioblastoma	B-Disease	D018325
.	O	O

Regulation	O	O
of	O	O
transcript	O	O
elongation	O	O
is	O	O
an	O	O
important	O	O
control	O	O
mechanism	O	O
for	O	O
gene	O	O
expression	O	O
and	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
might	O	O
modify	O	O
the	O	O
expression	O	O
of	O	O
proto	O	O
-	O	O
oncogenes	O	O
and	O	O
growth	O	O
suppressor	O	O
genes	O	O
during	O	O
embryogenesis	O	O
.	O	O

We	O	O
therefore	O	O
investigated	O	O
the	O	O
expression	O	O
of	O	O
VHL	B-Disease	D006623
mRNA	O	O
during	O	O
human	O	O
embryogenesis	O	O
by	O	O
in	O	O
situ	O	O
hybridization	O	O
studies	O	O
at	O	O
4	O	O
,	O	O
6	O	O
and	O	O
10	O	O
weeks	O	O
post	O	O
conception	O	O
.	O	O

Although	O	O
VHL	B-Disease	D006623
mRNA	O	O
was	O	O
expressed	O	O
in	O	O
all	O	O
three	O	O
germ	O	O
layers	O	O
,	O	O
strong	O	O
expression	O	O
was	O	O
noted	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
,	O	O
kidneys	O	O
,	O	O
testis	O	O
and	O	O
lung	O	O
.	O	O

Within	O	O
the	O	O
kidney	O	O
,	O	O
VHL	B-Disease	D006623
mRNA	O	O
was	O	O
differentially	O	O
expressed	O	O
within	O	O
renal	O	O
tubules	O	O
suggesting	O	O
that	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
product	O	O
may	O	O
have	O	O
a	O	O
specific	O	O
role	O	O
in	O	O
kidney	O	O
development	O	O
.	O	O

Two	O	O
alternatively	O	O
spliced	O	O
VHL	B-Disease	D006623
mRNAs	O	O
characterized	O	O
by	O	O
inclusion	O	O
(	O	O
isoform	O	O
I	O	O
)	O	O
or	O	O
exclusion	O	O
(	O	O
isoform	O	O
II	O	O
)	O	O
of	O	O
exon	O	O
2	O	O
are	O	O
transcribed	O	O
in	O	O
adult	O	O
tissues	O	O
.	O	O

To	O	O
investigate	O	O
if	O	O
the	O	O
two	O	O
isoforms	O	O
are	O	O
differentially	O	O
expressed	O	O
during	O	O
embryogenesis	O	O
,	O	O
VHL	B-Disease	D006623
mRNA	O	O
was	O	O
reverse	O	O
transcribed	O	O
from	O	O
13	O	O
fetal	O	O
tissues	O	O
(	O	O
8	O	O
-	O	O
10	O	O
weeks	O	O
gestation	O	O
)	O	O
.	O	O

The	O	O
quantitative	O	O
distribution	O	O
of	O	O
VHL	B-Disease	D006623
mRNA	O	O
within	O	O
fetal	O	O
tissues	O	O
reflected	O	O
that	O	O
seen	O	O
by	O	O
in	O	O
situ	O	O
hybridization	O	O
and	O	O
the	O	O
ratio	O	O
of	O	O
the	O	O
two	O	O
VHL	B-Disease	D006623
isoforms	O	O
was	O	O
similar	O	O
between	O	O
tissues	O	O
.	O	O

Although	O	O
the	O	O
genes	O	O
regulated	O	O
by	O	O
the	O	O
VHL	B-Disease	D006623
gene	O	O
product	O	O
have	O	O
not	O	O
yet	O	O
been	O	O
identified	O	O
,	O	O
our	O	O
findings	O	O
are	O	O
compatible	O	O
with	O	O
the	O	O
hypothesis	O	O
that	O	O
VHL	B-Disease	D006623
-	O	O
mediated	O	O
control	O	O
of	O	O
transcriptional	O	O
elongation	O	O
may	O	O
have	O	O
a	O	O
role	O	O
in	O	O
normal	O	O
human	O	O
development	O	O
.	O	O

.	O	O

Screening	O	O
for	O	O
ESR	O	O
mutations	O	O
in	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
patients	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
leukocyte	O	O
DNA	O	O
from	O	O
143	O	O
patients	O	O
with	O	O
familial	O	O
clustering	O	O
of	O	O
breast	B-Disease	D061325
and	I-Disease	D061325
/	I-Disease	D061325
or	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
and	O	O
tumour	B-Disease	D009369
DNA	O	O
from	O	O
96	O	O
breast	B-Disease	D001943
carcinomas	I-Disease	D001943
were	O	O
screened	O	O
for	O	O
base	O	O
mutations	O	O
in	O	O
the	O	O
estrogen	O	O
receptor	O	O
gene	O	O
(	O	O
ESR	O	O
)	O	O
.	O	O

Three	O	O
patients	O	O
with	O	O
a	O	O
family	O	O
history	O	O
of	O	O
cancer	B-Disease	D009369
were	O	O
carrying	O	O
a	O	O
Gly160Cys	O	O
germline	O	O
substitution	O	O
.	O	O

This	O	O
alteration	O	O
was	O	O
also	O	O
detected	O	O
in	O	O
eight	O	O
(	O	O
four	O	O
females	O	O
and	O	O
four	O	O
males	O	O
)	O	O
of	O	O
729	O	O
controls	O	O
(	O	O
366	O	O
female	O	O
,	O	O
363	O	O
males	O	O
)	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
substitution	O	O
probably	O	O
represents	O	O
a	O	O
polymorphism	O	O
.	O	O

However	O	O
,	O	O
in	O	O
the	O	O
229	O	O
female	O	O
controls	O	O
in	O	O
whom	O	O
family	O	O
history	O	O
of	O	O
cancer	B-Disease	D009369
was	O	O
known	O	O
,	O	O
one	O	O
of	O	O
two	O	O
who	O	O
had	O	O
a	O	O
sister	O	O
with	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
was	O	O
carrying	O	O
the	O	O
variant	O	O
allele	O	O
.	O	O

Hence	O	O
,	O	O
a	O	O
possible	O	O
clinical	O	O
significance	O	O
of	O	O
the	O	O
glycine	O	O
into	O	O
cysteine	O	O
cannot	O	O
be	O	O
completely	O	O
ruled	O	O
out	O	O
and	O	O
should	O	O
be	O	O
further	O	O
investigated	O	O
.	O	O

Somatic	O	O
mutations	O	O
were	O	O
not	O	O
detected	O	O
in	O	O
any	O	O
of	O	O
the	O	O
tumours	B-Disease	D009369
studied	O	O
,	O	O
and	O	O
the	O	O
present	O	O
data	O	O
do	O	O
not	O	O
provide	O	O
support	O	O
for	O	O
somatic	O	O
ESR	O	O
base	O	O
mutations	O	O
as	O	O
an	O	O
important	O	O
mechanism	O	O
for	O	O
hormonal	O	O
therapy	O	O
resistance	O	O
in	O	O
estrogen	B-Disease	D001943
receptor	I-Disease	D001943
-	I-Disease	D001943
positive	I-Disease	D001943
breast	I-Disease	D001943
carcinomas	I-Disease	D001943
.	O	O

.	O	O

Increased	O	O
coronary	B-Disease	D003327
heart	I-Disease	D003327
disease	I-Disease	D003327
in	O	O
Japanese	O	O
-	O	O
American	O	O
men	O	O
with	O	O
mutation	O	O
in	O	O
the	O	O
cholesteryl	O	O
ester	O	O
transfer	O	O
protein	O	O
gene	O	O
despite	O	O
increased	O	O
HDL	O	O
levels	O	O
.	O	O

Plasma	O	O
high	O	O
density	O	O
lipoprotein	O	O
(	O	O
HDL	O	O
)	O	O
levels	O	O
are	O	O
strongly	O	O
genetically	O	O
determined	O	O
and	O	O
show	O	O
a	O	O
general	O	O
inverse	O	O
relationship	O	O
with	O	O
coronary	B-Disease	D003327
heart	I-Disease	D003327
disease	I-Disease	D003327
(	O	O
CHD	B-Disease	D003327
)	O	O
.	O	O

The	O	O
cholesteryl	O	O
ester	O	O
transfer	O	O
protein	O	O
(	O	O
CETP	O	O
)	O	O
mediates	O	O
the	O	O
transfer	O	O
of	O	O
cholesteryl	O	O
esters	O	O
from	O	O
HDL	O	O
to	O	O
other	O	O
lipoproteins	O	O
and	O	O
is	O	O
a	O	O
key	O	O
participant	O	O
in	O	O
the	O	O
reverse	O	O
transport	O	O
of	O	O
cholesterol	O	O
from	O	O
the	O	O
periphery	O	O
to	O	O
the	O	O
liver	O	O
.	O	O

A	O	O
high	O	O
prevalence	O	O
of	O	O
two	O	O
different	O	O
CETP	O	O
gene	O	O
mutations	O	O
(	O	O
D442G	O	O
,	O	O
5	O	O
.	O	O

1	O	O
%	O	O
;	O	O
intron	O	O
14G	O	O
A	O	O
,	O	O
0	O	O
.	O	O

5	O	O
%	O	O
)	O	O
,	O	O
was	O	O
found	O	O
in	O	O
3	O	O
,	O	O
469	O	O
men	O	O
of	O	O
Japanese	O	O
ancestry	O	O
in	O	O
the	O	O
Honolulu	O	O
Heart	O	O
Program	O	O
and	O	O
mutations	O	O
were	O	O
associated	O	O
with	O	O
decreased	O	O
CETP	O	O
(	O	O
-	O	O
35	O	O
%	O	O
)	O	O
and	O	O
increased	O	O
HDL	O	O
chol	O	O
levels	O	O
(	O	O
+	O	O
10	O	O
%	O	O
for	O	O
D442G	O	O
)	O	O
.	O	O

However	O	O
,	O	O
the	O	O
overall	O	O
prevalence	O	O
of	O	O
definite	O	O
CHD	B-Disease	D003327
was	O	O
21	O	O
%	O	O
in	O	O
men	O	O
with	O	O
mutations	O	O
and	O	O
16	O	O
%	O	O
in	O	O
men	O	O
without	O	O
mutations	O	O
.	O	O

The	O	O
relative	O	O
risk	O	O
(	O	O
RR	O	O
)	O	O
of	O	O
CHD	B-Disease	D003327
was	O	O
1	O	O
.	O	O

43	O	O
in	O	O
men	O	O
with	O	O
mutations	O	O
(	O	O
P	O	O
<	O	O
.	O	O

05	O	O
)	O	O
;	O	O
after	O	O
adjustment	O	O
for	O	O
CHD	B-Disease	D003327
risk	O	O
factors	O	O
,	O	O
the	O	O
RR	O	O
was	O	O
1	O	O
.	O	O

55	O	O
(	O	O
P	O	O
=	O	O
.	O	O

02	O	O
)	O	O
;	O	O
after	O	O
additional	O	O
adjustment	O	O
for	O	O
HDL	O	O
levels	O	O
,	O	O
the	O	O
RR	O	O
was	O	O
1	O	O
.	O	O

68	O	O
(	O	O
P	O	O
=	O	O
.	O	O

008	O	O
)	O	O
.	O	O

Similar	O	O
RR	O	O
values	O	O
were	O	O
obtained	O	O
for	O	O
the	O	O
D442G	O	O
mutation	O	O
alone	O	O
.	O	O

Increased	O	O
CHD	B-Disease	D003327
in	O	O
men	O	O
with	O	O
mutations	O	O
was	O	O
primarily	O	O
observed	O	O
for	O	O
HDL	O	O
chol	O	O
41	O	O
-	O	O
60	O	O
mg	O	O
/	O	O
dl	O	O
;	O	O
for	O	O
HDL	O	O
chol	O	O
>	O	O
60	O	O
mg	O	O
/	O	O
dl	O	O
men	O	O
with	O	O
and	O	O
without	O	O
mutations	O	O
had	O	O
low	O	O
CHD	B-Disease	D003327
prevalence	O	O
.	O	O

Thus	O	O
,	O	O
genetic	O	O
CETP	B-Disease	OMIM:143470
deficiency	I-Disease	OMIM:143470
appears	O	O
to	O	O
be	O	O
an	O	O
independent	O	O
risk	O	O
factor	O	O
for	O	O
CHD	B-Disease	D003327
,	O	O
primarily	O	O
due	O	O
to	O	O
increased	O	O
CHD	B-Disease	D003327
prevalence	O	O
in	O	O
men	O	O
with	O	O
the	O	O
D442G	O	O
mutation	O	O
and	O	O
HDL	O	O
cholesterol	O	O
between	O	O
41	O	O
and	O	O
60	O	O
mg	O	O
/	O	O
dl	O	O
.	O	O

The	O	O
findings	O	O
suggest	O	O
that	O	O
both	O	O
HDL	O	O
concentration	O	O
and	O	O
the	O	O
dynamics	O	O
of	O	O
cholesterol	O	O
transport	O	O
through	O	O
HDL	O	O
(	O	O
i	O	O
.	O	O

e	O	O
.	O	O

,	O	O
reverse	O	O
cholesterol	O	O
transport	O	O
)	O	O
determine	O	O
the	O	O
anti	O	O
-	O	O
atherogenicity	O	O
of	O	O
the	O	O
HDL	O	O
fraction	O	O
.	O	O

Analysis	O	O
of	O	O
meiotic	O	O
segregation	O	O
,	O	O
using	O	O
single	O	O
-	O	O
sperm	O	O
typing	O	O
:	O	O
meiotic	O	O
drive	O	O
at	O	O
the	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
locus	O	O
.	O	O

Meiotic	O	O
drive	O	O
at	O	O
the	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
DM	B-Disease	D009223
)	O	O
locus	O	O
has	O	O
recently	O	O
been	O	O
suggested	O	O
as	O	O
being	O	O
responsible	O	O
for	O	O
maintaining	O	O
the	O	O
frequency	O	O
,	O	O
in	O	O
the	O	O
human	O	O
population	O	O
,	O	O
of	O	O
DM	B-Disease	D009223
chromosomes	O	O
capable	O	O
of	O	O
expansion	O	O
to	O	O
the	O	O
disease	O	O
state	O	O
.	O	O

In	O	O
order	O	O
to	O	O
test	O	O
this	O	O
hypothesis	O	O
,	O	O
we	O	O
have	O	O
studied	O	O
samples	O	O
of	O	O
single	O	O
sperm	O	O
from	O	O
three	O	O
individuals	O	O
heterozygous	O	O
at	O	O
the	O	O
DM	B-Disease	D009223
locus	O	O
,	O	O
each	O	O
with	O	O
one	O	O
allele	O	O
larger	O	O
and	O	O
one	O	O
allele	O	O
smaller	O	O
than	O	O
19	O	O
CTG	O	O
repeats	O	O
.	O	O

To	O	O
guard	O	O
against	O	O
the	O	O
possible	O	O
problem	O	O
of	O	O
differential	O	O
PCR	O	O
amplification	O	O
rates	O	O
based	O	O
on	O	O
the	O	O
lengths	O	O
of	O	O
the	O	O
alleles	O	O
,	O	O
the	O	O
sperm	O	O
were	O	O
also	O	O
typed	O	O
at	O	O
another	O	O
closely	O	O
linked	O	O
marker	O	O
whose	O	O
allele	O	O
size	O	O
was	O	O
unrelated	O	O
to	O	O
the	O	O
allele	O	O
size	O	O
at	O	O
the	O	O
DM	B-Disease	D009223
locus	O	O
.	O	O

Using	O	O
statistical	O	O
models	O	O
specifically	O	O
designed	O	O
to	O	O
study	O	O
single	O	O
-	O	O
sperm	O	O
segregation	O	O
data	O	O
,	O	O
we	O	O
find	O	O
no	O	O
evidence	O	O
of	O	O
meiotic	O	O
segregation	O	O
distortion	O	O
.	O	O

The	O	O
upper	O	O
limit	O	O
of	O	O
the	O	O
two	O	O
-	O	O
sided	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
for	O	O
the	O	O
estimate	O	O
of	O	O
the	O	O
common	O	O
segregation	O	O
probability	O	O
for	O	O
the	O	O
three	O	O
donors	O	O
is	O	O
at	O	O
or	O	O
below	O	O
.	O	O

515	O	O
for	O	O
all	O	O
models	O	O
considered	O	O
,	O	O
and	O	O
no	O	O
statistically	O	O
significant	O	O
difference	O	O
from	O	O
.	O	O

5	O	O
is	O	O
detected	O	O
in	O	O
any	O	O
of	O	O
the	O	O
models	O	O
.	O	O

This	O	O
suggests	O	O
that	O	O
any	O	O
greater	O	O
amount	O	O
of	O	O
segregation	O	O
distortion	O	O
at	O	O
the	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
locus	O	O
must	O	O
result	O	O
from	O	O
events	O	O
following	O	O
sperm	O	O
ejaculation	O	O
.	O	O

Isolation	O	O
of	O	O
full	O	O
-	O	O
length	O	O
ATM	O	O
cDNA	O	O
and	O	O
correction	O	O
of	O	O
the	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
cellular	O	O
phenotype	O	O
.	O	O

A	O	O
gene	O	O
mutated	O	O
in	O	O
the	O	O
human	O	O
genetic	B-Disease	D030342
disorder	I-Disease	D030342
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
)	O	O
,	O	O
ATM	O	O
,	O	O
was	O	O
recently	O	O
identified	O	O
by	O	O
positional	O	O
cloning	O	O
.	O	O

ATM	O	O
is	O	O
a	O	O
member	O	O
of	O	O
the	O	O
phosphatidylinositol	O	O
-	O	O
3	O	O
-	O	O
kinase	O	O
superfamily	O	O
,	O	O
some	O	O
of	O	O
which	O	O
are	O	O
protein	O	O
kinases	O	O
and	O	O
appear	O	O
to	O	O
have	O	O
important	O	O
roles	O	O
in	O	O
cell	O	O
cycle	O	O
control	O	O
and	O	O
radiation	O	O
signal	O	O
transduction	O	O
.	O	O

We	O	O
describe	O	O
herein	O	O
,	O	O
to	O	O
our	O	O
knowledge	O	O
,	O	O
for	O	O
the	O	O
first	O	O
time	O	O
,	O	O
the	O	O
cloning	O	O
of	O	O
a	O	O
full	O	O
-	O	O
length	O	O
cDNA	O	O
for	O	O
ATM	O	O
and	O	O
correction	O	O
of	O	O
multiple	O	O
aspects	O	O
of	O	O
the	O	O
radio	O	O
-	O	O
sensitive	O	O
phenotype	O	O
of	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
cells	O	O
by	O	O
transfection	O	O
with	O	O
this	O	O
cDNA	O	O
.	O	O

Overexpression	O	O
of	O	O
ATM	O	O
cDNA	O	O
in	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
cells	O	O
enhanced	O	O
the	O	O
survival	O	O
of	O	O
these	O	O
cells	O	O
in	O	O
response	O	O
to	O	O
radiation	O	O
exposure	O	O
,	O	O
decreased	O	O
radiation	O	O
-	O	O
induced	O	O
chromosome	O	O
aberrations	O	O
,	O	O
reduced	O	O
radio	O	O
-	O	O
resistant	O	O
DNA	O	O
synthesis	O	O
,	O	O
and	O	O
partially	O	O
corrected	O	O
defective	O	O
cell	O	O
cycle	O	O
checkpoints	O	O
and	O	O
induction	O	O
of	O	O
stress	O	O
-	O	O
activated	O	O
protein	O	O
kinase	O	O
.	O	O

This	O	O
correction	O	O
of	O	O
the	O	O
defects	O	O
in	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
cells	O	O
provides	O	O
further	O	O
evidence	O	O
of	O	O
the	O	O
multiplicity	O	O
of	O	O
effector	O	O
functions	O	O
of	O	O
the	O	O
ATM	O	O
protein	O	O
and	O	O
suggests	O	O
possible	O	O
approaches	O	O
to	O	O
gene	O	O
therapy	O	O
.	O	O

.	O	O

The	O	O
spectrum	O	O
of	O	O
RB1	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
in	O	O
hereditary	B-Disease	D012175
retinoblastoma	I-Disease	D012175
.	O	O

We	O	O
have	O	O
searched	O	O
for	O	O
germ	O	O
-	O	O
line	O	O
RB1	O	O
mutations	O	O
in	O	O
119	O	O
patients	O	O
with	O	O
hereditary	B-Disease	D012175
retinoblastoma	I-Disease	D012175
.	O	O

Previous	O	O
investigations	O	O
by	O	O
Southern	O	O
blot	O	O
hybridization	O	O
and	O	O
PCR	O	O
fragment	O	O
-	O	O
length	O	O
analysis	O	O
had	O	O
revealed	O	O
mutations	O	O
in	O	O
48	O	O
patients	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
on	O	O
the	O	O
analysis	O	O
of	O	O
the	O	O
remaining	O	O
71	O	O
patients	O	O
.	O	O

By	O	O
applying	O	O
heteroduplex	O	O
analysis	O	O
,	O	O
nonisotopic	O	O
SSCP	O	O
,	O	O
and	O	O
direct	O	O
sequencing	O	O
,	O	O
we	O	O
detected	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
resulting	O	O
in	O	O
premature	O	O
termination	O	O
codons	O	O
or	O	O
disruption	O	O
of	O	O
splice	O	O
signals	O	O
in	O	O
51	O	O
(	O	O
72	O	O
%	O	O
)	O	O
of	O	O
the	O	O
71	O	O
patients	O	O
.	O	O

Four	O	O
patients	O	O
also	O	O
showed	O	O
rare	O	O
sequence	O	O
variants	O	O
.	O	O

No	O	O
region	O	O
of	O	O
the	O	O
RB1	O	O
gene	O	O
was	O	O
preferentially	O	O
involved	O	O
in	O	O
single	O	O
base	O	O
substitutions	O	O
.	O	O

Recurrent	O	O
transitions	O	O
were	O	O
observed	O	O
at	O	O
most	O	O
of	O	O
the	O	O
14	O	O
codons	O	O
within	O	O
the	O	O
RB1	O	O
.	O	O

No	O	O
mutation	O	O
was	O	O
observed	O	O
in	O	O
exons	O	O
25	O	O
-	O	O
27	O	O
,	O	O
although	O	O
this	O	O
region	O	O
contains	O	O
two	O	O
CGA	O	O
codons	O	O
.	O	O

This	O	O
suggests	O	O
that	O	O
mutations	O	O
within	O	O
the	O	O
3	O	O
-	O	O
terminal	O	O
region	O	O
of	O	O
the	O	O
RB1	O	O
gene	O	O
may	O	O
not	O	O
be	O	O
oncogenic	O	O
.	O	O

When	O	O
these	O	O
data	O	O
were	O	O
combined	O	O
with	O	O
the	O	O
results	O	O
of	O	O
our	O	O
previous	O	O
investigations	O	O
,	O	O
mutations	O	O
were	O	O
identified	O	O
in	O	O
a	O	O
total	O	O
of	O	O
99	O	O
(	O	O
83	O	O
%	O	O
)	O	O
of	O	O
119	O	O
patients	O	O
.	O	O

The	O	O
spectrum	O	O
comprises	O	O
15	O	O
%	O	O
large	O	O
deletions	O	O
,	O	O
26	O	O
%	O	O
small	O	O
length	O	O
alterations	O	O
,	O	O
and	O	O
42	O	O
%	O	O
base	O	O
substitutions	O	O
.	O	O

No	O	O
correlation	O	O
between	O	O
the	O	O
location	O	O
of	O	O
frameshift	O	O
or	O	O
nonsense	O	O
mutations	O	O
and	O	O
phenotypic	O	O
features	O	O
,	O	O
including	O	O
age	O	O
at	O	O
diagnosis	O	O
,	O	O
the	O	O
number	O	O
of	O	O
tumor	B-Disease	D009369
foci	O	O
,	O	O
and	O	O
manifestation	O	O
of	O	O
nonocular	B-Disease	D009369
tumors	I-Disease	D009369
was	O	O
observed	O	O
.	O	O

.	O	O

Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
protein	O	O
,	O	O
a	O	O
novel	O	O
effector	O	O
for	O	O
the	O	O
GTPase	O	O
CDC42Hs	O	O
,	O	O
is	O	O
implicated	O	O
in	O	O
actin	O	O
polymerization	O	O
.	O	O

The	O	O
Rho	O	O
family	O	O
of	O	O
GTPases	O	O
control	O	O
diverse	O	O
biological	O	O
processes	O	O
,	O	O
including	O	O
cell	O	O
morphology	O	O
and	O	O
mitogenesis	O	O
.	O	O

We	O	O
have	O	O
identified	O	O
WASP	O	O
,	O	O
the	O	O
protein	O	O
that	O	O
is	O	O
defective	O	O
in	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
(	O	O
WAS	B-Disease	D014923
)	O	O
,	O	O
as	O	O
a	O	O
novel	O	O
effector	O	O
for	O	O
CDC42Hs	O	O
,	O	O
but	O	O
not	O	O
for	O	O
the	O	O
other	O	O
Rho	O	O
family	O	O
members	O	O
,	O	O
Rac	O	O
and	O	O
Rho	O	O
.	O	O

This	O	O
interaction	O	O
is	O	O
dependent	O	O
on	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
G	O	O
protein	O	O
-	O	O
binding	O	O
domain	O	O
.	O	O

Cellular	O	O
expression	O	O
of	O	O
epitope	O	O
-	O	O
tagged	O	O
WASP	O	O
produces	O	O
clusters	O	O
of	O	O
WASP	O	O
that	O	O
are	O	O
highly	O	O
enriched	O	O
in	O	O
polymerized	O	O
actin	O	O
.	O	O

This	O	O
clustering	O	O
is	O	O
not	O	O
observed	O	O
with	O	O
a	O	O
C	O	O
-	O	O
terminally	O	O
deleted	O	O
WASP	O	O
and	O	O
is	O	O
inhibited	O	O
by	O	O
coexpression	O	O
with	O	O
dominant	O	O
negative	O	O
CDC42Hs	O	O
-	O	O
N17	O	O
,	O	O
but	O	O
not	O	O
with	O	O
dominant	O	O
negative	O	O
forms	O	O
of	O	O
Rac	O	O
or	O	O
Rho	O	O
.	O	O

Thus	O	O
,	O	O
WASP	O	O
provides	O	O
a	O	O
novel	O	O
link	O	O
between	O	O
CDC42Hs	O	O
and	O	O
the	O	O
actin	O	O
cytoskeleton	O	O
,	O	O
which	O	O
suggests	O	O
a	O	O
molecular	O	O
mechanism	O	O
for	O	O
many	O	O
of	O	O
the	O	O
cellular	O	O
abnormalities	O	O
in	O	O
WAS	B-Disease	D014923
.	O	O

The	O	O
WASP	O	O
sequence	O	O
contains	O	O
two	O	O
novel	O	O
domains	O	O
that	O	O
are	O	O
homologous	O	O
to	O	O
other	O	O
proteins	O	O
involved	O	O
in	O	O
action	O	O
organization	O	O
.	O	O

.	O	O

Adult	B-Disease	D007965
onset	I-Disease	D007965
globoid	I-Disease	D007965
cell	I-Disease	D007965
leukodystrophy	I-Disease	D007965
(	O	O
Krabbe	B-Disease	OMIM:245200
disease	I-Disease	OMIM:245200
)	O	O
:	O	O
analysis	O	O
of	O	O
galactosylceramidase	O	O
cDNA	O	O
from	O	O
four	O	O
Japanese	O	O
patients	O	O
.	O	O

We	O	O
examined	O	O
galactosylceramidase	O	O
(	O	O
GALC	O	O
)	O	O
cDNA	O	O
in	O	O
four	O	O
Japanese	O	O
patients	O	O
with	O	O
adult	B-Disease	D007965
onset	I-Disease	D007965
globoid	I-Disease	D007965
cell	I-Disease	D007965
leukodystrophy	I-Disease	D007965
(	O	O
Krabbe	B-Disease	OMIM:245200
disease	I-Disease	OMIM:245200
;	O	O
AO	B-Disease	D007965
-	I-Disease	D007965
GLD	I-Disease	D007965
)	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
/	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
(	O	O
PCR	O	O
-	O	O
SSCP	O	O
)	O	O
analysis	O	O
,	O	O
subsequent	O	O
sequence	O	O
determination	O	O
,	O	O
and	O	O
restriction	O	O
enzyme	O	O
digestion	O	O
of	O	O
PCR	O	O
products	O	O
,	O	O
initial	O	O
symptoms	O	O
were	O	O
the	O	O
onset	O	O
of	O	O
slowly	O	O
progressive	O	O
spastic	B-Disease	D010264
paraplegia	I-Disease	D010264
from	O	O
the	O	O
middle	O	O
of	O	O
the	O	O
second	O	O
decade	O	O
,	O	O
and	O	O
all	O	O
patients	O	O
had	O	O
diminished	B-Disease	C538554
GALC	I-Disease	C538554
activity	I-Disease	C538554
in	O	O
their	O	O
leukocytes	O	O
.	O	O

We	O	O
identified	O	O
three	O	O
missense	O	O
mutations	O	O
(	O	O
I66M	O	O
,	O	O
G270D	O	O
,	O	O
L618S	O	O
)	O	O
and	O	O
one	O	O
exon	O	O
-	O	O
6	O	O
skipping	O	O
(	O	O
535	O	O
-	O	O
573del	O	O
)	O	O
.	O	O

Two	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
only	O	O
the	O	O
I66M	O	O
mutant	O	O
mRNA	O	O
,	O	O
and	O	O
one	O	O
only	O	O
the	O	O
G27OD	O	O
mutant	O	O
mRNA	O	O
.	O	O

The	O	O
fourth	O	O
patient	O	O
carried	O	O
a	O	O
compound	O	O
heterozygous	O	O
mutation	O	O
of	O	O
535	O	O
-	O	O
573del	O	O
and	O	O
L618S	O	O
.	O	O

To	O	O
determine	O	O
the	O	O
enzymatic	O	O
activities	O	O
produced	O	O
by	O	O
these	O	O
mutations	O	O
,	O	O
we	O	O
constructed	O	O
mutated	O	O
GALC	O	O
cDNAs	O	O
and	O	O
expressed	O	O
them	O	O
in	O	O
COS	O	O
-	O	O
1	O	O
cells	O	O
.	O	O

Three	O	O
mutations	O	O
,	O	O
viz	O	O
.	O	O

,	O	O
G270D	O	O
,	O	O
L618S	O	O
,	O	O
and	O	O
exon	O	O
-	O	O
6	O	O
skipping	O	O
(	O	O
535	O	O
-	O	O
573del	O	O
)	O	O
,	O	O
produced	O	O
diminished	B-Disease	C538554
GALC	I-Disease	C538554
activity	I-Disease	C538554
as	O	O
expected	O	O
.	O	O

The	O	O
I66M	O	O
mutation	O	O
in	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
GALC	O	O
cDNA	O	O
(	O	O
I289	O	O
)	O	O
had	O	O
normal	O	O
activity	O	O
,	O	O
but	O	O
when	O	O
this	O	O
mutation	O	O
and	O	O
the	O	O
V289	O	O
polymorphism	O	O
were	O	O
introduced	O	O
into	O	O
the	O	O
same	O	O
allele	O	O
,	O	O
it	O	O
had	O	O
decreased	O	O
activity	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
combination	O	O
of	O	O
a	O	O
unique	O	O
mutation	O	O
and	O	O
polymorphism	O	O
causes	O	O
conformational	O	O
change	O	O
in	O	O
the	O	O
GALC	O	O
enzyme	O	O
,	O	O
resulting	O	O
in	O	O
low	O	O
enzymatic	O	O
activity	O	O
.	O	O

AO	B-Disease	D007965
-	I-Disease	D007965
GLD	I-Disease	D007965
mutations	O	O
,	O	O
including	O	O
those	O	O
found	O	O
here	O	O
,	O	O
are	O	O
located	O	O
in	O	O
the	O	O
N	O	O
-	O	O
terminus	O	O
(	O	O
I66M	O	O
,	O	O
G270D	O	O
,	O	O
535	O	O
-	O	O
573del	O	O
)	O	O
or	O	O
C	O	O
-	O	O
terminus	O	O
(	O	O
L618S	O	O
)	O	O
of	O	O
the	O	O
GALC	O	O
enzyme	O	O
,	O	O
whereas	O	O
the	O	O
reported	O	O
mutations	O	O
in	O	O
the	O	O
infantile	O	O
form	O	O
(	O	O
IF	B-Disease	D007965
-	I-Disease	D007965
GLD	I-Disease	D007965
)	O	O
are	O	O
in	O	O
the	O	O
central	O	O
domain	O	O
.	O	O

This	O	O
difference	O	O
in	O	O
mutation	O	O
sites	O	O
may	O	O
affect	O	O
the	O	O
clinical	O	O
features	O	O
of	O	O
GLD	B-Disease	D007965
.	O	O

BRCA1	O	O
is	O	O
secreted	O	O
and	O	O
exhibits	O	O
properties	O	O
of	O	O
a	O	O
granin	O	O
.	O	O

Germline	O	O
mutations	O	O
in	O	O
BRCA1	O	O
are	O	O
responsible	O	O
for	O	O
most	O	O
cases	O	O
of	O	O
inherited	B-Disease	D061325
breast	I-Disease	D061325
and	I-Disease	D061325
ovarian	I-Disease	D061325
cancer	I-Disease	D061325
.	O	O

However	O	O
,	O	O
the	O	O
function	O	O
of	O	O
the	O	O
BRCA1	O	O
protein	O	O
has	O	O
remained	O	O
elusive	O	O
.	O	O

We	O	O
now	O	O
show	O	O
that	O	O
BRCA1	O	O
encodes	O	O
a	O	O
190	O	O
-	O	O
kD	O	O
protein	O	O
with	O	O
sequence	O	O
homology	O	O
and	O	O
biochemical	O	O
analogy	O	O
to	O	O
the	O	O
granin	O	O
protein	O	O
family	O	O
.	O	O

Interestingly	O	O
,	O	O
BRCA2	O	O
also	O	O
includes	O	O
a	O	O
motif	O	O
similar	O	O
to	O	O
the	O	O
granin	O	O
consensus	O	O
at	O	O
the	O	O
C	O	O
terminus	O	O
of	O	O
the	O	O
protein	O	O
.	O	O

Both	O	O
BRCA1	O	O
and	O	O
the	O	O
granins	O	O
localize	O	O
to	O	O
secretory	O	O
vesicles	O	O
,	O	O
are	O	O
secreted	O	O
by	O	O
a	O	O
regulated	O	O
pathway	O	O
,	O	O
are	O	O
post	O	O
-	O	O
translationally	O	O
glycosylated	O	O
and	O	O
are	O	O
responsive	O	O
to	O	O
hormones	O	O
.	O	O

As	O	O
a	O	O
regulated	O	O
secretory	O	O
protein	O	O
,	O	O
BRCA1	O	O
appears	O	O
to	O	O
function	O	O
by	O	O
a	O	O
mechanism	O	O
not	O	O
previously	O	O
described	O	O
for	O	O
tumour	B-Disease	D009369
suppressor	O	O
gene	O	O
products	O	O
.	O	O

.	O	O

Insulin	O	O
gene	O	O
region	O	O
contributes	O	O
to	O	O
genetic	O	O
susceptibility	O	O
to	O	O
,	O	O
but	O	O
may	O	O
not	O	O
to	O	O
low	O	O
incidence	O	O
of	O	O
,	O	O
insulin	B-Disease	OMIM:125852
-	I-Disease	OMIM:125852
dependent	I-Disease	OMIM:125852
diabetes	I-Disease	OMIM:125852
mellitus	I-Disease	OMIM:125852
in	O	O
Japanese	O	O
.	O	O

In	O	O
the	O	O
Caucasian	O	O
population	O	O
,	O	O
it	O	O
has	O	O
been	O	O
demonstrated	O	O
that	O	O
the	O	O
insulin	O	O
gene	O	O
(	O	O
INS	O	O
)	O	O
region	O	O
contains	O	O
the	O	O
insulin	B-Disease	OMIM:125852
-	I-Disease	OMIM:125852
dependent	I-Disease	OMIM:125852
diabetes	I-Disease	OMIM:125852
mellitus	I-Disease	OMIM:125852
locus	O	O
(	O	O
IDDM2	O	O
)	O	O
.	O	O

In	O	O
the	O	O
Japanese	O	O
population	O	O
,	O	O
however	O	O
,	O	O
there	O	O
has	O	O
been	O	O
no	O	O
report	O	O
demonstrating	O	O
the	O	O
contribution	O	O
of	O	O
IDDM2	O	O
to	O	O
the	O	O
pathogenesis	O	O
of	O	O
IDDM	B-Disease	D003922
.	O	O

We	O	O
conducted	O	O
an	O	O
association	O	O
study	O	O
of	O	O
IDDM	B-Disease	D003922
in	O	O
a	O	O
large	O	O
number	O	O
of	O	O
Japanese	O	O
subjects	O	O
with	O	O
multiple	O	O
polymorphisms	O	O
in	O	O
INS	O	O
region	O	O
.	O	O

We	O	O
found	O	O
a	O	O
significant	O	O
association	O	O
of	O	O
the	O	O
INS	O	O
region	O	O
with	O	O
IDDM	B-Disease	D003922
.	O	O

Alleles	O	O
positively	O	O
associated	O	O
with	O	O
IDDM	B-Disease	D003922
in	O	O
INS	O	O
region	O	O
were	O	O
the	O	O
same	O	O
as	O	O
those	O	O
positively	O	O
-	O	O
associated	O	O
with	O	O
IDDM	B-Disease	D003922
in	O	O
Caucasian	O	O
population	O	O
,	O	O
although	O	O
positively	O	O
-	O	O
associated	O	O
alleles	O	O
are	O	O
very	O	O
common	O	O
(	O	O
allele	O	O
frequencies	O	O
>	O	O
0	O	O
.	O	O

9	O	O
)	O	O
in	O	O
the	O	O
Japanese	O	O
general	O	O
population	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
IDDM2	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
genetic	O	O
susceptibility	O	O
to	O	O
IDDM	B-Disease	D003922
in	O	O
Japanese	O	O
.	O	O

The	O	O
high	O	O
frequencies	O	O
of	O	O
disease	O	O
-	O	O
associated	O	O
alleles	O	O
in	O	O
the	O	O
general	O	O
population	O	O
suggest	O	O
that	O	O
IDDM2	O	O
locus	O	O
is	O	O
not	O	O
responsible	O	O
for	O	O
the	O	O
low	O	O
incidence	O	O
of	O	O
IDDM	B-Disease	D003922
in	O	O
Japanese	O	O
.	O	O

Association	O	O
of	O	O
anxiety	B-Disease	OMIM:607834
-	I-Disease	OMIM:607834
related	I-Disease	OMIM:607834
traits	I-Disease	OMIM:607834
with	O	O
a	O	O
polymorphism	O	O
in	O	O
the	O	O
serotonin	O	O
transporter	O	O
gene	O	O
regulatory	O	O
region	O	O
.	O	O

Transporter	O	O
-	O	O
facilitated	O	O
uptake	O	O
of	O	O
serotonin	O	O
(	O	O
5	O	O
-	O	O
hydroxytryptamine	O	O
or	O	O
5	O	O
-	O	O
HT	O	O
)	O	O
has	O	O
been	O	O
implicated	O	O
in	O	O
anxiety	B-Disease	D001008
in	O	O
humans	O	O
and	O	O
animal	O	O
models	O	O
and	O	O
is	O	O
the	O	O
site	O	O
of	O	O
action	O	O
of	O	O
widely	O	O
used	O	O
uptake	O	O
-	O	O
inhibiting	O	O
antidepressant	O	O
and	O	O
antianxiety	O	O
drugs	O	O
.	O	O

Human	O	O
5	O	O
-	O	O
HT	O	O
transporter	O	O
(	O	O
5	O	O
-	O	O
HTT	O	O
)	O	O
gene	O	O
transcription	O	O
is	O	O
modulated	O	O
by	O	O
a	O	O
common	O	O
polymorphism	O	O
in	O	O
its	O	O
upstream	O	O
regulatory	O	O
region	O	O
.	O	O

The	O	O
short	O	O
variant	O	O
of	O	O
the	O	O
polymorphism	O	O
reduces	O	O
the	O	O
transcriptional	O	O
efficiency	O	O
of	O	O
the	O	O
5	O	O
-	O	O
HTT	O	O
gene	O	O
promoter	O	O
,	O	O
resulting	O	O
in	O	O
decreased	O	O
5	O	O
-	O	O
HTT	O	O
expression	O	O
and	O	O
5	O	O
-	O	O
HT	O	O
uptake	O	O
in	O	O
lymphoblasts	O	O
.	O	O

Association	O	O
studies	O	O
in	O	O
two	O	O
independent	O	O
samples	O	O
totaling	O	O
505	O	O
individuals	O	O
revealed	O	O
that	O	O
the	O	O
5	O	O
-	O	O
HTT	O	O
polymorphism	O	O
accounts	O	O
for	O	O
3	O	O
to	O	O
4	O	O
percent	O	O
of	O	O
total	O	O
variation	O	O
and	O	O
7	O	O
to	O	O
9	O	O
percent	O	O
of	O	O
inherited	O	O
variance	O	O
in	O	O
anxiety	B-Disease	D001008
-	O	O
related	O	O
personality	O	O
traits	O	O
in	O	O
individuals	O	O
as	O	O
well	O	O
as	O	O
sibships	O	O
.	O	O

.	O	O

Cloning	O	O
and	O	O
characterization	O	O
of	O	O
human	O	O
very	O	O
-	O	O
long	O	O
-	O	O
chain	O	O
acyl	O	O
-	O	O
CoA	O	O
dehydrogenase	O	O
cDNA	O	O
,	O	O
chromosomal	O	O
assignment	O	O
of	O	O
the	O	O
gene	O	O
and	O	O
identification	O	O
in	O	O
four	O	O
patients	O	O
of	O	O
nine	O	O
different	O	O
mutations	O	O
within	O	O
the	O	O
VLCAD	O	O
gene	O	O
.	O	O

Very	O	O
-	O	O
long	O	O
-	O	O
chain	O	O
acyl	O	O
-	O	O
CoA	O	O
dehydrogenase	O	O
(	O	O
VLCAD	O	O
)	O	O
is	O	O
one	O	O
of	O	O
four	O	O
straight	O	O
-	O	O
chain	O	O
acyl	O	O
-	O	O
CoA	O	O
dehydrogenase	O	O
(	O	O
ACD	O	O
)	O	O
enzymes	O	O
,	O	O
which	O	O
are	O	O
all	O	O
nuclear	O	O
encoded	O	O
mitochondrial	O	O
flavoproteins	O	O
catalyzing	O	O
the	O	O
initial	O	O
step	O	O
in	O	O
fatty	O	O
acid	O	O
beta	O	O
-	O	O
oxidation	O	O
.	O	O

We	O	O
have	O	O
used	O	O
the	O	O
very	O	O
fast	O	O
,	O	O
Rapid	O	O
Amplification	O	O
of	O	O
cDNA	O	O
Ends	O	O
(	O	O
RACE	O	O
)	O	O
based	O	O
strategy	O	O
to	O	O
obtain	O	O
the	O	O
sequence	O	O
of	O	O
cDNAs	O	O
encoding	O	O
human	O	O
VLCAD	O	O
from	O	O
placenta	O	O
and	O	O
fibroblasts	O	O
.	O	O

Alignment	O	O
of	O	O
the	O	O
predicted	O	O
amino	O	O
acid	O	O
sequence	O	O
of	O	O
human	O	O
VLCAD	O	O
with	O	O
those	O	O
of	O	O
the	O	O
other	O	O
human	O	O
ACD	O	O
enzymes	O	O
revealed	O	O
extensive	O	O
sequence	O	O
homology	O	O
.	O	O

Moreover	O	O
,	O	O
human	O	O
VLCAD	O	O
and	O	O
human	O	O
acyl	O	O
-	O	O
CoA	O	O
oxidase	O	O
showed	O	O
extensive	O	O
sequence	O	O
homology	O	O
corroborating	O	O
the	O	O
notion	O	O
that	O	O
these	O	O
genes	O	O
are	O	O
evolutionarily	O	O
related	O	O
.	O	O

Southern	O	O
blot	O	O
analysis	O	O
of	O	O
genomic	O	O
DNA	O	O
from	O	O
hybrid	O	O
cell	O	O
lines	O	O
was	O	O
used	O	O
to	O	O
localize	O	O
the	O	O
VLCAD	O	O
gene	O	O
to	O	O
human	O	O
chromosome	O	O
17p11	O	O
.	O	O

2	O	O
-	O	O
p11	O	O
.	O	O

13105	O	O
.	O	O

Using	O	O
Northern	O	O
and	O	O
Western	O	O
blot	O	O
analysis	O	O
to	O	O
investigate	O	O
the	O	O
tissue	O	O
specific	O	O
distribution	O	O
of	O	O
VLCAD	O	O
mRNA	O	O
and	O	O
protein	O	O
in	O	O
several	O	O
human	O	O
tissues	O	O
we	O	O
showed	O	O
that	O	O
VLCAD	O	O
is	O	O
most	O	O
abundant	O	O
in	O	O
heart	O	O
and	O	O
skeletal	O	O
muscle	O	O
.	O	O

This	O	O
agrees	O	O
well	O	O
with	O	O
the	O	O
fact	O	O
that	O	O
cardiac	O	O
and	O	O
muscle	O	O
symptoms	O	O
are	O	O
characteristic	O	O
for	O	O
patients	O	O
with	O	O
VLCAD	B-Disease	C536353
deficiency	I-Disease	C536353
.	O	O

Northern	O	O
blot	O	O
analysis	O	O
and	O	O
sequencing	O	O
of	O	O
cloned	O	O
PCR	O	O
amplified	O	O
VLCAD	O	O
cDNA	O	O
from	O	O
four	O	O
unrelated	O	O
patients	O	O
with	O	O
VLCAD	B-Disease	C536353
deficiency	I-Disease	C536353
showed	O	O
that	O	O
VLCAD	O	O
mRNA	O	O
was	O	O
undetectable	O	O
in	O	O
one	O	O
patient	O	O
and	O	O
that	O	O
the	O	O
other	O	O
three	O	O
have	O	O
mutations	O	O
in	O	O
both	O	O
VLCAD	O	O
alleles	O	O
.	O	O

Western	O	O
blot	O	O
analysis	O	O
of	O	O
patient	O	O
fibroblasts	O	O
showed	O	O
that	O	O
the	O	O
identified	O	O
mutations	O	O
result	O	O
in	O	O
severely	O	O
reduced	O	O
amounts	O	O
of	O	O
VLCAD	O	O
protein	O	O
.	O	O

Genetic	O	O
bases	O	O
of	O	O
human	O	O
complement	B-Disease	OMIM:610102
C7	I-Disease	OMIM:610102
deficiency	I-Disease	OMIM:610102
.	O	O

Complement	B-Disease	OMIM:610102
C7	I-Disease	OMIM:610102
deficiency	I-Disease	OMIM:610102
(	O	O
C7D	B-Disease	OMIM:610102
)	O	O
is	O	O
associated	O	O
frequently	O	O
with	O	O
recurrent	O	O
bacterial	B-Disease	D001424
infections	I-Disease	D001424
,	O	O
especially	O	O
meningitis	B-Disease	D008581
caused	O	O
by	O	O
Neisseria	B-Disease	D008589
meningitidis	I-Disease	D008589
.	O	O

We	O	O
report	O	O
in	O	O
this	O	O
work	O	O
the	O	O
molecular	O	O
bases	O	O
of	O	O
C7D	B-Disease	OMIM:610102
in	O	O
two	O	O
unrelated	O	O
Japanese	O	O
males	O	O
.	O	O

We	O	O
used	O	O
exon	O	O
-	O	O
specific	O	O
PCR	O	O
/	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
analysis	O	O
as	O	O
a	O	O
screening	O	O
step	O	O
for	O	O
mutations	O	O
.	O	O

Subsequent	O	O
direct	O	O
sequencing	O	O
of	O	O
the	O	O
target	O	O
exons	O	O
identified	O	O
homozygous	O	O
mutations	O	O
in	O	O
exon	O	O
16	O	O
of	O	O
case	O	O
1	O	O
and	O	O
in	O	O
exon	O	O
15	O	O
of	O	O
case	O	O
2	O	O
.	O	O

The	O	O
mutation	O	O
of	O	O
case	O	O
1	O	O
was	O	O
a	O	O
homozygous	O	O
T	O	O
to	O	O
A	O	O
transversion	O	O
at	O	O
nucleotide	O	O
2250	O	O
,	O	O
the	O	O
third	O	O
nucleotide	O	O
of	O	O
the	O	O
codon	O	O
TGT	O	O
for	O	O
Cys728	O	O
,	O	O
leading	O	O
to	O	O
a	O	O
stop	O	O
codon	O	O
TGA	O	O
(	O	O
C728X	O	O
)	O	O
.	O	O

In	O	O
case	O	O
2	O	O
,	O	O
a	O	O
homozygous	O	O
2	O	O
-	O	O
bp	O	O
deletion	O	O
(	O	O
2137delTG	O	O
/	O	O
2138delGT	O	O
/	O	O
2139delTG	O	O
)	O	O
caused	O	O
a	O	O
frameshift	O	O
,	O	O
generating	O	O
a	O	O
premature	O	O
termination	O	O
codon	O	O
4	O	O
to	O	O
6	O	O
nucleotides	O	O
downstream	O	O
.	O	O

Family	O	O
study	O	O
in	O	O
case	O	O
1	O	O
confirmed	O	O
the	O	O
genetic	O	O
nature	O	O
of	O	O
the	O	O
defect	O	O
.	O	O

Moreover	O	O
,	O	O
we	O	O
detected	O	O
a	O	O
novel	O	O
polymorphism	O	O
in	O	O
intron	O	O
11	O	O
that	O	O
presumably	O	O
is	O	O
linked	O	O
to	O	O
the	O	O
mutation	O	O
responsible	O	O
for	O	O
C7D	B-Disease	OMIM:610102
in	O	O
case	O	O
1	O	O
.	O	O

Our	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
pathogenesis	O	O
of	O	O
C7D	B-Disease	OMIM:610102
is	O	O
heterogeneous	O	O
like	O	O
most	O	O
of	O	O
the	O	O
other	O	O
deficiencies	B-Disease	D007153
of	I-Disease	D007153
complement	I-Disease	D007153
components	I-Disease	D007153
.	O	O

.	O	O

Defective	O	O
dimerization	O	O
of	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
factor	O	O
subunits	O	O
due	O	O
to	O	O
a	O	O
Cys	O	O
-	O	O
>	O	O
Arg	O	O
mutation	O	O
in	O	O
type	B-Disease	D056728
IID	I-Disease	D056728
von	I-Disease	D056728
Willebrand	I-Disease	D056728
disease	I-Disease	D056728
.	O	O

The	O	O
same	O	O
heterozygous	O	O
T	O	O
-	O	O
>	O	O
C	O	O
transition	O	O
at	O	O
nt	O	O
8567	O	O
of	O	O
the	O	O
von	B-Disease	D014842
Willebrand	I-Disease	D014842
factor	O	O
(	O	O
vWF	O	O
)	O	O
transcript	O	O
was	O	O
found	O	O
in	O	O
two	O	O
unrelated	O	O
patients	O	O
with	O	O
type	B-Disease	D056728
IID	I-Disease	D056728
von	I-Disease	D056728
Willebrand	I-Disease	D056728
disease	I-Disease	D056728
,	O	O
with	O	O
no	O	O
other	O	O
apparent	O	O
abnormality	O	O
.	O	O

In	O	O
one	O	O
family	O	O
,	O	O
both	O	O
alleles	O	O
were	O	O
normal	O	O
in	O	O
the	O	O
parents	O	O
and	O	O
one	O	O
sister	O	O
;	O	O
thus	O	O
,	O	O
the	O	O
mutation	O	O
originated	O	O
de	O	O
novo	O	O
in	O	O
the	O	O
proposita	O	O
.	O	O

The	O	O
second	O	O
patient	O	O
also	O	O
had	O	O
asymptomatic	O	O
parents	O	O
who	O	O
,	O	O
however	O	O
,	O	O
were	O	O
not	O	O
available	O	O
for	O	O
study	O	O
.	O	O

The	O	O
structural	O	O
consequences	O	O
of	O	O
the	O	O
identified	O	O
mutation	O	O
,	O	O
resulting	O	O
in	O	O
the	O	O
CyS2010	O	O
-	O	O
>	O	O
Arg	O	O
substitution	O	O
,	O	O
were	O	O
evaluated	O	O
by	O	O
expression	O	O
of	O	O
the	O	O
vWF	O	O
carboxyl	O	O
-	O	O
terminal	O	O
domain	O	O
containing	O	O
residues	O	O
1366	O	O
-	O	O
2050	O	O
.	O	O

Insect	O	O
cells	O	O
infected	O	O
with	O	O
recombinant	O	O
baculovirus	O	O
expressing	O	O
normal	O	O
vWF	O	O
sequence	O	O
secreted	O	O
a	O	O
disulfide	O	O
linked	O	O
dimeric	O	O
molecule	O	O
with	O	O
an	O	O
apparent	O	O
molecular	O	O
mass	O	O
of	O	O
150	O	O
kDa	O	O
before	O	O
reduction	O	O
,	O	O
yielding	O	O
a	O	O
single	O	O
band	O	O
of	O	O
80	O	O
kDa	O	O
after	O	O
disulfide	O	O
bond	O	O
reduction	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
cells	O	O
expressing	O	O
the	O	O
mutant	O	O
fragment	O	O
secreted	O	O
a	O	O
monomeric	O	O
molecule	O	O
of	O	O
apparent	O	O
molecular	O	O
mass	O	O
of	O	O
80	O	O
kDa	O	O
,	O	O
which	O	O
remained	O	O
unchanged	O	O
after	O	O
reduction	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
CyS2010	O	O
is	O	O
essential	O	O
for	O	O
normal	O	O
dimerization	O	O
of	O	O
vWF	O	O
subunits	O	O
through	O	O
disulfide	O	O
bonding	O	O
of	O	O
carboxyl	O	O
-	O	O
terminal	O	O
domains	O	O
and	O	O
that	O	O
a	O	O
heterozygous	O	O
mutation	O	O
in	O	O
the	O	O
corresponding	O	O
codon	O	O
is	O	O
responsible	O	O
for	O	O
defective	O	O
multimer	O	O
formation	O	O
in	O	O
type	B-Disease	D056728
IID	I-Disease	D056728
von	I-Disease	D056728
Willebrand	I-Disease	D056728
disease	I-Disease	D056728
.	O	O

.	O	O

Ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
:	O	O
founder	O	O
effect	O	O
among	O	O
north	O	O
African	O	O
Jews	O	O
.	O	O

The	O	O
ATM	O	O
gene	O	O
is	O	O
responsible	O	O
for	O	O
the	O	O
autosomal	B-Disease	D030342
recessive	I-Disease	D030342
disorder	I-Disease	D030342
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
)	O	O
,	O	O
characterized	O	O
by	O	O
cerebellar	B-Disease	D013132
degeneration	I-Disease	D013132
,	O	O
immunodeficiency	B-Disease	D007153
and	O	O
cancer	B-Disease	D009369
predisposition	I-Disease	D009369
.	O	O

A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
carriers	O	O
were	O	O
reported	O	O
to	O	O
be	O	O
moderately	O	O
cancer	B-Disease	D009369
-	I-Disease	D009369
prone	I-Disease	D009369
.	O	O

A	O	O
wide	O	O
variety	O	O
of	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
mutations	O	O
,	O	O
most	O	O
of	O	O
which	O	O
are	O	O
unique	O	O
to	O	O
single	O	O
families	O	O
,	O	O
were	O	O
identified	O	O
in	O	O
various	O	O
ethnic	O	O
groups	O	O
,	O	O
precluding	O	O
carrier	O	O
screening	O	O
with	O	O
mutation	O	O
-	O	O
specific	O	O
assays	O	O
.	O	O

However	O	O
,	O	O
a	O	O
single	O	O
mutation	O	O
was	O	O
observed	O	O
in	O	O
32	O	O
/	O	O
33	O	O
defective	O	O
ATM	O	O
alleles	O	O
in	O	O
Jewish	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
families	O	O
of	O	O
North	O	O
African	O	O
origin	O	O
,	O	O
coming	O	O
from	O	O
various	O	O
regions	O	O
of	O	O
Morocco	O	O
and	O	O
Tunisia	O	O
.	O	O

This	O	O
mutation	O	O
,	O	O
103C	O	O
-	O	O
-	O	O
>	O	O
T	O	O
,	O	O
results	O	O
in	O	O
a	O	O
stop	O	O
codon	O	O
at	O	O
position	O	O
35	O	O
of	O	O
the	O	O
ATM	O	O
protein	O	O
.	O	O

In	O	O
keeping	O	O
with	O	O
the	O	O
nature	O	O
of	O	O
this	O	O
mutation	O	O
,	O	O
various	O	O
antibodies	O	O
directed	O	O
against	O	O
the	O	O
ATM	O	O
protein	O	O
failed	O	O
to	O	O
defect	O	O
this	O	O
protein	O	O
in	O	O
patient	O	O
cells	O	O
.	O	O

A	O	O
rapid	O	O
carrier	O	O
detection	O	O
assay	O	O
detected	O	O
this	O	O
mutation	O	O
in	O	O
three	O	O
out	O	O
of	O	O
488	O	O
ATM	O	O
alleles	O	O
of	O	O
Jewish	O	O
Moroccan	O	O
or	O	O
Tunisian	O	O
origin	O	O
.	O	O

This	O	O
founder	O	O
effect	O	O
provides	O	O
a	O	O
unique	O	O
opportunity	O	O
for	O	O
population	O	O
-	O	O
based	O	O
screening	O	O
for	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
carriers	O	O
in	O	O
a	O	O
large	O	O
Jewish	O	O
community	O	O
.	O	O

.	O	O

Mutations	O	O
associated	O	O
with	O	O
variant	O	O
phenotypes	O	O
in	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
.	O	O

We	O	O
have	O	O
identified	O	O
14	O	O
families	O	O
with	O	O
ataxia	B-Disease	D001260
-	I-Disease	D001260
telangiectasia	I-Disease	D001260
(	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
)	O	O
in	O	O
which	O	O
mutation	O	O
of	O	O
the	O	O
ATM	O	O
gene	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
less	O	O
severe	O	O
clinical	O	O
and	O	O
cellular	O	O
phenotype	O	O
(	O	O
approximately	O	O
10	O	O
%	O	O
-	O	O
15	O	O
%	O	O
of	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
families	O	O
identified	O	O
in	O	O
the	O	O
United	O	O
Kingdom	O	O
)	O	O
.	O	O

In	O	O
10	O	O
of	O	O
these	O	O
families	O	O
,	O	O
all	O	O
the	O	O
homozygotes	O	O
have	O	O
a	O	O
137	O	O
-	O	O
bp	O	O
insertion	O	O
in	O	O
their	O	O
cDNA	O	O
caused	O	O
by	O	O
a	O	O
point	O	O
mutation	O	O
in	O	O
a	O	O
sequence	O	O
resembling	O	O
a	O	O
splice	O	O
-	O	O
donor	O	O
site	O	O
.	O	O

The	O	O
second	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
allele	O	O
has	O	O
a	O	O
different	O	O
mutation	O	O
in	O	O
each	O	O
patient	O	O
.	O	O

We	O	O
show	O	O
that	O	O
the	O	O
less	O	O
severe	O	O
phenotype	O	O
in	O	O
these	O	O
patients	O	O
is	O	O
caused	O	O
by	O	O
some	O	O
degree	O	O
of	O	O
normal	O	O
splicing	O	O
,	O	O
which	O	O
occurs	O	O
as	O	O
an	O	O
alternative	O	O
product	O	O
from	O	O
the	O	O
insertion	O	O
-	O	O
containing	O	O
allele	O	O
.	O	O

The	O	O
level	O	O
of	O	O
the	O	O
137	O	O
-	O	O
bp	O	O
PCR	O	O
product	O	O
containing	O	O
the	O	O
insertion	O	O
was	O	O
lowest	O	O
in	O	O
two	O	O
patients	O	O
who	O	O
showed	O	O
a	O	O
later	O	O
onset	O	O
of	O	O
cerebellar	B-Disease	D002524
ataxia	I-Disease	D002524
.	O	O

A	O	O
further	O	O
four	O	O
families	O	O
who	O	O
do	O	O
not	O	O
have	O	O
this	O	O
insertion	O	O
have	O	O
been	O	O
identified	O	O
.	O	O

Mutations	O	O
detected	O	O
in	O	O
two	O	O
of	O	O
four	O	O
of	O	O
these	O	O
are	O	O
missense	O	O
mutations	O	O
,	O	O
normally	O	O
rare	O	O
in	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
patients	O	O
.	O	O

The	O	O
demonstration	O	O
of	O	O
mutations	O	O
giving	O	O
rise	O	O
to	O	O
a	O	O
slightly	O	O
milder	O	O
phenotype	O	O
in	O	O
A	B-Disease	D001260
-	I-Disease	D001260
T	I-Disease	D001260
raises	O	O
the	O	O
interesting	O	O
question	O	O
of	O	O
what	O	O
range	O	O
of	O	O
phenotypes	O	O
might	O	O
occur	O	O
in	O	O
individuals	O	O
in	O	O
whom	O	O
both	O	O
mutations	O	O
are	O	O
milder	O	O
.	O	O

One	O	O
possibility	O	O
might	O	O
be	O	O
that	O	O
individuals	O	O
who	O	O
are	O	O
compound	O	O
heterozygotes	O	O
for	O	O
ATM	O	O
mutations	O	O
are	O	O
more	O	O
common	O	O
than	O	O
we	O	O
realize	O	O
.	O	O

.	O	O

